Hip Osteoarthritis: Genetics, epidemiological risk factors and burden of the disease by Castaño Betancourt, M.C. (Martha)
    Martha C. Castaño Betancourt
1.Hip Osteoarthritis
Genetics, epidemiological risk factors 
and burden of the disease
    The work described in this thesis was conducted at the Department of Internal Medicine
at Erasmus MC University Medical Center Rotterdam. The Rotterdam Study is
supported by Erasmus MC University Medical Center and Erasmus University Rotter-
dam; the Netherlands Organization for Scientific Research (NWO); the Netherlands
Organization for Health Research and Development (ZonMW); the Research Institute
for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the
Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the
Municipality of Rotterdam. Additional funding for the work described in this thesis
was provided by the Netherlands Genomics Initiative (NGI)/Netherlands Organization
for Scientific Research (NWO) project nr. 050-060-810, VIDI Grant 917103521 and the
European Commission seven framework program TREAT-OA (grant 200800).
Financial support for publications of this thesis has been provided by:
Erasmus University Rotterdam, the Netherlands
Dutch Arthritis Foundation (Reumafonds), the Netherlands
Stichting Artrose Zorg, the Netherlands
Anna Foundation| NOREF, the Netherlands
    
Nederlandse Vereniging voor Calcium- en Botstofwisseling (NVCB), the Netherlands
Cover design: Proefschriftenmaken.nl and Danny Kooij 
Layout: Danny Kooij
Printed & published by: Proefschriftmaken.nl / Uitgeverij BOXPress
ISBN: 978-94-6295-093-1
Copyright © 2015 M.C. Castaño Betancourt
All rights reserved. No part of this thesis may be reproduced, distributed, stored in a re-
trieval system or transmitted in any form or by any means without written permission of
the author, or, when appropriate of the publishers of the publications.
    Hip Osteoarthritis:
Genetics, epidemiological risk factors
 and burden of the disease
Heup-artrose: 
Genetica, epidemiologische risicofactoren
 en ziektelast
Proefschrift
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam
 op gezag van de rector magnificus
Prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 25 maart 2015 om 11:30 uur
door
Martha Cecilia Castaño Betancourt
geboren te Ibague, Colombia
    PROMOTIECOMMISSIE
Promotor:
Prof.dr. A.G. Uitterlinden
Overige leden:
Prof.dr. C. M. van Duijn
Prof.dr.ir. H. H. Weinans
Dr. A.M. Valdes
Co-promotor:
Dr. J.B.J. van Meurs
 Chapter 1. Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  9
Chapter 2. Genetics of cartilage thickness and hip osteoarthritis. . . 27
2.1. Genome wide association and functional 
studies identify the DOT1L gene to be involved 
in cartilage thickness and hip osteoarthritis  . . . . . . . . . . . 29
2.2. Identification by GWAS meta-analysis of new signals 
and pathways that confer risk for hip osteoarthritis  . . . . . . 57
2.3. Bivariate analysis of correlated traits: 
joint space width and height . . . . . . . . . . . . . . . . . . . . . 87
Chapter 3. Bone related factors predictive of hip OA: 
hip geometry and bone mineral density . . . . . . . . . . . . 109
3.1. The contribution of hip geometry to the 
prediction of hip osteoarthritis . . . . . . . . . . . . . . . . . . . .111
3.2. Dual energy X-ray absorptiometry analysis contributes 
to the prediction of hip osteoarthritis progression  . . . . . . 135
Chapter 4. Osteoporotic fracture risk in osteoarthritis . . . . . . . . . . 153
4.1. Bone parameters across different types of hip 
osteoarthritis and its relation to osteoporotic fracture risk . 155
4.2. Association of lumbar disc
degeneration with osteoporotic fractures . . . . . . . . . . . . 173
Chapter 5. Osteoarthritis and mortality  . . . . . . . . . . . . . . . . . . . . . 193
5.1. Association of hip and knee osteoarthritis with mortality. . 195
Chapter 6. General discussion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
Chapter 7. Summary / Samenvatting . . . . . . . . . . . . . . . . . . . . . . . 233
Acknowledgements. . . . . . . . . . . . . . . . . . . . . . . . . . . . 243
List of publications & PhD portfolio  . . . . . . . . . . . . . .  247
List of publications  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248
PhD portfolio  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251
List of abbreviations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255
TABLE OF CONTENTS5
6
 PUBLICATIONS AND MANUSCRIPTS BASED 
ON THE 
STUDIES DESCRIBED IN THIS THESIS
Chapter 2.1
Genome-wide association and functional studies identify the DOT1L gene to be
involved in cartilage thickness and hip osteoarthritis. Castaño-Betancourt MC, Cailotto
F, Kerkhof HJ, Cornelis FM, Doherty SA, Hart DJ, Hofman A, Luyten FP, Maciewicz
RA, Mangino M, Metrustry S, Muir K, Peters MJ, Rivadeneira F, Wheeler M, Zhang W,
Arden N, Spector TD, Uitterlinden AG, Doherty M, Lories RJ, Valdes AM, van Meurs
JB. Proc Natl Acad Sci U S A. 2012 May 22;109(21):8218-23.
Chapter 2.2
Identification by GWAS meta-analysis of new signals and pathways that confer risk for
hip osteoarthritis. Castaño-Betancourt MC, Evans D, de Boer C, Liu Y, Yau M, Zhang
W, Hofman A, Arden N, Spector TD, Kraus V, Valdes AM, Meulenbelt I, Lane N,
Uitterlinden AG, van Meurs JB. Manuscript in preparation.
Chapter 2.3
Bivariate analysis of correlated traits: Joint space width and height. Castaño-
Betancourt MC, Medina Gomez C, Eijgelsheim M, Estrada K, Rivadeneira F, Hofman
A, Uitterlinden AG, van Meurs JB. Manuscript in preparation.
Chapter 3.1
The contribution of hip geometry to the prediction of hip osteoarthritis Castaño-
Betancourt MC, Van Meurs JB, Bierma-Zeinstra S, Rivadeneira F, Hofman A, Weinans
H, Uitterlinden AG, Waarsing JH. Osteoarthritis Cartilage. 2013 Oct;21(10):1530-6.7
Chapter 3.2
Dual energy x-ray absorptiometry analysis contributes to the prediction of hip
osteoarthritis progression. Castaño-Betancourt MC, Linden JC, Rivadeneira F,
Rozendaal RM, Bierma-Zeinstra SM, Weinans H, Waarsing JH. Arthritis Res Ther.
2009;11(6):R162.
Chapter 4.1
Bone parameters across different types of hip osteoarthritis and their relationship to
osteoporotic fracture risk. Castaño-Betancourt MC, Rivadeneira F, Bierma-Zeinstra
SM, Kerkhof HJ, Hofman A, Uitterlinden AG, van Meurs JB. Arthritis Rheum. 2013
Mar;65(3):693-700.
Chapter 4.2
Association of lumbar disc degeneration with osteoporotic fractures; the Rotterdam
study and meta-analysis from systematic review. Castaño-Betancourt MC, Oei L,
Rivadeneira F, de Schepper EI, Hofman A, Bierma-Zeinstra S, Pols HA, Uitterlinden
AG, Van Meurs JB. Bone. 2013 Nov;57(1):284-9.
Chapter 5.1
Osteoarthritis as a risk factor for mortality: The Rotterdam study. Castaño-Betancourt
MC, Campos N, Dehghan A, Oei L, Hoeven T, Oei E, Rivadeneira F, Franco O, Hofman
A, Uitterlinden AG, Bierma-Zeinstra SM, Van Meurs JB. Manuscript in preparation.8
   
Int
rod
uct
ion
 Chapter 1
1.Introduction9
    10
   
Int
rod
uct
ion
 Osteoarthritis (OA) is the most common degenerative joint disease, characterized by
progressive damage of the articular cartilage, osteophyte formation and alterations in the
subchondral bone. OA is associated with an extremely high burden in terms of health and
economics on individuals, communities, and health systems; This burden is largely
attributable to the effects of disability, comorbid disease, and the expense of OA-
treatment [1,2]. According with worldwide estimates 9.6% of men and 18.0% of women
aged over 60 years have symptomatic osteoarthritis [3]. Hip and knee are joints
commonly affected by OA; in these joints, structural damage is accompanied by clinical
symptoms as joint pain, stiffness, loss of function and different degrees of disability. 
General aspects of hip osteoarthritis
Activity, Disability, Life Perception and Mortality 
OA has a major impact on physical and mental health of individuals. Hip and knee OA
have been strongly associated with increased disability and difficulty in activities of
daily life [4,5]. OA has also effects on individual’s mental health; subjects with OA
usually experience pessimism and distressing feelings as consequence of the pain and
difficulty in daily activities [6]. In general, individuals with OA report lower levels of
quality of life and a negative perception of life compared to individuals without OA [5-
7]. This might -in part- be due to difficulties and frustration of not being able to manage
the disease, especially the pain and disability. A total of 10% to 25% of the remaining
quality-adjusted survival of persons aged 50 to 84 years are lost due to knee OA [8].
More than 60% of individuals with OA have one or more comorbidity [7], which
contributes to an increased the burden of the disease and possibly leading to a shorter and
less-productive life. In this respect, it has been suggested that subjects with hip or knee
OA have a higher mortality risk compared with general population [8, 10, 11]. Together
all this evidence make OA one of the most important diseases in elderly that represents a
substantial loss in productivity and major costs for individuals and for our society.
Definition and Prevalence 
Prevalence of hip OA varies according to the definition and method used to evaluate the
affected joint. It also depends on the age and ethnic origin of the investigated population,
being radiographic OA higher in older individuals of Caucasian-origin and symptomatic
OA in African-American women [12,13]. There are many different definitions
circulating in literature; they can be divided into two major categories: the first is based11
    only on radiological evidence of joint damage, while the second category is defined by
both radiographical damage as well as clinical symptoms, such as pain and stiffness. For
definitions based on radiographic damage, several scoring systems exist, which mainly
focus on cartilage damage (seen at the X-ray as joint space narrowing: JSN) and
presence of bone spurs on joint margins (osteophytes). The Kellgren and Lawrence score
(KL) (Table 1a) and measuring of minimal Joint Space Width (mJSW) including Croft
score (Table 1b), are two of the radiological definitions most frequently used to evaluate
hip OA. Both methods show good reproducibility and strong association with joint pain,
being better for measure of mJSW [14-17]. A definition of OA based on the presence of
symptoms and radiographic alterations has been defined by the American College of
Rheumatology [18]. 
The severity and progression of hip OA is also commonly assessed by the methods
previously described: Kellgren and Lawrence and the degree of Joint Space Narrowing
(JSN) on radiographs, while Kellgren and Lawrence score appears as a strong predictor
of progression of hip OA defined only by the same method [19]. JSN has a higher
sensitivity detecting structural progression, pain and predicting future joint replacement
[20-22]. Changes in mJSW of at least 0.5 mm/year or 20% decrease compared to
baseline joint space in a period of two years have been presented as relevant change for
radiological progression of hip OA with clinical implications [22-24]. Several definitions
of hip OA have been used in epidemiological, clinical and genetic studies. This variety is
partially explained by the absence of successful pharmacological treatments and the lack
of knowledge regarding its etiological factors, leading researchers to explore other
alternative definitions. It is also due to the fact that a definition as KL implies several
underlying sub-phenotypes (osteophytes/ sclerosis/ narrowing/ joint replacement). Some
of them, may only be present in part of the population affected by OA, and maybe more
frequent in one gender.
Table 1a.  Kellgren and Lawrence grading system based on radiographic findings for OA.
A hip classified as KL grade 2 or higher is defined as being OA.
Grade Description
0 No osteoarthritis
1 Doubtful Possible narrowing of the joint space and possible osteophytes around
femoral head; or osteophytes alone.
2 Mild Definite narrowing of the joint space, definite osteophytes and slight
sclerosis.
3 Moderate Marked narrowing of the joint space, definite osteophytes, some sclerosis
and cyst formation and deformity of femoral head and acetabulum.
4 Severe Gross loss of joint space with sclerosis and cysts, marked deformity of
femoral head and acetabulum and large osteophytes.12
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 Table 1b.  Croft measurement of minimal Joint Space Width (mJSW) on radiographs.
Minimal Joint Space Width (mJSW) is the shortest distance between the femoral head and the acetabulum.
Heritability and familial aggregation
OA is a multifactorial disease with a significant genetic component that has been
demonstrated using twin-pairs and sibling risk studies. It has been estimated that
between 40-60% of risk for OA might be explained by genetic factors. However, there
are differences in the degree of heritability between different joints reported by these
studies, being for example higher for hip OA than for knee OA. In 2000, two different
genetic studies presented evidence of the high heritability and familial aggregation of hip
OA. A twins-study reported that genetic factors accounted for approximately 60% of the
variation in population liability to hip OA [25]. 
Additionally, hip OA has demonstrated a high familial aggregation which has been
estimated using sib recurrence risk [26]. Sib recurrence risk (λs) is the risk ratio for a
relative of an affected individual, compared with the population prevalence. In general,
someone having a first degree relative affected has between 4 to 6 times more chances of
having hip OA than someone without relatives affected [27]. A sib-pair study in ~600
index patients and sibpairs, found an age adjusted odds ratios in siblings between 4.9 and
6.4 for probable and definite hip OA, respectively [27]. Differences in risk estimates are
not only due to differences in OA severity but also between those receiving a THR and
those with just radiographic hip OA, suggesting that genetic influences are going beyond
the changes seen on a radiograph perhaps influencing clinical symptoms [27]. 
Differences in degree of heritability between joints and phenotypic differences displayed
in the same joint between affected individuals (explored along this thesis) point to the
fact that specificity, severity degree and correct discrimination between the phenotypes
that define the disease is needed to reduce heterogeneity when searching for the
implicated genes.
Grade Description
0 MJS>2.5mm
1 MJS>1.5 mm and ≤2.5mm
2 MJS≤1.5 mm13
    Risk factors for hip osteoarthritis and correlated traits
Genetics
Different methods have been explored trying to identify the genes associated with OA
that could explain its high heritability. Linkage and candidate gene studies have been
used in the last decades trying to elucidate the genetics of OA with a “relative success”.
In the case of hip OA, some genes received especial attention which were previously
found associated with chondrodysplasias and were related to collagen (COL2A1),
inflammation (IL1, IL4R, IL6), estrogen (ESR1), bone (LRP5, VDR), apoptosis
(ANP32A), in addition to genes found from linkage studies (DIO2, FRZB), as the most
cited in literature [29-34]. However, in spite of the plausible functionality of those
candidate genes, only modest associations with hip OA have been found, with
difficulties for the association to be replicated in general populations [35-37]. It might be
in part due to the few selected variants for candidate genes to be tested in a usually small
sample size. However, the limited success from candidate genes studies is also due to the
lack of understanding of the etiology of the disease. It does not allow establishing the
relevant biological pathways implicated and correctly define the set of genes to be tested.
OA is considered as a complex disease; complex in nature and of multi-factorial cause,
arising from a combination of environmental and numerous genetic factors (most of
which have not yet been identified). Complex diseases do not obey the single-gene
dominant or single-gene recessive Mendelian pattern of inheritance [38, 39]. They are
attributable in part to allelic variants present in more than 1–5% of the population (38).
Therefore, OA might be considered an oligogenic disease with several common and
uncommon variants from different genes that need to be discovered. Nevertheless,
difficulties finding the genes that explain the high heritability of complex diseases is not
specific for OA, it has been similar to other complex diseases [40]. 
Genome-wide association studies (GWAS) have been a successful approach to
investigate the association between common genetic variation, traits and diseases [40].
In fact until now, many significant associations have been found for common and/or
complex traits with common variants [41]. However, identification of genetic variants
robustly associated with OA at a genome-wide significant level (GWS=Pvalue≤5·0×10-
8) has been more difficult than for other diseases. Trying to search for OA-associated
genetic variants, GWAS on OA have used different phenotypes or a combination of them
trying to increase the power of the studies and/or trying to find common susceptibility
variants for OA at different joint sites (Hip OA by Kellgren and Lawrence (KL>=2),14
   
Int
rod
uct
ion
 Total Hip Replacement) (THR), Total Knee Replacement (TKR)). With the GWAS
approach, GDF5 and a locus on chromosome 7 were identified in association with hand
and knee OA in Caucasian, and not with hip OA [42-44]. GDF5 has been found
associated with hip OA only in Asian populations as it was a variant in DVWA [45].
Genetic associations differ between Asiatic and European descendants and in spite of
some concordance between knee and hip OA there is evidence of a genetic joint
specificity. Table 2 shows the variants that have been reported across several GWAS
performed until now, to be associated with hip OA at GWS level (Table 3). The locus on
chromosome 13 localized in the MCF2L gene was associated with hip and/or knee OA,
having stronger association with knee than with hip OA [46]. The last meta-analysis
including patients with severe OA (from the arcOGEN consortium), identified 6 novel
loci associated with hip and/or knee osteoarthritis at GWS level using different
radiological definitions [47]. 
Table 2. Genetic loci associated with Hip OA identified using the Genome Wide Association approach.
Results from these GWAS evidenced large heterogeneity, finding differences in the
effect of the variants reported between genders and joints. Finally, a two-stage meta-
analysis on more than 78,000 participants, recently discovered a new locus for hip OA
near the NCOA3 (nuclear receptor co-activator 3) gene [48]. 
SNP Chr. 
location
Nearest 
gene
Phenotype used Effect
OR(95%CI)
P value Ref.
rs11842874 13q34 MCFL2 Hip OA
(KL or THR)
1.11
(1.03–1.19)
3.54×10-03 42
rs10492367 12p27.9 PTHLH/
KLHDC5
Hip OA
(KL or THR)
1·14 
(1·09–1·20)
1·48×10-08 43
rs10948172 6p21.1 SUPT3H/
CDC5L
Hip OA
in males
1·14 
(1·09–1·20)
7·92×10-08 43
rs9350591 6q12 FILIP1/
SENP6
Hip or Knee OA 1·18 
(1·12–1·25)
2·42×10-09 43
rs11177 3p21.1 GLN3 THR or TKR 1·12 
(1·08–1·16)
1·25×10-10 43
rs4836732 9q33 ASTN2 THR–female 1·20 
(1·13–1·27)
6·11×10-10 43
rs835487 12q24.1 CHST1L THR 1·13 
(1·09–1·18)
1·64×10-08 43
rs12982744 19p13.3 DOT1L mJSW and Hip
OA-in males
1·17 
(1.11-1.23)
7.8×10-09 This 
thesis
rs6094710 20q13.1 NCOA3 Hip OA 1.28        
(1.18-1.39
5.6x10-08 4415
    Bone Related Factors
Hip Geometry. Biomechanical factors seem to have an important role in the
development and progression of hip OA. The shape of the joint, including geometrical
variance results in differences in biomechanical loading patterns in the joint. First
evidences on the relation of OA and incongruence in hip morphology were presented in
Wiberg’s doctoral thesis about dysplasia in 1939 [49]. In hip with dysplasia, the majority
part of the femoral head is not covered by the acetabulum (Figure 1a). Later on,
dysplasia was presented as a potential factor for development of hip OA in younger and
older individuals [50-52]. On the other hand, excessive coverage or retroversion of the
acetabulum known as Coxa profunda deformity (the floor of the acetabulum touches the
ilio-ischial line) will affect the normal spatial relationship between the femoral head and
the acetabulum restricting flexion of the femoral neck [53]. Coxa profunda has been
mentioned as one of the possible causes of impingement [53], other type of incongruence
between femoral head and acetabulum. Impingement has also been related to hip OA in
younger and older populations [54-57]. Different types of impingement at the hip joint
can occur (Figure 1b & 1c). Additionally, wider femoral neck and differences in the
external shape of the hip joint have been found to be associated with prevalent and
incident cases of hip OA [58-59]. 
                                                                            
Figure 1 Dysplasia and different type of impingement of the hip joint. a). Radiograph shows a decreased 
(abnormal) Wiberg or Center Edge Angle <15 degrees. b). Radiograph shows a typical Cam impingement at 
the transition between femoral head and neck. c). Radiograph shows a mixed impingement with a Cam 
deformity at the transition between femoral head and neck and a pincer deformity at the acetabular roof. 
Other geometry measures analyzed in relation with hip OA have been less studied and
include pelvic, acetabular and hip size measures and angles: femoral head, neck length
and/or hip axis length, pelvic width, offset (distance between the center of femoral head
(a)a)a) c)b)16
   
Int
rod
uct
ion
 and the most lateral point of the major trochanter) and neck shaft angle (represent the
inclination of the femoral head respect to the vertical axis), between others. 
Recently, Statistical Shape Modeling (SSM) has been used to measure the differences in
hip morphology in relation with hip OA. SSM is a comprehensive method to quantify the
external shape of an object in this case the hip joint, including acetabulum and pelvis in
the radiographic images. SSM analysis has identified different types of variations of
femoral shape associated to clinical or radiological hip OA [59, 60].
Bone Mineral Density (BMD) and Fractures. In the last years, more attention was
given for the role of subchondral bone changes in the initiation of OA. Not only changes
in bone shape as previously described but, also bone mineral density (BMD) and
subchondral bone mechanical properties differences have been reported in the presence
of radiographic signs of hip OA [61-63]. Not only locally increased density of
subchondral bone, but also systemically higher BMD have been reported in the presence
of radiographic signs of hip OA. There is accumulated evidence that a higher BMD is
associated to an increased risk for radiographic OA in hip, knees, spine and hands [64-
68]. BMD changes have been found near the affected joint (for example increased FN-
BMD in hip OA patients), and also at other distant skeletal sites in patients with
radiographic OA. It has been widely discussed whether higher BMD plays a role in OA
development or progression. This relationship can be studied using genetics. It might be
that common pathways play a role in BMD and OA. In a recent study it was shown that;
the association between lumbar disc degeneration and BMD is attributable to variants in
common genes [68]. The possible pleiotropic genes implicated in this relation need to be
investigated. Although higher BMD is a protective factor for osteoporotic fractures. OA
and osteoporosis can co-exist [66, 69,70] and some reports even suggested that subjects
with OA may have increased fracture risk [71-73]. 
Growth and Developmental OA-associated factors
Hip Joint Development
Human hip development is an ordered and sequenced processes that starts with the
formation of the limb bud at 4 weeks of life, followed by extensive cell multiplication
and differentiation where primitive chondroblast condense at proximal, central and distal
centers which will fusion to model the femur [74]. Although hip differentiation continues
until approximately 20 weeks of development, the major anatomic structures of the hip
are visible microscopically by the eighth week (Figure 2) [75]. During this initial bone17
    development, the mesenchyme receives patterning signals that determine the shape, size
and number of mesenchymal condensations [76]. Cells in the condensations differentiate
into chondrocytes. These chondrocytes deposit an extracellular matrix that is cartilage-
specific, undergo unidirectional proliferation forming vertical columns, exit the cell
cycle becoming hypertrophic and die. This sequence of events is responsible for the
longitudinal bone growth and hip joint formation [77]. The pathways of chondrocyte and
osteoblast differentiation are thus interconnected during endochondral bone formation
and must be coordinated. 
Key transcription factors and signalling molecules coordinate this complex process of
chondrocyte and osteoblast differentiation. Molecules that provide such patterning
information are polypeptides of the Wnt, Hedgehog, fibroblast growth factor (FGF),
Parathyroid hormone related peptide (PTHrP) and the TGF-β superfamily (including
BMPs subfamily also called Growth and differentiation factors (GDFs), epidermal
growth factor (EGF) that is antagonistic to BMPs (78), as well as a series of transcription
factors of the Hox, Pax, homeodomain- containing, Forkhead and basic helix–loop–helix
(bHLH) families and SMAD factors [76, 79].
Consequently, any change or disturbance of this coordinate differentiation process of
cartilage and bone might have important consequences on bone and cartilage including
differences in bone size (height) defects in cartilage and bone structure, maintenance
and/or healing that depending of its severity might be found at birth (chondrodysplasia)
or later in life as higher risk for bone and cartilage diseases as OA. 
Association of Height with OA
Epidemiological and genetic studies have associated height with the risk of OA; it has
been found that individuals of short stature are at higher risk for hip and knee OA [44,
80]. Since bone and cartilage tissue share a common process of endochondral bone
formation during growth and development, the hypothesis of common biological
pathways regulating variation in both (OA and height) seems very plausible [81-83]. 
Common variants in the OA-associated locus GDF5 contribute to variation in height and
increase susceptibility to hip and knee OA in Asian and European populations [83-85].
GDF5 is part of the TGF beta signalling pathway and is involved in the development of
cartilage in the legs and other long bones. SMAD3 is another example of a gene where
genetic variants are involved in both OA and height. Early-onset joint abnormalities,18
   
Int
rod
uct
ion
 including OA have been reported in subjects with mutations in SMAD3 gene [82, 86].
SMAD proteins function as a transcriptional modulator activated by transforming
growth factor-beta. Common genetic variations in the TGF-beta signalling pathways
have been reported as significant contributors to height differences [87]. 
However, there are more factors and possibly other unknown variants that might
contribute to explain the association between height and OA. Despite advances in
understanding the molecular processes that underlie joint development and growth the
discovery of new variants and genes implicated in both traits: height and OA will give a
better understanding of these mechanisms.
AIM AND OUTLINE
The main objectives of this thesis were: 1) To identify genetic and bone-related risk
factor for hip OA using quantitative and qualitative OA-endophenotypes and 2) To
determine the risk for osteoporotic fractures and mortality in subjects with OA. Chapter
2, consists of three studies focusing on the identification of common genetic variants
associated with joint space width and hip OA. The first analysis on minimal joint space
width identified variants in DOT1L associated with cartilage thickness and OA (Chapter
2.1), a final meta-analysis of minimal joint space width discovering new variants
associated with both, cartilage thickness and hip OA (Chapter 2.2) and a bivariate
analysis of joint space width and height (Chapter 2.3). Chapter 3 contains two studies
analysing the contribution of two bone related factors: hip geometry (Chapter 3.1) and
bone mineral density (Chapter 3.2) in the prediction of hip OA. Chapter 4 analyses the
osteoporotic fracture risk in subjects with different types of hip OA (Chapter 4.1) and
lumbar disc degeneration (Chapter 4.2). Chapter 5, will describe the association of hip
and knee OA with mortality and how different comorbidities have an important role in
this relation. Finally, Chapter 6 will provide a general discussion.19
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    ABSTRACT
Hip osteoarthritis (OA) is one of the most disabling and common joint disorders with a
large genetic component which is, however, still ill defined. To date, genome-wide
association studies (GWAS) in OA and specifically in hip OA have yielded only few loci,
which is partly explained by heterogeneity in the OA definition. Therefore, we here fo-
cused on radiographically measured joint space width (JSW), a proxy for cartilage thick-
ness and an important underlying intermediate trait for hip OA. In a GWAS of 6,523
individuals on JSW of the hip, we identified the G-allele of rs12982744 on chromosome
19p13.3 to be associated with a 5% larger joint space width (P = 4.8×10-10). The associa-
tion was replicated in 4,442 individuals from 3 UK-cohorts with an overall meta-analysis
P value of 1.1×10-11. The SNP was also strongly associated with a 12% reduced risk for
hip OA (P =1×10-4). The SNP is located in the DOT1L gene, which is an evolutionarily
conserved histone methyltransferase, recently identified as a potentially dedicated en-
zyme for Wnt target gene activation in leukemia. Immunohistochemical staining of
DOT1L protein in mouse limbs supports a role for DOT1L in chondrogenic
differentiation and adult articular cartilage. DOT1L is also expressed in osteoarthritic ar-
ticular chondrocytes. Silencing of Dot1l inhibited chondrogenesis in vitro. Dot1l knock-
down reduces proteoglycan and collagen content, and mineralization during chondrogen-
esis. In the ATDC5 chondrogenesis model system, DOT1L interacts with TCF and Wnt
signalling. These data are a further step to better understand the role of Wnt-signaling
during chondrogenesis and cartilage homeostasis. DOT1L may represent a therapeutic
target for OA. 
INTRODUCTION
OA, the most common, age-related disease of the synovial joints, results in a substantial
reduced quality of life due to pain and disability. Current clinical management of OA fo-
cuses on pain control. In severe cases, joint prosthesis surgery may be the unique solution.
There are currently no targeted therapies that maintain homeostasis of the joint or stimu-
late cartilage repair. OA is characterized by progressive destruction of articular cartilage,
subchondral bone sclerosis and osteophyte formation and has a large genetic component,
which varies between the joint studied (1). Several GWAS on OA have been published,
but up to now few signals have been identified with reproducible association (2-6). In
Caucasians, only 3 loci reach the genome wide significance threshold. These include a
variant influencing expression of GDF5 (2-3) a locus on chromosome 7q22 near the or-
phan receptor GPR22 (4-5) and a variant in MCF2L (6). The low number of identified loci
can be explained by relatively low power caused by insufficient sample sizes and by phe-31
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    notype heterogeneity, which is a well-known problem in epidemiology of OA (7). The di-
agnosis of OA is based on a combination of parameters including both clinical features
(pain and stiffness) as well as a structural damage score (the most widely used is the Kell-
gren & Lawrence score), which includes formation of new bone spurs (osteophyte forma-
tion) and reduction of the joint space width (JSW) indicating cartilage degradation. JSW
is considered to be the surrogate for cartilage thickness in the joint and change in minimal
JSW is the primary structural endpoint used in clinical trials and epidemiological studies
of knee and hip OA (8-10). In this study we combined GWAS and functional studies to
identify new genes involved in cartilage thickness and OA. We first performed a discov-
ery GWAS on minimal JSW (mJSW) of the hip in 6,523 participants from the Rotterdam
cohorts I and II (RS-I and RS-II) and replication included population from three indepen-
dent UK studies (n=4,442) in which mJSW was measured (Table S1 for cohort specifics).
Additionally, we analyzed association of the genetic variants with hip OA in 3,717 cases
and 10,013 controls. Further, we carried out functional genetic studies using cell culture
experiments in human and mouse tissues. 
RESULTS
A GWAS on mJSW of the hip was performed in 6,523 participants from the Rotterdam
cohorts I and II (RS-I and RS-II, see Table S1 for cohort specifics). We applied extensive
quality control measures (see Table S2 for details on quality control and exclusion crite-
ria) leaving a total of 2,455,290 SNPs for association analysis. Genomic control inflation
factors for the P values of the RSI and RSII GWAS were low (lambda = 1.02 and 1.01
respectively), and the interquantile-quantile plot (Fig. S1) also indicated no substantial
population stratification due to cryptic relatedness, population substructure or other
biases. 
After meta-analyzing the association results of RS-I and RS-II, we identified a significant
association on chromosome 19 that satisfied our genome-wide significance (GWS)
threshold of P < 5×10-8 (Fig. 1a). A total of 18 SNPs were GWS and clustered around 1
locus on chromosome 19p13.3. The top SNP rs12982744 (P = 4.5×10-10) is localized in
the first intron of the gene DOT1-like, histone H3 methyltransferase (DOT1L). This SNP
is in high LD with the other 17 GWS SNPs representing the same signal (Fig. 1b). We
additionally found 8 loci with suggestive evidence for association (5×10-8 < P <1×10-5,
Table S3).  To validate the association with DOT1L, we performed a replication study us-
ing three independent UK studies: TwinsUK, Chingford, and GOAL (n=4,442 in total, see
Table S1 for details).32
    Figure 1a  Association results by chromosome. The -log P -values for each of the 2.5 million tests performed 
as part of the genome-wide association of Minimal Joint Space (MJS) of the hip. The black solid horizontal line 
corresponds to P-value threshold of 5×10-8 (genome-wide significance). 
Figure 1b  Regional association plot for the novel locus of joint space width (19 p31.3). SNPs are plotted by 
position in a 400kb window against association with mJSW (–log10 p). The purple diamond highlights the 
most significant SNP in discovery analysis. Blue peaks indicate recombination rates. The SNPs surrounding 
the most significant SNP are color coded to reflect their LD with this SNP (from pairwise r2 values from the 
HapMap CEU). Genes, exons and the direction of transcription from the UCSC genome browser are depicted 
underneath the plot.
Association between rs12982744 and mJSW in the replication cohorts was analysed by
linear regression including age and gender as covariates. The association of rs12982744
with mJSW was replicated (beta: 0.07 mm/allele; P = 9×10-3, Figure 2).
Results from the Rotterdam Studies and the replication cohorts were combined in a joined
meta-analysis. The combined analysis including discovery and replication studies showed
strong evidence for association of the DOT1L locus with mJSW in the general population
0
1 2 3 4 5 6 7 8
chromosome
9 10 11 12 13 14 15 16 17 18 19 20 21 22
2
4
6
-lo
g 
  (
P)
10
8
1033
Ch
apt
er 
2.1
    (beta: 0.09 mm/allele; P =1.1×10-11, I2=0%). These associations were corrected by age and
gender. The minor G-allele of rs12982744 (MAF=0.39) is associated with an increased
joint space width of 0.09 mm per copy of the G allele. This implicates that homozygote
carriers of the rs12982744 G-allele have approximately 5% thicker cartilage than the
reference group. 
We further investigated whether rs12982744 was influencing the risk for hip OA. This
was examined in all the five studies described previously and one additional large
case-control study (Nottingham); the total sample size was 3,717 cases and 10,013
controls for this analysis (Table S1). Risk for hip OA was calculated using logistic regres-
sion analysis and was adjusted for age and gender. As shown in Fig. 3, the minor allele of
rs12982744 was significantly associated with a 12% reduced risk for hip OA (O.R: 0.88,
CI: 0.82-0.94; P = 1.5×10-4, I2=0%; analysis adjusted for age and gender), with consistent
effects in all cohorts studied. Additional adjustment for height did not affect the
association (O.R: 0.88, CI: 0.82-0.94; P = 1.1×10-4). We observed that also in people
without radiographic hip OA, the association with mJSW was present (Table S4,
beta: 0.06 mm, SE: 0.011; P =7.3×10-9). This suggests that the association with cartilage
thickness is present already before onset of OA, and possibly implicates involvement of
this DNA-variant on the articular cartilage during development and growth.
Figure 2 Forest Plots for rs12982744. Black squares represent effect estimate and 95%CI for each study, and 
the red diamond is a summary effect estimates. Minimal joint space width measurements units are in 
millimeters.
The G allele of the identified SNP (rs12982744) was previously found to be associated
with increased height (11). This is in line with the thicker cartilage that was found in the
current study. We therefore tested whether our findings with mJSW were affected by dif-
ferences in stature, by including height as a covariate in the analysis. This did not substan-
tially change the results. It suggests that this locus has independent pleiotropic effects on
height as well as mJSW of the hip.
Study                  Beta (95%CI)        p-Value
Beta (95%CI)
Discovery
GOAL
TwinsUK
Chingford
Replication
Summary
0,09 (0,06-0,12)
0,09 (-0,01-0,18)
0,10 (0,00-0,21)
0,04 (-0,04-012)
0,07 (0,03-0,11)
-0,25 0,250
0,09 (0,06-0,11)
4,8x10-10
0,07
0,05
0,35
9,0x10-3
1,1x10-1134
    Figure 3 Risk for Hip OA. Values represent odds ratios (OR) and 95% confidence intervals (95%CI).
The associated polymorphisms are annotated in the DOT1L gene (Fig. 1b). DOT1L is an
evolutionarily conserved histone methyltransferase, identified as an essential and
dedicated enzyme for Wnt target gene activation in the intestine and needed for the
expression of genes that require high levels of Wnt signaling in Drosophila (12-13). We
hypothesized that DOT1L is the culprit gene underlying the association with mJSW and
height by influencing chondrogenic differentiation, which is important in growth and joint
formation. We examined the function of Dot1l during chondrogenesis in ATDC5 cells
which exhibit a multistep process of chondrogenic differentiation analogous to that ob-
served during endochondral bone formation (14-15). As depicted in Fig. 4a and Fig. S2,
ATDC5 cells stably-transfected with plasmid overexpressing shmiRNA directed against
Dot1l (Dot1l-) synthetized less sulphated proteoglycans than control cells, demonstrated
by the weaker Alcian blue and safranin O staining, respectively decreased by 1.35- and
2.5-fold. Moreover, mineralization in the micromasses was less efficient, as shown by the
1.4-fold decrease in Alizarin Red staining, which was restricted to the core of the micro-
masses in Dot1l- cells. Collagen content, revealed by Sirius red staining, was also 1.8 fold
reduced in these cells. These data indicate that chondrogenesis is severely affected by
Dot1l knock-down. These observations were supported by mRNA analyses. Indeed, type
II collagen expression was not increased in cells with Dot1l knock down, while type X
collagen and aggrecan induction was 3.3-fold and 4-fold reduced compared to normal
ATDC5 cells (Fig. 4b). Interestingly, type I collagen levels were 1.7-fold higher in Dot1l-
cells at D21. Moreover, evaluation of matrix metalloproteinases (MMPs) mRNA level al-
lowed to show a different pattern in Dot1l- cells compared to controls, as seen in Fig. S3.
Indeed, Mmp9 expression was dramatically increased in Dot1l- cells (35-fold increase at
D21), while Mmp13 was decreased by 1.7-fold at the same time. Mmp2 expression did
not differ between Dot1l- and controls.
Study               OR (95%CI)         p-Value
OR (95%CI)
0,5 21
RS-l 0,85 (0,76-0,95) 4x10-3
Summary 0,88 (0,82-0,94) 1x10-4
RS-ll 0,91 (0,72-1,15) 0,42
GOAL 0,92 (0,81-1,05) 0,23
TwinUK 0,78 (0,50-1,20) 0,25
Chingford 0,76 (0,54-1,06) 0,11
Nottingham 0,89 (0,78-1,01) 0,0835
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    Figure 4 Functional analysis of Dot1l during chondrogenesis. Stable ATDC5 clones were established using 
either the control noninterfering pGIPZ or the pGIPZ-shmiRNA directed against mouse Dot1l. Three different 
antibiotic-resistant clones were selected. Knockdown efficiency was assessed by quantitative RT-PCR. Stably-
transfected ATDC5 clones were cultured as micromasses as described previously (14, 15). Each condition was 
performed in triplicate. Total RNA from was isolated after 1, 7, 14, or 21 d. Data presented are representative 
of the three independent clonal colonies. Results are expressed as the mean ± SD of three independent 
replicates. Comparisons were made by ANOVA, followed by Fisher’s t post hoc test. Statistically significant 
differences vs. day 1 are indicated as *P < 0.05, and vs. control-transfected cells as #P < 0.05.
Figure 4a Dot1l knock-down reduces proteoglycan and collagen content, and mineralization during 
chondrogenesis. Stainings were performed on ATDC5 micromass cultures stably transfected with either control 
or Dot1l shmiRNA producing vector, over 21 days (D). ( AB = Alcian blue, SO = safranin O, AR = alizarin 
red, SR = sirius red).
Figure 4b Dot1l knock-down reduces mRNA expression of markers of chondrogenesis. mRNA levels were 
normalized to S29 (reference gene) (n=3). Quantitative Real-Time PCR conditions and primers are available 
upon request.
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    Figure 4c Dot1l knock-down affects Wnt signaling during chondrogenesis. mRNA levels of Wnt target genes 
Tcf1 and osteocalcin were normalized to S29 (reference gene) (n=3).
Figure 4d DOT1L interacts with the Wnt signaling pathway transcription factor TCF4. 
Coimmunoprecipitation of DOT1L and TCF4 using 100 µg of total proteins (input) from micromass cultures 
(at day 7 – D7) of either control or Dot1l knocked-down cells. Proteins were isolated from ATDC5 
micromasses. CoIPs were performed and 20 µl of elution fraction was probed after protein binding on either 
mock (donkey anti-goat IgG) or TCF4 column-immobilized antibody.
Figure 4e DOT1L is expressed during joint development and in mature articular cartilage of mice. 
Immunohistochemistry on paraffin embedded EDTA decalcified adult knee sections and non-decalcified 
embryonal sections, was performed with rabbit anti-Dot1L antibody (5µg/ml). After overnight incubation of 
the sections at 4°C, 1:100 peroxidase goat anti-rabbit IgG was applied and peroxidase activity was determined 
using DAB. In the developing limb (E15.5), expression was detected in resting (R), proliferating (P), 
prehypertrophic (PH) and hypertrophic (H) chondrocytes, as well as in the mesenchyme surrounding the bones 
(M). Immunohistochemistry also detected expression in articular cartilage chondrocytes in healthy mice knee 
(age 9 weeks). IgG as a negative control is also shown.
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    Because DOT1l was previously linked to beta-catenin signaling, we investigated
whether mRNA expression of Wnt target genes was affected in Dot1l- cells. As seen in
Fig. 4c, Tcf1 levels (positively regulated by Wnt/β-catenin signaling) were increased in
control ATDC5s at D7 (2.5-fold), but no induction was detected in Dot1l- cells. Other
Wnt target genes Axin2 and c-Myc followed the same pattern (Fig. S4). Moreover,
Osteocalcin level (negatively regulated by Wnt/β-catenin signaling) was increased by
2.8-fold at D21 in control cells, but the up-regulation was of 6.2-fold in Dot1l- ATDC5s
(2.2-fold more than in control cells). Taken together, these elements suggest a role for
DOT1L in the Wnt/β-catenin signaling cascade in developing chondrocytes.
Co-immunoprecipitation experiments strengthened these observations, as DOT1L was
found to directly interact with Transcription Factor 4 (TCF4), a transcription factor inter-
acting with β-catenin (Fig. 4d). These functional analyses seemed relevant in vivo, be-
cause DOT1L is very strongly present during chondrogenesis in mouse developing limbs
and still found in articular cartilage as seen in Fig. 4e. Interestingly, DOT1L mRNA was
clearly detected in adult human chondrocytes freshly extracted (without any passage)
from articular cartilage obtained from patients with osteoarthritis (Fig. S5).
DISCUSSION
This study identified a genetic variant in the DOT1L gene robustly associated with joint
space width and hip OA. We used an in vitro chondrogenesis model and ex vivo expres-
sion studies in mice to functionally characterize the role of Dot1l in chondrogenesis. We
found that DOT1L is involved in chondrogenic differentiation presumably through its role
in canonical Wnt-signaling.
DOT1 is an evolutionarily conserved histone methyltransferase, which was initially
identified as a disruptor of telomeric silencing in Saccharomyces cerevisiae (16). The
mammalian homolog, DOT1L, has been shown to be required for embryogenesis,
hematopoiesis, and cardiac function (17-20). DOT1L was recently identified as an essen-
tial and dedicated enzyme for Wnt target gene activation in the intestine and needed for
the expression of genes that require high levels of Wnt signaling in Drosophila (12-13).
We are unique providing evidence that demonstrate a role for DOT1L in chondrogenesis.
Knock down of Dot1l resulted in a reduced chondrogenic differentiation in the
ADTC5-cells. We additionally observed a pronounced reduction in expression of
Wnt-targeted genes. Together with the proven physical interaction of DOT1L and TCF4
proteins, this suggests that Dot1l influenced chondrogenic differentiation by regulating38
    transcription of Wnt target genes. The differential effect of Dot1l silencing on different
MMPs further highlights its complex role in cartilage biology. 
Wnt signaling is critical in the formation of cartilage and bone and in the development of
the synovial joint (21) Mutants in the Wnt have been shown to cause developmental ab-
normalities early in life (see for example WNT3 (22)). Variants with a less dramatic effect
on function, such as the one discovered in this study, result in a mild phenotype with late
onset. The same has been observed in the BMP-signaling pathway (another key develop-
mental pathway). Mutations in the GDF5 gene result in severe chondrodysplasia and skel-
etal malformations (23), while a milder variant that influences GDF5 expression levels,
results in a slightly elevated risk for knee OA later in life (2, 24). 
The exact same variant that we found associated with cartilage thickness has previously
been found associated with height both in young and old individuals (11, 25), which sug-
gests a role in skeletal formation. Although the specific differentiation process in the
growth plate and articular cartilage are different, common signaling pathways such as the
Wnt cascades are involved (26). Interestingly the association between the DOT1L genetic
variant and cartilage thickness was present also in people without OA. This indicates that
the association with cartilage thickness is present already before onset of OA, and
possibly implicates involvement of this DNA-variant on normal formation of the articular
cartilage during development, in agreement with a role for this variant in skeletal
development.
OA is a complex disease with a large genetic component. Twins studies have shown that
the influence of genetic factors for hip OA is about 60% (1). Nevertheless, it has been
difficult to find genes involved in OA and especially in hip OA. From the few genetic sig-
nals found, only one has shown a modest association with hip OA (6). GDF5 polymor-
phisms (3) and a locus on chromosome 7q22 near the GPR22 gene (4) have been
consistent associated with knee OA only across different European populations. Recently,
a locus on chromosome 13 localized in the MCF2L gene that regulates a nerve growth fac-
tor (NGF) points to pronounced association with OA affecting the knee and less signifi-
cantly for hip OA (6). These few signals have been found using the traditional composite
definitions of OA, which have features of structural damage to the joint (Kellgren and
Lawrence score of 2 or more including joint replacement) as well as clinical parameters
such as pain. This may lead to considerable heterogeneity and consequently low power. 
In the case of HOA, where degeneration of articular cartilage is the most important
feature, the approach to identify genetic variants of OA studying only one of the39
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    components of the physiopathology (cartilage thickness) can result in less heterogeneity
in the phenotype definition and therefore in more power to pick up true signals. Both,
intrarater and interrater reliability has been significantly higher for joint space measure-
ment than for KL (10, 27) and the findings that decline of JSW in OA proceeds in a linear
manner (28) and that JSW is predictive of long- term progression of joint space narrowing
(29) make measurement of JSW suitable for clinical trials and prioritize the identification
of genes responsible for cartilage formation and homeostasis. 
The effect we report of the DOT1L variant on cartilage thickness is modest, similar in
magnitude to most of the identified variants involved in risk of complex diseases.
Consequently, one might prematurely anticipate that the clinical relevance for this variant
is by default small. However, the effect size of an identified variant does not necessarily
reflect importance of the gene for a disease. Variants that strongly disrupt pivotal genes
are unlikely to result in a late onset disease that affects 40% of the population over the age
of 70. As DOT1L function is linked to Wnt signaling, genetic variation may not only
contribute to cartilage thickness with reduced cartilage volume, a likely risk factor for OA
development, but also to the deleterious processes that are activated when osteoarthritis is
progressing. Accordingly, DOT1L might be a target for the design of new
anti-osteoarthritis drugs that could be used in the prevention and treatment of OA.
Additionally, carriers of DOT1L variant might have a different response to possible treat-
ments targeting cartilage repair.
Another potential application of OA genetics is improved measurement of the disease
process in combination with other variants of modest but consistent effect forming a
"genetic risk score". A previous study has suggested that when several genetic markers
are added up, the aggregated genetic risk is substantial and similar in magnitude to clas-
sical risk markers such as obesity or knee injury (30) and which may help to identify
individuals at risk of OA years before disease onset.
Our results are not directly generalizable to other ethnicities, such as the Asian population.
Asian populations have a high prevalence of large joint OA despite a much lower
prevalence of obesity, suggesting etiological differences with regards to European-
descent patients. Specifically, strong evidence of heterogeneity in the genetic contribution
to OA between Asian and European populations has been widely reported (3, 31-34).
In particular, no loci influencing hip OA have been consistently reported in both ethnic
groups. Although the lack of inclusion of Asian patients may reduce the generalizability
of our results, it has the advantage, (by concentrating on a clearly defined phenotype in40
    homogenous Caucasian samples of Dutch and UK origin) of reducing heterogeneity and
thus achieving sufficient statistical power.
Considering the known important function of Wnt signaling pathway in cartilage and
bone formation and the role of DOT1L in chondrogenesis here presented, DOT1L may
represent a therapeutic target for modulation, and thus therapeutic intervention in
OA. It is apparent that DOT1L and its associated methylation activity are regulated in an
extremely complex way. As such, the regulation of DOT1L activity and the functional
consequences of manipulation of DOT1L need to be further elucidated before efficient
treatments can be developed. Future studies are therefore warranted to determine how to
target DOT1L in a selective and tissue specific manner. There are already initiatives for
targeting DOT1L in other pathologies, having in mind that DOT1l has a key role in other
normal cellular processes (35). This might represent an exciting opportunity for the de-
velopment of disease modifying drugs for OA.
MATERIALS AND METHODS
GWAS Meta-analysis. Genotyping of the samples in the discovery cohorts (RS-I and RS-
II) was carried out with the Illumina HumanHap 550v3 Genotyping BeadChip. The
Beadstudio GenCall algorithm was used for genotype calling and quality control proce-
dures, as described previously (36). The following quality control inclusion filters were
applied: call rate >=97.5%, MAF >=1%, P for Hardy-Weinberg equilibrium <1×10-6 (See
Table S2 for details on quality control and exclusion criteria). The total number of geno-
typed SNPs that passed these filters was 512,349 for RS-I and 466,389 for RS-II. Impu-
tation was done with reference to HapMap release 22 CEU using the maximum likelihood
method implemented in MACH (http://www.sph.umich.edu/csg/abecasis/MACH/in-
dex.html). Analysis of imputed genotype data accounted for uncertainty in each genotype
prediction by using the dosage information from MACH. For this analysis, MACH2QTL,
was used via GRIMP (37), which uses genotype dosage value (0–2, continuous) as a pre-
dictor in a linear regression framework. Genomic control correction was applied to the
standard errors and P-values before meta-analysis. We included only imputed SNPs that
had a good imputation quality leaving a total of 2,455,290. The summary statistics of
RS-I and RS-II were meta-analysed using METAL applying inverse-variance
methodology assuming fixed effects with Cochran's Q and I2 metrics used to quantify
between-study heterogeneity (www.sph.umich.edu/csg/abecasis/metal). The medical eth-
ics committee of Erasmus University Medical School approved the study and written in-
formed consent was obtained from each participant. 41
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    Replication Analysis. All samples from the TwinsUK cohort for this study were
genotyped with the HumanHap610Q (Illumina). The following quality control filters
were applied: call rate >=98%, MAF >=1%, P for Hardy-Weinberg equilibrium <1×10-6
(Table S2). The total number of genotyped SNPs that passed these filters was 598,207
SNPs. Imputation was done with reference to HapMap release 22 CEU using the IM-
PUTE software package (v2) (38). For the GOAL, Nottingham and Chingford study
participants, genomic DNA was extracted from peripheral blood leukocytes of affected
individuals and controls using standard protocols. Genotyping was carried out by
Kbioscience Ltd. SNPs were genotyped using the KASPar chemistry, which is a compet-
itive allele-specific polymerase chain reaction (PCR) SNP genotyping system using fluo-
rescence resonance energy transfer (FRET) quencher cassette oligos.
Association between rs12982744 and mJSW in the replication cohorts was analysed by
linear regression including age and gender as covariates. In addition, separate analyses
were carried out including age, gender and height as covariates. The R version 2.10.1 (The
R Foundation for Statistical Computing http://www.r-project.org/) was used for analysis.
Results from the Rotterdam Studies and the replication cohorts were combined in a joined
meta-analysis using inverse variance weighting with METAL as described before.
We declared results genome wide significant at =5×10-8 after adjusting for all common
variant tests in the human genome.
The replication studies were approved by the respective institutional review board and
informed consent was obtained from all participants involved.
Cell Culture Experiments. ATDC5 cells were cultured in growth medium (1:1 mixture
of Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium) (Gibco) containing
1% antibiotic-antimycotic (Gibco), 5% fetal bovine serum (Gibco), 10 µg/ml human
transferring (Sigma) and 3 × 10-8 M sodium selenite (Sigma). Cells were maintained in a
humidified atmosphere of 5% CO2 and 95% O2 at 37 °C.
Stable ATDC5 clones were established using either the control non-interfering pGIPZ
(Thermo Fisher) or the pGIPZ-shmiRNA directed against mouse Dot1l construct
(Thermo Fisher). Arrest-In transfection reagent (Thermo Fisher) was used for
transfection. After 24 hours, selection with 1 µg/ml puromycin (Invitrogen) was initiated
and continued for 10 days. In the end, three different antibiotic resistant clonal colonies
were isolated and grown independently. Knock-down efficiency was assessed by
qRT-PCR.42
    Stably-transfected ATDC5 clones were cultured as micromasses: trypsinized cells were
resuspended in medium at a concentration of 2×10-7 cells/ml. Three drops of 10 µl of this
cell suspension were placed in a well of a standard 24-well culture plate. The cells were
allowed to adhere for 3 h at 37 °C, and then 0.5 ml medium was added to each well. For
induction of chondrogenesis, the cells were cultured in growth medium containing 1% an-
tibiotic-antimycotic, 5% fetal bovine serum, supplemented with an ITS premix containing
10 µg/ml insulin, 5 µg/ml human transferrin and 3×10-8 M sodium selenite for 2 weeks
(Gibco). 5 µg/ml human transferrin (Sigma) was additionally added to reach a final con-
centration of 10 µg/ml. Alpha-MEM medium (Gibco) containing 5% fetal bovine serum
(Gibco), and the same mix of insulin, human transferrin and sodium selenite was added
supplemented with 7 mM beta-glycerolphosphate (Sigma) from day 14 until day 21. The
medium was replaced daily. Each condition was performed in triplicate. Total RNA from
ATDC5 cell micromasses was isolated after 1, 7, 14 or 21 days in culture using the
Nucleospin RNA II kit (Macherey-Nagel). Some ATDC5 micromasses were fixed in 95%
ice-cold methanol for 30 minutes at 4°C. After washing with water, they were stained for
1h in either Alcian Blue (0.1% Alcian Blue 8GX, (Sigma) in 0.1 M HCl pH 0.2), Safranin
O (Klinipath), Alizarin Red (1% Alizarin Red S (Sigma) in water pH 4.2) or Sirius Red
(0.1% Direct Red 80 (Sigma) in a saturated aqueous solution of picric acid). To remove
unbound staining, cells were washed with water until the washing solution remained
colourless. 
Co-Immunoprecipitation (CoIP) Analyses. Proteins were isolated from ATDC5
micromasses using the IP Lysis/Wash buffer (Thermo Fisher) supplemented with 5% Pro-
tease Cocktail Inhibitor (Sigma) and 1 mM phenylmethanesulfonyl (Sigma). After two
homogenization cycles (7 sec) with an ultrasonic cell disruptor (MicrosonTM, Misonix),
total cell lysates were centrifuged 10 min at 13,000 g, and supernatant containing proteins
was collected.  CoIP were performed using the ProFound™ Co-Immunoprecipitation Kit
(Thermo Scientific). Columns were conditioned following manufacturer’s recommenda-
tions, to activate a gel slurry retained in a spin-column system, ensuring the proper bind-
ing of antibodies. Antibody binding to the column was performed using 100 µg of either
a mock antibody (donkey anti-goat IgG) as a control or an anti-TCF4 antibody (Millipore)
in the gel slurry, followed by an overnight incubation at 4°C under constant mixing. The
day after, the columns were washed, and 100 µg of the lysate’s proteins were incubated
for 2 h at room temperature. After four washings, retained proteins were eluted using 50
µl of Elution Buffer (Thermo Fisher) pH 3, and stored at -80°C.
Western Blot Analyses. 20 µl of the elution fraction, supplemented with Laemmli Buffer
(Sigma) was heated for 5 minutes at 95°C, chilled at room temperature and separated on
a 4-12% Bis-Tris gel (Invitrogen). Proteins were then transferred onto a polyvinylidene43
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    fluoride membrane (Millipore). After 2 h in blocking buffer (TBS-0.1% Tween (TBST)
supplemented with 5% non-fat dry milk), membranes were washed three times with
TBST and incubated overnight at 4°C with primary antibodies. The antibody against
DOT1L (Abcam) was used at a 1/1000 dilution, while antibody against TCF4 (Millipore)
was used at a 1/500 dilution. After three washings with TBST, each blot was incubated
for 1 h at room temperature with either anti-rabbit IgG (for DOT1L) or anti-mouse
IgG (for TCF4) conjugated with HRP (both from Jackson ImmunoResearch Laboratories,
West Grove, USA) at 1/10,000 dilution in blocking buffer. After four washings in TBST,
protein bands were detected by chemiluminescence with the SuperSignal West Femto
Maximum Sensitivity Substrate system (Thermo Scientific) according to manufacturer’s
recommendations. Images were acquired with the LAS-3000 mini CCD camera
(Fujifilm).
cDNA synthesis and Quantitative Real-Time PCR. Complementary DNA (cDNA) was
synthesized of 500 ng RNA isolated from ATDC5 micromasses using the RevertAid H
minus First Strand cDNA synthesis kit (Fermentas). The Maxima®SYBRgreen qPCR
master mix system (Fermentas) was used to analyze differential mRNA expression of
Col2a1, Col10a1 Col1a1, Aggrecan, Tcf1 and Osteocalcin, Mmp2, Mmp9 and Mmp13
(primers available upon request) in the ATDC5 micromasses. To assess Dot1l knock-
down efficiency, primers were: forward 5’-CGAGGAAATCCCAGATCTCA-3’, reverse
5’-ATGGCCCGGTTGTATTTGT-3’. The following PCR conditions were used: incuba-
tion for 10 min at 95°C followed by 40 amplification cycles of 15 sec of denaturation at
95°C followed by 45 sec of annealing-elongation at 60°C. Melting curve analysis and 1%
agarose gel migration of amplicons were performed to determine the specificity the PCR
reaction. Results are expressed using the comparative threshold method (39) and were
normalized to housekeeping gene S29 mRNA level (forward 5’-CCAGCAGCTCTACT-
GGAGTCA-3’, reverse 5’-GCCTATGTCCTTCGCGTACT-3’). Expression of DOT1L
was also analyzed in articular chondrocytes (freshly isolated) from osteoarthritis patients
undergoing knee prosthesis surgery. 
Statistical analysis and Cell Culture Experiments. Data presented are representative of
the three independent clonal colonies. Results are expressed as the mean ± SD of three
independent replicates. Comparisons were made by ANOVA, followed by Fisher’s t post-
hoc test, using the Statview™ 5.0 software (SAS Institute Inc). A value of p < 0.05 was
considered significant.
Immunohistochemistry on Mouse Tissues. Immunohistochemistry on paraffin embed-
ded EDTA decalcified adult knee sections and non-decalcified embryonal sections, was
performed with rabbit anti-DOT1L antibody (Ab64077, Abcam, Camebridge, UK) (5µg/44
    ml). After overnight incubation of the sections at 4°C, 1:100 peroxidase goat anti-rabbit
IgG (Jackson Immunoresearch, Suffolk, UK) was applied for 30 minutes and peroxidase
activity was determined using DAB. Rabbit IgG (Santa Cruz Biotechnologies, Santa
Cruz, CA) was used as negative controls. 
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    Table S3.  Markers with suggestive evidence for association from the GWAS on minimal joint space width 
mJSW (p: 10-5>p>5x10-8).
A1: modeled allele, A2: the reference allele, MAF: modeled allele frequency, SE: standard error, Beta: delta
mm per allele, SE: standard error
Locus SNP A1/A2 MAF Closest Gene Effect estimate P-value
Beta SE
12p11.2 rs4931462 T/G 0.33 OVOS2 -0.084 0.017 4.30 x10-7
6p21.1 rs10948155 T/C 0.65 SUPT3H -0.079 0.016 7.70 x10-7
19p13.1 rs11665774 A/G 0.49 SLC27A1 0.07 0.015 4.00 x10-6
5q13 rs11738020 T/C 0.43 PIK3R1 -0.068 0.015 5.50 x10-6
15q26 rs2380165 A/G 0.68 BLM -0.076 0.017 5.60 x10-6
1p34.3 rs11206937 A/G 0.23 TRIT1/BMP8B 0.079 0.018 7.30 x10-6
15q23 rs12907468 A/T 0.36 TLE3 -0.075 0.017 7.80 x10-6
8q21.3 rs12544183 T/G 0.1 RUNX1T1 -0.126 0.028 8.50 x10-650
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    Figure S1  Quantile-Quantile plot (Q_Q plot) for minimal joint space width. The plot compares additive 
model statistics to those expected under the null distribution using fixed-effects for all analyzed HapMAP CEU 
imputed SNPs passing quality control criteria.52
    Figure S2  Dot1l knock-down efficiency during chondrogenesis and staining quantification. A, Dot1l knock-
down is effective during chondrogenesis. mRNA levels were normalized to S29 (reference gene) (n=3). B, 
Proteoglycan content (Alcian blue staining) is decreased in Dot1l- cells. Stainings were performed on ATDC5 
micromass cultures, stably transfected with either control or Dot1l shmiRNA producing vector, over 21 days 
(D). Absorbance was evaluated at 595 nm. (n=3). C, Proteoglycan content (Safranin O staining) is strongly 
reduced in Dot1l- cells. Stainings were performed on ATDC5 micromass cultures, stably transfected with either 
control or Dot1l shmiRNA producing vector, over 21 D. Absorbance was evaluated at 512 nm. (n=3). D, 
Mineralization is decreased in Dot1l- cells. Alizarin red stainings were performed on ATDC5 micromass 
cultures, stably transfected with either control or Dot1l shmiRNA producing vector, over 21 D. Absorbance 
was evaluated at 550 nm. (n=3). E, Collagen content is decreased in Dot1l- cells. Sirius red stainings were 
performed on ATDC5 micromass cultures, stably transfected with either control or Dot1l shmiRNA producing 
vector, over 21 D. Absorbance was evaluated at 540 nm. (n=3).Statistically significant differences vs. D1 
(internal control condition) are indicated as *P<0.05, and vs. control-transfected cells as #: p<0.05.
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    Figure S3  Dot1l knock-down modifies matrix metalloproteinases (MMPs) expression pattern during 
chondrogenesis. mRNA levels of Mmp9 (panel A, B for control alone), Mmp13 (panel C) and Mmp2 (panel D) 
were normalized to S29 (reference gene) (n=3). Statistically significant differences vs. day 1 (D1) (internal 
control condition) are indicated as *: P<0.05, and #P<0.05 for comparison to the GIPZ (control vector)-
transfected cells.
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    Figure S4  Dot1l knock-down affects Wnt signaling during chondrogenesis. mRNA levels of Wnt target genes 
c-Myc and Axin2 were normalized to S29 (reference gene) (n=3). Statistically significant differences vs. day 1 
(D1) (internal control condition) are indicated as *P<0.05, and #P<0.05 for comparison to the GIPZ (control 
vector)-transfected cells. 
Figure S5  DOT1L is expressed in adult human chondrocytes freshly isolated from osteoarthritic articular 
cartilage. mRNA levels of DOT1L was normalized to S29 (reference gene) (n=7 different patients). Horizontal 
bar indicates mean relative expression.
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    ABSTRACT
Background: Hip Osteoarthritis (OA) is the one of the most disabling diseases with a
prevalence of around 7% in elderly. Hip OA is principally characterized by a reduction
in cartilage thickness which is represented by narrowing of the joint space width on a
radiograph. Minimal Joint Space Width (mJSW) has demonstrated to be a successful
proxy for measuring cartilage thickness and to identify genetic variants related with hip
OA. Objective: We aim to identify genes involved in cartilage thickness and hip OA
through the use of mJSW as endophenotype of interest. We conducted a genome-wide
association study of mJSW in a discovery set of 13,013 participants from five different
cohorts (Discovery: Rotterdam Study I and II, TwinsUK, SOF and MrOS) using
standardized age-, gender and population stratification-adjusted residuals from linear
regression. We replicated signals with a P<1x10-5 in 6,168 individuals from 6
independent cohorts: GARP, JoCo, Chingford, GOAL, GOGO and CHECK. Results
were combined in a joined meta-analysis using inverse variance weighting (METAL).
Association with hip OA was tested using logistic regression in 36,341 participants in
total of 11 cohorts. We identified 5 genome-wide significant (GWS) loci (P<5·0×10-8)
on chromosomes 2, 5, 6 and 19. Top SNPs were localized on the intronic region of
TGFA: rs2862851, 200 Kb forward strand from SUPT3H (rs10948155), in the intronic
region a transcript variant (protein coding) of RUNX2 (rs12206662), an upstream gene
variant (rs10471753) which closest genes is PIK3R1 and finally a intronic variant in
DOT1L. The identified GWS variants (excepting rs10471753 and rs10948155) showed
association with hip OA at P value <=0.003. 
Our findings provide insight into the genetics of cartilage development and hip OA that
might be used as future therapeutic targets. We identified signals in genes with important
roles in endochondral differentiation process, growth and development.59
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In spite of the advances to understand osteoarthritis (OA), the absence of effective
therapeutic targets demonstrates that a better comprehension of its causes and
pathophysiological mechanisms are needed. Genetics studies have the possibility of
revealing associated genes and pathways involved in the disease, increasing
understanding of OA and offering future possibilities for treatment. The genetic
component of hip OA have been estimated to be around 60%. However, only few genetic
variants have been successfully identified [1, 2]. 
Recent findings in the search for genetic variants did not explain the high genetic
component of OA. However, it has revealed that some of the genes associated with OA
tend to be related to processes of synovial joint development and bone formation,
including differentiation of cartilage and bone tissue (endochondral ossification)
between others [3]. Some of the signals that have been associated with OA, have been
previously associated with skeletal traits as height and cartilage thickness [1, 2]. Genes
involved in joint formation and differentiation processes might have an important role in
OA and might determine the future risk for joint disease. 
Minimal Joint Space Width (mJSW) is a proxy for cartilage thickness measured on hip
radiographs which has previously demonstrated to be a successful endophenotype to
identify genes with a role in hip OA [4]. Therefore, we aim to identify genes implicated
in cartilage thickness using minimal Joint Space Width (mJSW) as a proxy and to
determine whether those genes have a role in hip OA. 
MATERIALS AND METHODS
Statistical Analyses
Discovery GWAS Meta-analysis. We conducted genome-wide association studies of
mJSW for each cohort of the discovery stage: Rotterdam Study I (RS-I), Rotterdam
Study II (RS-II), TwinsUK, SOF and MrOS using standardized age-, gender and
population stratification (four principal components) adjusted residuals from linear
regression. The R version 2.10.1 (The R Foundation for Statistical Computing http://
www.r-project.org/) and GRIMP were used for analyses [5]. Results from the Rotterdam
Study and the other cohorts used in the discovery stage were combined in a joined meta-
analysis using inverse variance weighting with METAL [6]. Genomic control correction60
    was applied to the standard errors and P-values before meta-analysis. SNPs with a P
value <=5×10-6 were selected for replication.
Replication. Selected signals from the discovery stage were taken for replication in
seven studies: the Genetics of Osteoarthritis and Lifestyle (GOAL) study, the Chingford
study, CHECK (Cohort Hip & Cohort Knee), the Genetics of Generalized Osteoarthritis
(GOGO) the Johnston County Osteoarthritis Project (JoCo) and additionally the
Nottingham OA case-control study for association with Hip OA. Association of the
SNPs with mJSW was additionally adjusted for height to test its independence.
Secondary analyses included: association of the top SNPs with hip OA using logistic
regression analysis (age and gender adjusted and by study centres when it was pertinent).
Discovery Cohorts: description, genotyping and QC
Rotterdam Study. The Rotterdam study is a population-based prospective cohort study
ongoing since 1990 to study determinants of chronic disabling disease [10]. The
Rotterdam Study I (RS-I) is the first cohort of 7,983 persons living in the Ommoord
district of Rotterdam in the Netherlands. All subjects were aged 55 years and older and
recruitment started in 1990. The Rotterdam Study II (RS-II) started in 1999 when 3,011
participants moved into the study since they became 55 years of age or moved into the
study district. Genotyping of the samples in the discovery cohorts (RS-I and RS-II) was
carried out with the Illumina HumanHap 550v3 Genotyping BeadChip. The Beadstudio
GenCall algorithm was used for genotype calling and quality control procedures, as
described previously [11]. The following quality control inclusion filters were applied:
call rate >=97.5%, MAF>= 1%, P for Hardy-Weinberg equilibrium <1×10-6 (Table S1
for details on quality control and exclusion criteria). The total number of genotyped
SNPs that passed these filters was 512,349 for RS-I and 466,389 for RS-II. Imputation
was done with reference to HapMap release 22 CEU using the maximum likelihood
method implemented in MACH (http://www.sph.umich.edu/csg/abecasis/MACH/
index.html). Analysis of imputed genotype data accounted for uncertainty in each
genotype prediction by using the dosage information from MACH. For this analysis,
MACH2QTL, was used via GRIMP [5], which uses genotype dosage value (0–2,
continuous) as a predictor in a linear regression framework. We included only imputed
SNPs that had a good imputation quality leaving a total of 2,451,799. The summary
statistics of RS-I and RS-II were meta-analysed using METAL applying inverse-
variance methodology assuming fixed effects with Cochran's Q and I2 metrics used to
quantify between-study heterogeneity (www.sph.umich.edu/csg/abecasis/metal).61
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    The medical ethics committee of Erasmus University Medical School approved the study
and written informed consent was obtained from each participant.
TwinsUK. The TwinsUK study participants were white monozygotic and dizygotic twin
pairs from the TwinsUK adult twin registry, a group used to study the heritability and
genetics of age-related diseases [9]. These unselected twins were recruited from the
general population through national media campaigns in the United Kingdom. All
samples from the TwinsUK cohort for this study were genotyped with the
HumanHap610Q (Illumina). The following quality control filters were applied: call rate
>=98%, MAF>= 1%, P for Hardy-Weinberg equilibrium >=1×10-6 (Table S1). The total
number of genotyped SNPs that passed these filters was 598,207 SNPs. Imputation was
done with reference to HapMap release 22 CEU using the IMPUTE software package
(v2) [10]. 
SOF. The Study of Osteoporotic Fractures (SOF) is a prospective multicenter study of
risk factors for vertebral and non-vertebral fractures[11]. The cohort at the baseline visit
is comprised of 9,704 community dwelling women 65 years old or older recruited from
populations-based listings in four U.S. areas: Baltimore, Maryland; Minneapolis,
Minnesota; Portland, Oregon; and the Monongahela Valley, Pennsylvania. Women
enrolled in the study were 99% Caucasian with African American women initially
excluded from the study due to their low incidence of hip fractures. The SOF study
recruited only women. Among the 9,704 SOF participants enrolled at the baseline visit,
6795 participants provided blood samples and consented to genetic testing. Among these
6795 SOF participants, DNA samples from 4,117 participants had sufficient DNA
quantity and were submitted to the Broad Institute for whole-genome genotyping.
All DNA samples eligible for whole-genome genotyping were genotyped using
Sequenom iPLEX technology for a 24-SNP “fingerprint” panel. The Illumina
HumanOmni1 Quad genotyping array, containing 1,016,423 probes, was used for whole-
genome genotyping in MrOS and SOF samples. Quality control procedures for SNPs and
samples are described in Table S2.   In addition to the SNP filters described in Table S2,
SNPs with GenTrain scores <0.6 or cluster separation scores <0.4 were excluded.
Additional samples were excluded based on: (1) genotypic sex mismatch using X and Y
chromosome probe intensities, (2) relatedness among genotyped samples using the
kinship coefficient that estimates probability that alleles are identical-by-descent, and (3)
gross chromosomal abnormalities detected using the LogR Ratio and B allele frequency.
Among the 3,924 SOF samples that underwent whole-genome genotyping, 3,68262
    samples had acceptable call rates. Among these 3,682 SOF samples, 4 were removed due
to relatedness and 53 were removed due to gross chromosomal abnormalities, leaving
3,625 SOF samples with whole genome genotyping data that passed QC. 
MrOS. The Osteoporotic Fractures in Men Study (MrOS) is a multi-center prospective,
longitudinal, observational study of risk factors for vertebral and all non-vertebral
fractures in older men, and of the sequelae of fractures in men [12, 13]. The MrOS study
population at the baseline visit consists of 5,994 community dwelling, ambulatory men
aged 65 years or older from six communities in the United States (Birmingham, AL;
Minneapolis, MN; Palo Alto, CA; Monongahela Valley near Pittsburgh, PA; Portland,
OR; and San Diego, CA). Inclusion criteria were designed to provide a study cohort that
is representative of the broad population of older men. The MrOS inclusion criteria were:
(1) ability to walk without the assistance of another, (2) absence of bilateral hip
replacements, (3) ability to provide self-reported data, (4) residence near a clinical site
for the duration of the study, (5) absence of a medical condition that (in the judgment of
the investigator) would result in imminent death, (6) ability to understand and sign an
informed consent, and (7) 65 years or older. To qualify as an enrolled, the participant had
to provide written informed consent, complete the self-administered questionnaire
(SAQ), attend the clinic visit, and complete at least the anthropometric, DXA, and
vertebral X-ray procedures. The MrOS cohort recruited only men. 
Genomic DNA from participants in the Osteoporotic Fractures in Men (MrOS) Study
was extracted from whole blood samples collected at the baseline visit using the
Flexigene protocol (Qiagen, Valencia, CA, USA) at the University of Pittsburgh.
Among the 5,994 MrOS participants enrolled at the baseline visit, 5,551 participants
provided blood samples and consented to genetic testing. DNA samples from these 5,551
participants were submitted to the Broad Institute for whole-genome genotyping. Among
the 5,506 MrOS samples that underwent whole-genome genotyping, 5,189 samples had
acceptable call rates. Among these 5,189 MrOS samples, 1 was removed due to
relatedness and 37 were removed due to gross chromosomal abnormalities, leaving
5,151 MrOS samples with whole genome genotyping data that passed QC. 
Replication Cohorts: description, genotyping and QC
GOAL. The Genetics of Osteoarthritis and Lifestyle (GOAL) study and the Nottingham
OA case-control study have been previously described [14]. Hip OA cases were
recruited from hospital orthopaedic surgery lists in Nottingham. Cases had been referred
to the hospital with symptomatic, clinically severe hip or knee OA and the majority had63
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    undergone unilateral or bilateral THR or TKR within the previous 5 years. Pre-operative
knee or pelvis radiographs were examined to confirm the diagnosis. Subjects were
excluded if they had another major arthropathy, Paget’s disease, overt child hip disease,
THR due to trauma or terminal illness. Controls were age-matched individuals from the
same catchment area free from radiographic OA and over the age of 55.
Chingford. The Chingford study is a prospective population-based longitudinal cohort,
which includes women derived from the age/sex register of a large general practice in
North London [15]. For these studies’ participants, genomic DNA was extracted from
peripheral blood leukocytes of affected individuals and controls using standard
protocols. Genotyping was carried out by Kbioscience Ltd. SNPs were genotyped using
the KASPar chemistry, which is a competitive allele-specific polymerase chain reaction
(PCR) SNP genotyping system using fluorescence resonance energy transfer (FRET)
quencher cassette oligos.
GARP. Genetics ARthrosis and Progression study (GARP). The GARP study is aimed
at identifying determinants of osteoarthritis susceptibility and progression. The study is
based on sibships of white Dutch ancestry with predominantly symptomatic
osteoarthritis at multiple sites. Patients (probands) aged between 40 to 70 years with
symptomatic osteoarthritis in the hands, knees, or hips—diagnosed by rheumatologists,
orthopaedic surgeons, and general practitioners in Leiden, The Hague, Delft, Haarlem,
and Amsterdam—were informed of the ongoing study by mail. Interested probands were
subsequently sent a mailed questionnaire about demographic data, medical history,
symptoms and signs of osteoarthritis, and family history of osteoarthritis. Subsequently
probands with osteoarthritis at multiple sites and with a positive family history were
requested to introduce a sibling “with joint complaints,” who was also sent a
questionnaire. After obtaining informed consent, all sibships underwent a physical
examination and were assessed by a single medical doctor (NR) at the outpatient clinic.
Patients with secondary osteoarthritis and familial syndromes with a Mendelian
inheritance pattern were excluded. Osteoarthritis developing under the following
conditions was considered secondary: major congenital or developmental diseases and
bone dysplasias; major local factors such as severe scoliosis and hypermobility; certain
metabolic diseases associated with joint disease such as haemochromatosis and Wilson’s
disease; inflammatory joint diseases such as rheumatoid arthritis; other bone diseases
such as Paget’s disease and osteochondritis; intra-articular fracture. Genotypes of the
GARP study and controls were performed by a fluorescent 5’ exonuclease assay from a
predesigned SNP TaqMan Genotyping Assay (Applied Biosystems, Foster City, CA).64
    Genotyping quality was manually checked. The accuracy was determined from the
8-10% duplicate samples and was100% and genotyping success rate was > 85%.
JoCo. The Johnston County Osteoarthritis Project (JoCo) is an ongoing population-
based prospective cohort study of the occurrence of knee and hip OA in African
Americans and Caucasians in Johnston County, North Carolina [16, 17]. This project
was designed as a long-term study of ethnic differences in OA occurrence and
progression. The samples were collected from six townships among the 17 townships in
Johnston County because they contained the largest proportion of African American
residents. The participants were initially recruited at the baseline between 1990 and 1997
and were followed up between 1999 and 2004. Additional new individuals were enrolled
in 2003–2004 to enrich the sample for African Americans and younger individuals who
were deliberately targeted for inclusion. A total of 2,583 participants from the Johnston
County Cohort were selected from the total study population for genotyping. Participants
selected for inclusion in the present association study were Caucasians of European
ancestry (68% of genotyped cohort) of both sexes (35% men). 
GOGO. The Genetics of Generalized Osteoarthritis (GOGO) Study is a collaborative
study involving seven academic sites, five in the United States (US) and two in the UK.
Recruitment began in all sites in 2000 and was completed in 2002. Participants were
recruited inform Rheumatology clinics, hospital databases of OA patients, pre-existing
OA cohort, ad from community, by advertisements. A qualifying family consisted of a
least two siblings with self-reported Caucasian ethnicity who fulfilled clinical GOGO
and OA criteria (bony enlargements of >=3 joints distributed bilaterally, including bone
enlargement of at least one DIP joint, and no more than three swollen
metacarpophalangeal joints). In a family the first individual that met clinical GOGO and
OA criteria was designated the proband. A total of 1145 families were recruited [18].
DNA was extracted from whole blood that was collected on the day of participants
assessment. All GOGO participants with longitudinal data were genotypes at the DAvid
H. Murdock Research Institue (Kannapolis, NC), using the illumina BeadChip that
consisted of 500 K HapMap SNPs and about 60,000 custom SNPs. The microarrays
were philantropic gifts to Duke University, teh coordination center for the GOGO study,
based on the stipulation that discovery results be published and not patented.
CHECK. It is a multi-centre cohort formed by the Dutch Arthritis Association (DAA)
with over 1,000 participants with pain of hip and/or knee expected to develop knee and
or hip OA: CHECK (Cohort Hip & Cohort Knee). The objective of CHECK is to study
the course of complaints, the mechanisms that cause joint damage, and to identify65
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    markers for diagnosis and prognosis, as well as to identify prognostic factors that predict
and explain the course of OA. On entry, all participants had pain of knee or hip, were
aged 45-65 years. They had not yet consulted their physician for these symptoms, or the
first consultation was within 6 months before entry. Any other pathological condition
that could explain the existing complaints was excluded(e.g. other rheumatic disease,
previous hip or knee joint replacement, congenital dysplasia, osteochondritis dissecans,
intra-articular fractures, septic arthritis, Perthes' Disease, ligament or meniscus damage,
plica syndrome, Bakers cyste). The study was approved by the medical ethics
committees of all participating centres, and all participants gave their written informed
consent before entering the study. Blood samples were collected at baseline and de-novo
genotyping of the selected SNPs for replication was carried out with Sequenom iPLEX
and Taqman Allelic Discrimination genotyping Genomic DNA was extracted from
samples of peripheral venous blood according to standard procedures. 4 ng genomic
DNA was dispensed into 384-wells plates using a Caliper Sciclone ALH3000 pipetting
robot (Caliper LS, Mountain View, CA, USA). Genotyping was done using Sequenom
iPLEX genotyping and Taqman Allelic Discrimination. For this, sequences containing
the SNP site and at least 100 bp of flanking sequence on either side of the SNP were
used. Briefly, 2 ng genomic DNA was amplified in a 5 ul reaction containing 1 × Taq
PCR buffer (Sequenom), 2 mM MgCl2, 500 uM each dNTP, 100 nM each PCR primer,
0.5 U Taq (Sequenom). More detail have been previously described [19].
The replication studies were approved by the respective institutional review board and
informed consent was obtained from all participants involved. 
OA definition: 
Radiographic hip OA was defined in the RS-I, RS-II, Twins-UK, Chingford, and JoCo
studies using Kellgren and Lawrence (K/L) scores and JSN. HOA cases were defined as
a K/L score >=2 and JSN >=2 on either side of the hip or THR due to OA. Hip OA
controls were defined as no THR for OA and K/L score <=1 and JSN <=1. In GOGO, hip
OA was defined as KL grade >=2 and excluded individuals with joint replacement.
In MrOS and SOF cohorts, Radiographic hip OA case-control was defined by a modified
Croft grade [20]. Radiographic hip OA cases in the GOAL and Nottingham OA studies
were defined by having THR, and controls were radiographically free of hip OA, as
previously described [14]. In GARP, hip OA was defined as pain or stiffness in the groin
and hip region on most days of the preceding month in addition to femoral or acetabular
osteophytes or axial joint space narrowing on radiographs or prosthesis due to OA. In
GOGO, hip OA was defined as KL grade >=2, or minimal joint space width <=2.5 mm,66
    or the combination of joint space narrowing grade >=2 and any osteophyte of grade >=1,
or history of joint replacement for OA.
Biological relevance and Pathways. We also investigated whether significant relevant
connections existed between the associated loci, using two different computation
approaches. Molecular function, pathways and biological processes were analysed using
(Protein ANalysis THrough Evolutionary Relationships) PANTHER [21, 22]. These
analyses included: the function of the protein by itself or with directly interacting
proteins at a biochemical level, the function of the protein in the context of a larger
network of proteins that interact to accomplish a process at the level of the cell or
organism and a pathway that also explicitly specifies the relationships between the
interacting molecules. Additionally we used Gene Relationships Across Implicated Loci
(GRAIL). GRAIL is a text-mining algorithm to search for connectivity between genes
near the associated SNPs, based on existing literature on PubMed text data source (till
August 2012) was run on the selected variants (P<1.0×10-5) lifted over the human
genome hg18 coordinates with gene size correction turned on [23]. 
RESULTS
Association of minimal JSW (mJSW) of the hip and genetic variants was performed in a
discovery set including 13,013 individuals (see Table S2 for cohort specifics). We
applied extensive quality control measures (see Table S1 for details on quality control
and exclusion criteria) leaving a total of 2,385,183 SNPs for association analysis.
Genomic control inflation factors for the P values of the RS, TwinsUK, MrOS, SOF
GWAS were low (lambda = 1.02, 1.01, 1.02 and 0.99 respectively), and the
interquantile-quantile plot (Fig. S1) also indicated no substantial population stratification
due to cryptic relatedness, population substructure or other biases. The estimated median
lambda combining the discovery cohorts was 1.04. In the discovery stage, signals from
five different loci achieved GWS threshold (Fig.1). 
Top SNPs of these 5 regions and 13 top SNPs from loci with a P value <1×10-5 were
selected for replication in another 6,168 individual from six different cohorts. Table 1
shows the association results of each SNP in the meta-analysis of mJSW. We declared
results genome wide significant at P<=5×10-8 after adjusting for all variants tested. A
total of 6 SNPs replicated at nominal significance in the correct direction, when
discovery and replication were combined. 67
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    Figure 1 Manhattan Plot for Association of Cartilage Thickness in the Discovery page. Association results 
by chromosome. The log P values for each of the 2.5 million tests performed as part of the genome-wide 
association of minimal joint space (MJS) of the hip in the discovery stage. The gray solid horizontal line 
corresponds to P value threshold of 5×10-8 (GWS). Dotted gray line corresponds to a P value of 1×10-5.
 
After replication, five of 18 loci had genome-wide significance (P<=5·0×10-8) and 4
were suggestive for association being close to this threshold (Table 1, SNPs with
P<=5×10-6). 
Effect size estimates for all loci were lower in the replication than in the discovery
analysis (Table 1). The most associated signal for mJSW was rs1180992 localized in the
intronic region of DOT1L. This signals was also associated with hip OA in our meta-
analysis with a P value of 9.7×10-5 (all-subjects). This variant is very close to
rs12982744 (D=1, r2=1), previously found associated with mJSW hip OA [1, 4]. The
next signal was located on chromosome two, rs2862851 localized in the intronic region
of TGFA, GWS for mJSW (P=1.6×10-10) and with strong association with hip OA
(OR=1.06, 95% confidence interval (CI)= 1.03-1.09, P= 6.9×10-5).
A variant at 554 Kb of SUPT3H, rs10948155, was associated to mJSW in the discovery
and replication meta-analysis with a final P value of 4.1×10-10. This variant is in high
LD with rs10948172 (D’=0.95 and r2=0.90), previously associated with hip OA in males
at borderline GWS level [2]. However, the variant in our study, rs10948155 (t), was only
modestly associated with hip OA: (OR:0.96 (0.93-0.99), Table 2, P=2.3×10-2). 
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    Figure 2 Regional association plot for the locus of JSW (6p 21). SNPs are plotted by position in a 800-kb 
window against association with mJSW (-log10 P). The purple diamond highlights the most significant SNP in 
discovery analysis close to SUPT3H. SNP rs12206662 on RUNX2 gene showing low correlation with 
rs10948155. Blue peaks indicate recombination rates. The SNPs surrounding the most significant SNP are 
color coded to reflect their LD with this SNP (from pairwise r2 values from the HapMap CEU). Genes, exons 
and the direction of transcription from the University of California at Santa Cruz genome browser are depicted 
underneath the plot.
A variant in RUNX2: rs12206662, having a minor allele frequency of less than 10% (a-
allele=9%) had the strongest effect on mJSW and hip OA (table 1, Beta=-0.146,
P=6.0×10-10 for mJSW and table 2, OR=1.15 (1.07-1.24), P= 1.3×10-4   for association
with hip OA. This SNP on RUNX2 was independent of the SNP rs10948155 close to
SUPT3H, being localized at ~700Kb and showing no correlation with the mentioned
variant (Figure 2). Finally, between the GWS signals is rs10471753, a intergenic variant
closer to PIK3R1 (~450 Kb) than to SLC30A5 (~750Kb). This variant was only
associated with mJSW (Table 1, P=4.9×10-9) and not with hip OA (Table 2, P=7.6×10-
1). Other suggestive signals for association with mJSW at a P<=5·0×10-6 that were
replicated but did not achieve the GWS threshold were: rs717433 (approximately 60kbp
from HAO1), rs496547 a downstream gene variant located 3' of TREH and correlated
with rs494459 SNP previously associated with height at GWS level (r2=0.290, D’=1)
and an intron variant on SLBP (rs2236995) in high LD (r2=0.65, D’=1) with rs2247341
previously associated with height. Another gene close to this variant that might be a good
candidate for its role in bone development and maintenance is FGFR3. From these
suggestive signals, only the variant in SLBP showed significant association with hip OA
(Table 2, OR=0.96 (0.93-0.98) P= 2.5×10-3). 70
    Table 2. Association of top hits for mJSW with hip osteoarthritis in meta-analysis of 10,065 cases and 26,276 
controls.
Cohorts included: Treat-OA meta-analysis (arcOGEN part 1, deCODE, EGCUT, Framingham, GARP, RSI, 
RSII, RSIII, TwinsUK), SOF, MrOS, CHECK, GOAL, Nottingham, JoCo, GoGo, Chingford
Additional adjustment for height did not have effect on the association with mJSW of the
described signals showing an independent effect (possibly pleiotropic) on both traits. All
other additional signals selected in the discovery stage lacked genome-wide significance
and did not replicate, including a intron variant in ASTN2 (rs4837613), in high LD
(D’=0.91, r2=0.73) with a variant previously reported as GWS for association with total
hip replacement in females (rs4836732) [2].
All other additional signals selected in the discovery stage lacked genome-wide
significance and did not replicate, including a intron variant in ASTN2 (rs4837613), in
SNP Chr position A1 Freq1 Beta SE P NEAREST GENE
rs10495106 1 217017809 t 0.935 -0.055 0.031 8.0E-02 TGFB2
rs6429001 1 235495143 a 0.828 -0.013 0.021 5.2E-01 RIR2
rs2862851 2 70566310 t 0.467 0.058 0.015 6.9E-05 TGFA
rs6437120 2 158493396 t 0.507 -0.005 0.015 7.2E-01 ACVR1/UPP2
rs2061109 3 35380584 c 0.513 -0.011 0.016 4.8E-01 ARPP-21
rs2236995 4 1674340 t 0.484 -0.038 0.015 2.5E-03 SLBP/FGFR3
rs13148031 4 145679788 a 0.592 0.018 0.016 2.6E-01 HHIP/GYPA
rs10471753 5 67854708 c 0.614 0.005 0.016 7.6E-01 PIK3R1
rs10948155 6 44795935 t 0.668 -0.037 0.016 2.3E-02 SUPT3H
rs12206662 6 45484199 a 0.078 0.140 0.037 1.3E-04 RUNX2
rs7739938 6 139823110 a 0.078 0.069 0.054 1.9E-01 CITED2
rs4837613 9 118349346 c 0.490 -0.028 0.015 7.1E-02 ASTN2
rs496547 11 118081673 a 0.359 0.009 0.016 5.8E-01 TREH/DOX6
rs6592847 11 78889654 a 0.248 -0.006 0.019 7.5E-01 NARS2
rs11045356 12 20683368 a 0.181 -0.053 0.022 1.5E-02 PPE3A
rs2703529 17 74709369 a 0.076 0.018 0.029 5.4E-01 HRN3P3
rs11880992 19 2127403 a 0.386 -0.064 0.016 9.7E-05 DOT1L
rs717433 20 7786135 t 0.777 0.005 0.019 7.8E-01 HAO171
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    high LD (D’=0.91, r2=0.73) with a variant previously reported as GWS for association
with total hip replacement in females (rs4836732) [2].
Biological process in common for some of these nine described signals associated with
hip OA and/or cartilage thickness were identified using PANTHER and are described in
Supplementary table 4. They include: cell connection, cell cycle, cellular process,
developmental process and metabolism. The pathways found for these signals according
with the analysis using PANTHER are the EGF receptor signalling pathway (TGFA),
gonadotropin realising hormone receptor pathway (TGFB2), TGF-beta signalling
pathway (TGFB2) and several pathways for PIK3R1, including Insulin/IGF pathway
protein kinase B signalling, PI3 kinase pathway, angiogenesis and Endothelin signalling
pathway between others. 
We used GRAIL to identify significant connections between the SNPs associated to
cartilage thickness selected at the discovery stage (P<1x10-5). We found the next 13
keywords describing functional connections of our locis: 'transforming', 'growth',
'hedgehog', 'factor', 'beta', 'phosphodiesterase', 'cardiac', 'alpha', 'mice', 'differentiation',
'bone', 'development', 'osteoblast'. 
Group of genes and significance of the connections between each other were calculated
by GRAIL and are presented in suplementary table 5. The candidate genes with most
significant connections with other genes according with GRAIL and significant for its
association with hip OA are: TGFA and RUNX2 which showed high similarity with a
GRAIL P-value 5.5×10-4 and 9×10-3, respectively. Connections between genes are
represented in the Supplementary figure 2.
DISCUSSION
This study identified nine novel loci that are associated with cartilage thickness, five
surpassed genome-wide significance and four of them were suggestive for association
with cartilage thickness. From these loci, three were associated with hip OA after
correction for multiple testing and two more were significant at a nominal level. Seven of
the nine genes that here we reported associated with mJSW have been reported in
literature as having a role in early development and growth (except HA01 and PIK3R1).
In addition, variants in six of them also previously associated with height at GWS level
24, 25]. 72
    The most significant variants for association with cartilage thickness and hip OA were
localized on different regions: chromosome 2p13, 6p21 and the previous reported locus
of chromosome 19p31.1. Rs2862851 on chromosome 2 lies in the intronic region of the
Transforming Growth Factor Alpha (TGFA). This gene encodes a growth factor that is a
ligand for the epidermal growth factor receptor, which activates a signalling pathway for
cell proliferation, differentiation and development. TGFA is present in limb-forming
mesoderm and in apical ectodermal ridge (AER)-forming ectoderm and may be
important for initial limb formation [25]. Tgfa knockout mice have a delay in bone
development specifically the conversion of hypertrophic cartilage to true bone [26].
Furthermore, TGF inhibit articular chondrocyte anabolic capacity and induces
endothelin receptor A expression in osteoarthritis [27, 28]. Interestingly, the tgfa-
knockout mice expressed less RUNX2 in their cartilage growth plates than controls did
[26], further corroborating our findings.
On chromosome 6, we found rs12206662, a transcript protein coding variant of Runt-
related transcription factor 2 (RUNX2). RUNX2 negatively regulates osteoblast
differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and
regulatory factors involved in skeletal gene expression [29]. RUNX2 is considered a
master transcription factor controlling chondrocyte hypertrophic differentiation and its
expression has been demonstrated in human articular cartilage [30]. Rs12206662 showed
the strongest effect on cartilage thickness and hip OA between the analysed loci. There is
some evidence that modifications in this gene cause chondrocyte hypertrophy; a
hallmark for OA-cartilage. We here provided evidence that this gene plays an important
role in the development of hip OA in general population thought variations in cartilage
thickness. 
Rs10948155, associated with cartilage thickness is localized between SUPT3H and
CDC5L and it was highly correlated with other SNPs that have been previously
associated with OA and height. Reported association with OA and height for SNPs in
this area might involve regulation of RUNX2. Moreover, no functional data has been
presented to support this argument. Here we found two distant and independent signals
from each area, with a different frequency and effects on both traits, cartilage thickness
and hip OA.
The reported SNP on DOT1L is in high linkage with a previously reported SNP
(rs12982744) associated with both traits cartilage thickness and OA, being the same
signal [1]. DOT1L was identified using the same approach; through a GWAS association73
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    study on mJSW as a proxy for cartilage thickness and later on rs12982744 demonstrated
to be also associated with hip OA in males at a GWS level [4]. 
We found a novel loci on chromosome 5, rs10471753, which closest gene is PIK3R1,
Phosphatidylinositol 3-kinase phosphorylates the inositol ring of phosphatidylinositol at
the 3-prime position. Phosphatidylinositide 3-kinases (PI 3-kinases or PI3Ks) are a
family of enzymes involved in cellular functions such as cell growth, proliferation,
differentiation, motility, survival and intracellular trafficking, involved in cancer, body
fat, leptin and insulin metabolism [31-33]. Recently, it has been found that PIK3R1
mutations are a major cause of SHORT syndrome. SHORT syndrome is a rare multi-
systemic disease, characterized by short stature, eye anomalies, characteristic facial
features, lipodystrophy, hernias, hyperextensibility and delay dentition. This gene has
been proposed to participate in pathways involve in control of skeletal myogenesis by
HDAC & calcium/calmodulin-dependent kinase (CaMK), G, Growth Hormone, EGF
IGF-1 Signaling Pathways. Erk and PI-3 Kinase are Necessary for Collagen Binding in
Corneal Epithelia. 
Other signals associated with cartilage thickness are rs10495106 and r1717433, which
annotated closest gene are TGFB2 and HAO1, respectively. TGFB2 encodes a member
of the transforming growth factor beta (TGFB) family of cytokines, which are
multifunctional peptides that regulate proliferation, differentiation, adhesion, migration,
and other functions in many cell types by transducing their signal through combinations
of transmembrane type I and type II receptors (TGFBR1 and TGFBR2) and their
downstream effectors, the SMAD proteins. Disruption of the TGFB/SMAD pathway has
been implicated in osteoarthritis and cancer [34, 35]. Other SNP in the TGFB2 has been
previously associated with height [24]. Hydroxyacid Oxidase/Glycolate Oxidase 1
(HAO1) is one of three related genes that have 2-hydroxyacid oxidase activity yet differ
in encoded protein amino acid sequence, tissue expression and substrate preference.
HAO1 have a role in metabolism of amino acids and derivatives and has been associated
with colorectal cancer [36]. It is unknown whether HAO1 is associated with muscle-
skeletal traits.
The closest gene to rs496547 is trehalase (TREH), brush-border membrane glycoprotein
that encodes an enzyme that hydrolyses trehalose, a disaccharide formed from two
glucose molecules found mainly in fungi, plants, and insects. Deficiency of TREH
produces isolated trehalose intolerance causing gastrointestinal symptoms after ingestion
of edible mushrooms [37, 38]. Another variants in this gene have been associated with
the risk of height and glioma [24, 39].74
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histone mRNAs [40]. According with our results and its association with height at GWS
level, it seems that this gene also have an active role in muscle-skeletal traits.
Between the set of words from GRAIL that best describe the signals associated with
cartilage thickness are words reflecting the role of these genes in bone differentiation
process that start early, during embryonic development, and conclude in adulthood after
establishment of definitive bone and cartilage characteristics. Key transcription factors
and signalling molecules that coordinated cartilage and bone development also regulate
adult physiology. RUNX2, Wnt, EGF, IGF, TGFB superfamily between others are
known to have a very important role in the processes of endochondral bone formation
and development of the hip joint, including chondrocyte proliferation and differentiation
(Figure 3). Some of the genes associated with cartilage thickness have been also
identified in the analysis of height, showing a possible pleiotropic effect for these traits.
 
Figure 3 Schematic diagram providing an overview of the influence of signaling pathways and transcription 
factors during the processes of condensation, chondrogenesis, chondrocyte proliferation, differentiation, 
hypertrophy and calcification during endochondral bone and cartilage formation. Some of the genes associated 
with cartilage thickness: DOT1L (Wnt signaling), PIK3R1 (IGF & PI-3 Kinase), RUNX2, TGFA (EGFR) and 
possibly TGFB2 (not replicated) are part of these signaling pathways. Signaling and growth factors are shown 
in light gray boxes. 
Deregulation of genes and mechanisms during endochondral ossification might have a
role in hip OA initiation and progression. Chondrocyte apoptosis has been identified as
involved in OA progression [41]. In addition, it seems that induction of a transcriptional
activator Runx2 in chondrocytes under mechanical stress contributes to the pathogenesis
of OA through chondrocyte hypertrophy, between other possible mechanisms [41].
Understanding of the regulatory processes that finally shape the hip joint, including
formation of articular cartilage and healing will be relevant to identify the best
therapeutics targets for hip OA. Expression and functional studies with the genes here
described are warranted.
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    Rs2236995 is an intronic variant of Stem-Loop Binding Protein (SLBP). This gene
encodes a protein that binds to the stem-loop structure in replication-dependent histone
mRNAs. Histone mRNAs do not contain introns or polyadenylation signals, and are
processed by endonucleolytic cleavage. The stem-loop structure is essential for efficient
processing but this structure also controls the transport, translation and stability of 
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    Supplementary Table 5.    GRAIL data for selected individual SNPs of interest (P<1x10-5).
Supplementary Figure 1 Interquantile-quantile plot for the analysis of mJSW in the discovery cohorts.
GENE GRAIL-P val ue SELECTED SIMILAR GENES (Rank in parentheses)
TGFA 0.00056 TGFB2(2), CITED2(53), PIK3R1(358), TACC3(737), 
RUNX2(993), AMH(1571)
TGFB2 0.0010 TGFA(5), CITED2(45), RUNX2(472), PIK3R1(818), 
TACC3(856), AMH(1546), AP3D1(1585), HHIP(1957)
CITED2 0.00415 TGFB2(24), TGFA(90), RUNX2(834), TACC3(980), 
AP3D1(1059), PIK3R1(1101)
DOT1L/AMH 0.00677 PLEKHJ1(2), SF3A2(11), TGFB2(88), TGFA(89), CITED2(288), 
TACC3(506), RUNX2(1048),  AP3D1(1248), DDX6(1495), 
PIK3R1(1771), HHIP(1780)
PAPPA 0.00764 TGFB2(123), TGFA(135), PIK3R1(370), CITED2(447), 
RUNX2(1140), AP3D1(1478), AMH(1616)
RUNX2 0.00905 CITED2(81), TGFB2(112), TGFA(256), PIK3R1(901), 
AP3D1(1069), TACC3(1616), HHIP(1803)
HHIP 0.02133 CITED2(203), TGFB2(256), TGFA(296), RUNX2(692), 
TACC3(1088), PIK3R1(1364), AP3D1(1949)
TACC3 0.04850 CITED2(160), TGFA(406), TGFB2(517), DDX6(825), 
TXLNB(1396), SF3A2(1489), AP3D1(1727)84
    Supplementary Figure 2  Graphical representation of the connections between the selected SNPs associated 
with cartilage thickness (P<1x10-5) and corresponding genes using GRAIL. GRAIL analysis identified non-
random connectivity (P<0.05) between associated genes (Black color text). Thicker and redder lines imply 
stronger literature-based connectivity. 
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    ABSTRACT
Hip osteoarthritis (OA) is characterized by cartilage degradation leading to narrowing of
the joint space width (JSW). Hip OA has been associated with height and part of the
genetic variants associated to hip OA are localized in genes that also explain variation in
height. Additionally, both traits JSW (a proxy for cartilage thickness) and height have a
common origin during development; chondrocyte differentiation during endochondral
bone formation, which determines cartilage thickness as well as the length of the bones.
We aim to identify common variants associated to cartilage thickness of the hip and
height. We used a bivariate analysis of the traits. The meta-analysis of hip-JSW and
height datasets was performed using an inverse variance-weighted method. This method
combines single trait genome-wide association results of correlated traits using Z-score
test statistic and Fisher’s methods based meta-analysis. For JSW, we used meta-analysed
results  from two cohorts: RS-I and RS-II in 6482 participants, while for height, we used
the meta-analysed result from the GIANT consortium. We considered as Genome-wide
significant a combined Fisher P value <= 5x10-8 when the variants were associated in
both traits with a P value <=5x10-4 for JSW and a P value <=5x10-5 for height.
Association with OA was tested using logistic regression. We identified variants in or
near eight different genes: DOT1L, DYM, FBXW11, TEAD1, IGF2BP3, SUPTH3,
ASTN2 and IER3 associated with cartilage thickness. The variants in DOT1L, SUPTH3
were associated with OA in males and ASTN2 in females (P=2.1x10-4, P=2.4x10-5 and
P=3.5x10-3, respectively). Variants in these genes were previously reported to be
associated with height. These genes might provide a framework for joint formation
during development, embryogenesis and in general have an important role in
endochondral ossification process, including formation of cartilage thickness and hip
joint. 89
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    INTRODUCTION
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive damage
of the articulate cartilage that on radiographs can be identified as narrowing of the joint
space, new bone formation and alterations in subchondral bone. Heritability studies have
shown that more than half of the variation in susceptibility to osteoarthritis in the
population is explained by genetic factors, but these factors have been difficult to
identify [1, 2].  
Epidemiological studies have associated height with the risk for hip osteoarthritis [3].
Well known signalling pathways involved in growth and differentiation of the skeleton
are the TGF-beta and Wnt-signalling pathways between others. Variants in genes having
a role in these pathways have been identified in association with OA and height and
deregulation of these signalling pathways has been shown to be involved in OA and
height [4-10]. Common variants in the growth differentiation factor 5 (GDF5) gene
contribute to variation in height and increase susceptibility to hip and knee osteoarthritis
in Asian and European populations [6, 11, 12]. GDF5 is part of the TGF beta signalling
pathway and is involved in the development of cartilage in the legs and other long bones.
SMAD3 is another example of a gene where genetic variants are involved in both OA and
height [5, 14]. Early-onset joint abnormalities, including osteoarthritis have been
reported in a big percentage of subjects with mutations in SMAD3 gene, while more
common variation was also reported as significant contributor of height differences.
Recently a DNA variant in the DOT1L gene was found to be associated with variations
in Joint Space Width (JSW) and hip OA. This same variant was previously found to be
associated with height [7, 14, 15]. JSW is a good surrogate for cartilage thickness in hips
and it is used to radiographically define hip OA [16, 17]. Narrowing of the JSW is
considered to be a strong predictor of progression of hip OA [18].
Since there is a common biological process underlying cartilage thickness (represented
by JSW) and height (endochondral bone formation), we hypothesize that these two traits
might be under genetic influence of more and still unknown shared genes. A significant
excess of shared signals between osteoarthritis and height has been reported [19].
However, the responsible signals have not been identified.
Using a bivariate analysis, it is possible to identify associated genetic loci that have an
effect on correlated phenotypes [20-22]. This method takes benefit of the mutual
correlation between traits, in this case JSW and height, to increase the power to identify
signals that are relevant for both traits. Using this method, we aim to identify those90
    variants playing a role in both cartilage thickness and height. Identifying the genes
involved in both traits will help to elucidate unknown aspects of joint formation that are
relevant to understand the pathogenesis of important diseases of the hip joint including
hip OA. 
METHODS
Study design, population and data collection procedure
We used data of the Rotterdam study, a large prospective population-based cohort study
among men and women ≥55 years of age. In summary, the objective of the study is to
investigate the determinants, incidence and progression of chronic disabling diseases in
the elderly [23]. A total number of 6,482 participants from Rotterdam study I (RS-I) and
II (RS-II) with measures of JSW and genetic data were included. The medical ethics
committee of Erasmus Medical Center approved the study and written informed consent
was obtained from each participant.
Clinical evaluation and physical examination
At baseline, medical information and physical examination of participants of the RS-I
and RS-II including measurements of height and weight were obtained.
Radiographic assessment
Weight-bearing antero-posterior pelvic radiographs were taken with both of the patient’s
feet positioned in 10° internal rotation and the x-ray beam centered on the umbilicus. At
baseline and follow up, the JSW of the hip joints was measured using a 0.5-mm
graduated magnifying glass laid directly over the radiograph. JSW is defined as the
distance between the superior part of femoral head and the acetabulum at three different
positions: lateral, superior and medial (Figure 1). Hip osteoarthritis was defined as a
grade 2 or more using Kellgren and Lawrence score (at least one hip with definite
narrowing and at least possible femoral osteophyte(s).
Data analysis procedure 
Correlation between variables, height and JSW adjusted for age and gender was done
using Pearson correlation coefficient. The variable of JSW (lateral, superior or medial)
with the highest correlation with height was used for the bivariate analysis for both traits.91
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    Figure 1 Radiograph from Rotterdam study I (RS-I) showing the Joint Space Width (JSW) measured at 
different locations of hip joint. JSW measured at lateral, superior and medial locations. 
Meta-analysis of single traits:
JSW meta-analysis 
Residuals from linear regression analysis of JSW in 6,482 participants from RS-I and
RS-II corrected for age, gender and population stratification (four principal components)
were used for genetic association analysis in each cohort. Creation and quality control of
the GWAS data for the Rotterdam study has been described earlier. In short, we used
MACH for imputation with reference to HapMap release 22 CEU [24]. Analysis of
imputed genotype data accounted for uncertainty in each genotype prediction by using
the dosage information from MACH. For this analysis, MACH2QTL was used via
GRIMP, which uses genotype dosage value (0-2, continuous) as a predictor in a linear-
regression framework [25]. The following quality control inclusion filters were applied:
call rate >97.5%, MAF >1%, P for Hardy-Weinberg equilibrium <1×10-6 (see Table 1 for
details on quality control and exclusion criteria). The total number of genotypes SNPs
that passed these filters were 512,349 for RS-I and 466,389 for RS-II. Genomic control
correction was done to the standard error and P-values before meta-analysis. We
included only imputed SNPs that had a good imputation quality leaving a total of
2,355,290. The summary statistics of RS-I and RS-II were meta-analysed using METAL
applying inverse-variance methodology assuming fixed effects. 92
    Height meta-analysis
Meta-analyzed results of Genome Wide Association Study (GWAS) of height (GIANT
consortium) in 183,727 individuals from different populations were used for the
bivariate analysis.Results from meta-analysis of height are freely available in the website
of GIANT consortium: (http://www.broadinstitute.org/collaboration/giant/index.php/
GIANT_consortium_data_files). Other methodological details have been described
previously [7, 14].
Bivariate analysis 
The method used combines single trait genome-wide association results of correlated
traits using Z-score test statistic and Fisher’s methods based meta-analysis [26]. In this
case we used meta-analyzed results of JSW from two cohorts: RS-I and RS-II and meta-
analyzed results from GIANT as previously described [14]. To detect associations of the
same and opposite directions, two tests were performed. First, the directional meta-
analysis; with the original results of each trait, followed by a second where the direction
of association was flipped in one dataset and an opposite-allelic effect analysis was
performed. The observed chi-square value was divided by the lambda value to derive the
corresponding chi-square meta-adjusted value and therefore the P-adjusted values. The
final step consists of combining the two independent P-adjusted distributions using the
Fisher’s methods for combining independent P-values [26]. The resulting chi-square
value distribution with four degrees of freedom (two times the number of traits) provide
the overall association evidence for each genetic variant taking underlying correlation
and directionality of the effects into accounts. In both traits the genomic control
corrected results were used for final Fisher meta-analysis. Further details of the bivariate
analysis have been previously described [27]. Variants associated in both traits with a P
value <=5x10-4 for JSW and with a P value <=5x10-5 for height, were considered.
Conditional analyses were used to determine whether two associated variants had an
independent effect on the trait (JSW). It was done adding the associated variants into the
linear model for joint space width. Two variants are considered as independent when in
the same model have an significant effect on JSW. Analyses were performed in R
package and Plink [28]. We considered as Genome-wide significant a combined Fisher
P-value <= 5x10-8. 93
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    Association with hip OA
Association of the top SNPs found in the bivariate analysis with hip OA was verified
using the TREAT-OA meta-analysis that includes 5,244 hip OA cases and 17,836
controls. In summary, the arcOGEN consortium, the EGCUT study and deCODE are
studies including symptomatic OA cases. The Rotterdam Study and TwinsUK defined
OA on the basis of X-rays where at least 2 definite osteophytes and possible joint space
narrowing or a (partial or total) knee replacement due to OA were considered as OA. 
OA cases in the GARP study have symptomatic OA at multiple joint sites and for this
study knee OA was defined in the same way as for the Rotterdam Study and TwinsUK
Study. For this study, the arcOGEN consortium used controls from population-based,
unrelated UK controls which came from 5 distinct sources: the 1958 Birth Cohort and
the UK Blood Donor Service from the Wellcome Trust Case Control Consortium 2
study, the 1958 Birth Cohort from the Type 1 Diabetes Genetics Consortium (T1DGC)
study, the Avon Longitudinal Study of Parents and Children (ALSPAC) study and the
People of the British Isles (PoBI) study. Details of the studies cohorts included are
presented in Supplementary table 1.
Association of each of the top SNPs (P<=5x10-8) found using the bivariate analysis of
height and JSW was tested using logistic regression age and gender adjusted or gender
stratified. We considered a significant association with OA when the P value was equal
or less than 0.0062 (P<=6.2x10-3).
RESULTS
Table 1 presents the baseline characteristics of the study populations, quality control
procedures and exclusion criteria of individuals for GWAS of Superior JSW in RS-I and
RS-II. JSW is thicker at the superior site of the hip joint, more than at medial or lateral
sides. Table 2 shows the correlation coefficients between measures of JSW at different
locations of the hip joint and height. We found a significant correlation between JSW at
different locations of the hip and height (Table 2). Superior JSW was the most correlated
phenotype of the hip joint with height (Table 2, r2: 0.18, P<0.001). Therefore we used
superior JSW as selected trait for the bivariate analysis with height, considering that for
this type of method higher correlation between studied variables represents an advantage
to increase power to localize common variants for both traits [31]. The GWAS on
superior JSW was performed in 6,482 participants from RS-I and RS-II (Figure 2).94
    Meta-analysed results from this GWAS was used for bivariate analysis with the meta-
analysed results obtained in the height-study as it was previously explained. After quality
control (QC) measures a total of 2.359.324 SNPs remained for the association analysis.
Figure 2 shows the results of the association of all remaining SNPs after QC with
Superior JSW. Since strong association of some known variants with height might inflate
the final P value in the bivariate analysis, we selected SNPs with at least P<=5x10-5 for
height and P<=5x10-4 for superior JSW and final Fisher P value <=5x10-8. We only
detected significant associations for both traits in the directional meta-analysis (effects
with the same direction for both traits). 
A total of eight different independent signals were identified. The strongest signal related
to both: JSW and height was rs2864419 (Table 3, P=1.2x10-20 for combined Fisher
P value), is localized on the intronic region of DOT1L gene previously reported
associated to both traits: height and JSW at genome wide significant level, being the
same signal (r2=0.87 with rs12982794) [32, 33]. Followed by rs2156250 on Chr 18q21
in the intronic region of the Dymeclin (DYM) gene. This SNP represent the same signal
as rs9967417, previously reported for association with height and according with our
results, it is associated with superior JSW with a P value of 4.8x10-5 (Table 3). 
Additionally, rs1368380 was associated with both traits at a GWS level (Table 3,
P value=3.6x10-11). Rs1368380 is a variant in a regulatory region of FBXW11 A
previously reported SNP for height is at around 100 Kbp from rs1368380 (rs12153391,
r2=0.03) [14]. 
Rs9888179 is localized on Chr. 11, between two genes: PARVA and TEAD1, TEAD1
being the closest gene reported as responsible for the associated with height (rs7926971,
r2=0.58) and more biological plausible for its relation with growth and size [14]. 
Rs10950947, an intronic variant in the IGF2BP3 gene was associated with JSW and
height, with a combined P-fisher=1.2x10-9. A linked variant (rs12534093, r2=0.55), was
previously associated with height.95
Ch
apt
er 
2.3
    Table 1. Characteristics of the study populations, quality control procedures and exclusion criteria for 
individuals of the GWA of superior JSW.
Means are given with standard deviations between brackets. BMI: body mass index, JSW: Joint Space Width 
of the hip, Nr HOA: number of hip osteoarthritis (OA) cases and controls NA: not available
Table 2. Correlation between measures of JSW at different joint locations and Height.
* Pearson coefficient (r²) for correlation between the measures of JSW at different location of the hip joint and
height after correction for age and gender. Correlations between joint space width (JSW) at any location of the
hip joint and height were significant (P<0.001).
Description of the Studies
Variables RS1 RS2
Number 4770 1712
Female (%) 56.6 54.4
Age  (years) 67.7 (7.8) 64.5 (7.8)
Height (cm) 167.6 (9.2) 168.8 (9.2)
Weight (kg) 73.8 (11.7) 77.6 (13.3)
BMI (kg/m2) 26.3 (3.6) 27.2 (3.9)
Superior JSW  (mm) 4.80 (0.82) 5.26 (0.82)
Lateral JSW (mm) 4.69 (0.93) 5.02 (1.0)
Medial JSW (mm) 4.45 (0.83) 4.51 (0.86)
Nr HOA cases/controls 771/4436 166/1795
Genotyping Platform(s) / Chip(s) Illumina HumanHap 550K V.3 DUO
Call rate* selection  ≥97.5%
Sample QC / Other exclusions
1) Gender mismatch with typed X-linked markers;
2) Excess autosomal heterozygosity >0.336~FDR>0.1%;
3) Duplicates and/or 1st or 2nd degree relatives using IBS
probabilities >97% from PLINK;
4) Ethnic outliers using IBS distances >3SD from PLINK;
5) Missing JSW measurements.
Genotyping facility Genetic Laboratory Dept Internal MedicineErasmus MC, The Netherlands
Measures of JSW Lateral JSW mJSW Superior JSW Height*
Lateral JSW 1 0.48 0.51 0.092
Medial JSW 0.48 1 0.64 0.095
Superior JSW 0.51 0.64 1 0.18496
    Figure 2 Manhattan plot: -log p-values for each of the ~2.4 million tests performed for the genome wide 
association analysis on Superior JSW of the hip. The gray dashed line correspond to a p-value of 5x10-8. 
The gray solid horizontal line corresponds to the p-value threshold of 5x10-8.
On chromosome 6, rs10948194, localized in the intronic region of SUPTH3 and
associated at GWS level in the bivariate analysis of both traits, height and superior JSW
(Table 3, P-Fisher=6.9x10-9). The SNP is correlated with rs10948172 (D’=1, r2=0.31),
previously shown associated with hip OA in males at a borderline GWS level
(P value= 6x10-7) [34]. Another SNP rs9472414 moderated linked to rs10948194 was
reported in association with height in the GIANT meta-analysis (r2=031).
Rs2208562 localized in the intronic region of the astrotactin 2 gene (ASTN2). The SNP
reported as associated with height at GWS level (rs751543) is an intronic variant in
PAPPA with a very low correlation with rs2208562 (r2=0.006). On the other hand,
rs4836732 is another intronic variant of ASTN2 and was previously reported as
associated with total hip replacement due to OA only in females   (D’=0.88, r2=0.53).
Finally, rs12527415 (Table 3, P-fisher: 2.9x10-8), is a intergenic variant localized around
86 kbp of IER3 and 90 kbp from the FLOT1 gene. Immediate Early Response 3 (IER3)
has a role in cellular stress response, inflammation and tumorigenesis [35]. This genomic
locus has not been associated at GWS level with height before.
The association of these signals with JSW did remain after correction for height
demonstrating an independent effect and indicating a possible pleiotropic effect of these
genes on both traits.
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    Association with OA was significant for rs2864419 (DOT1L) and rs2208562 (ASTN2) at
a P<0.0062 (Table 4, P=5.1x10-4 and 3.5x10-3 respectively, for association in all
subjects). Previously, a variant in high LD with rs2864419 was reported as GWS only in
males with OA [36]. 
A signal in ASTN2 was previously reported associated at GWS level with OA in females
(arcOGEN stage 2 meta-analysis) [34]. Therefore, we analysed the association with hip
OA in each gender. We found the variant rs10948194 significantly associated with hip
OA in males and not in females (Table 4, P=2.4x10-5 and P=0.80 respectively). The
betas from association of this SNP with hip OA are significantly different between
females and males (P<0.001). Similarly, there is a significant difference in the betas
between genders for the variants in ASTN2 and DOT1L, having ASTN2 variant stronger
effect in females and DOT1L in males (P<0.005 and P<0.001, for differences in betas
respectively). The other signals (close or on FBXW11, IER3, IGF2BP3 and TEAD1)
were not significantly associated with hip OA. Although rs9888179 (PARVA/TEAD1)
reached a nominal significance (Table 4, P=0.05). 
Five genes from the list here presented as candidate genes for the association between
the variants associated with cartilage thickness and height are in at least one pathway.
SUPT3H and DOT1L are present in the Transcriptional misregulation in cancer in
human. Additionally, DOT1L is present in the Wnt signalling pathway. Dymeclin has
been found expressed in cartilage during early development and it is involved in two
secretion pathways: GOLM1 and PPIB, known in endochondral bone formation being
interacting partners. Two of the candidate genes (FBX11 and TEAD1) are present in the
Hippo signalling pathway. The Hippo signalling pathway coordinates cell proliferation,
apoptosis, and differentiation, and has emerged as a major regulator of organ
development and regeneration. Transcriptional regulators in the Hippo pathway, Tead4
and Yap1, are required for general vertebrate epimorphic regeneration as well as for
organ size control in appendage regeneration in Xenopus [37]. Given the roles of the
Hippo pathway in directing cell fate and tissue regeneration has been proposed that
regulatory elements in this pathway will be essential for regenerative medicine [38].  99
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    DISCUSSION
In this bivariate analysis using GWAS of two correlated traits, we identified new signals
on chromosomes 5, 6, 7, 9, 11, 18 and 19 that are associated with joint space from the
superior side of the hip joint, representing cartilage thickness and height. The SNPs
reported here might have pleiotropic effect on both traits: height and cartilage thickness
since the effect of the variants was independent of the association with height. We
confirmed our previous hypothesis that these two traits are under genetic influence of
common genes, some of them being identified using this approach. Additionally, we
found that three of these variants were associated with hip OA, showing gender
specificity.
It has been hypothesized that genes underlying certain skeletal disorders might have
pleiotropic effects. Pleiotropy results when a gene has different phenotypic effects
depending on circumstances of expression of the gene during development and aging
[39, 40]. The discovery of genes with independent effect on both traits (as it was the case
of DOT1L) supports this hypothesis. There have been other previous examples of
variation in genes that have effect on height, cartilage thickness and osteoarthritis: GDF5
and IHH [4, 6, 14]. Those genes share in common participation in important processes of
chondrocytes differentiation during endochondral bone formation which might be the
case for some of the other genes reported in this bivariate analysis of height and joint
space width. There are other effects in common, part of endochondral ossification
processes  as hypertrophy of chondrocytes, cartilage volume and hip geometry (joint
size, orientation and shape) that might influence the correlation between these traits
(height, cartilage thickness and hip osteoarthritis). Chondrocytes hypertrophy, joint size
(longitudinal and cross-sectional) and hip geometry are possibly influenced by common
genes as it has been previously demonstrated for GDF5 [41]. Chondrocytes hypertrophy
is an essential step required for longitudinal bone growth and for maintaining the
cartilage synovial joint surface [42]. Abnormal chondrocyte hypertrophy in articular
cartilage has been associated with osteoarthritis [43]. Additionally, adult height
correlates with joint dimensions and substantial genetic correlations have been found
between femoral geometric traits, height and initiation and progression of hip
osteoarthritis [44, 45]. 
We identified variants in/near DOT1L, DYM, FBXW11, TEAD1, IGF2BP3, SUPTH3,
ASTN2 and IER3 associated to cartilage thickness. Variants in these genes were
previously reported as associated with height excepting IER3. For the majority of these
genes (except for DOT1L) their expression in articular cartilage and joint tissues have101
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    not been evaluated. It has been demonstrated that variants in DOT1L, SUPTH3 and
ASTN2 are associated with hip OA [33, 34, 36]. However, the variants here reported are
only in moderate LD with those that have been previously reported, excepting the
DOT1L variant. ASTN2 encodes a protein that is expressed in the brain and may function
in neuronal migration. It has been associated with cognition and bipolar disorder,
migraine and schizophrenia and recently with total hip replacement in females [34, 46-
48]. According with our results, the association of ASTN2 with OA seems to be mediated
through its possible role in cartilage thickness (development/maintenance). The
expression and function of ASTN2 in joint tissue (cartilage and/or bone) needs to be
demonstrated. The variants in DOT1L, SUPT3H and ASTN2 showed to be gender
specific. It might be considered that part of the complexity of OA rely on these genetic
gender differences which need to be elucidated. In addition, DOT1L and SUPT3H
interact in the same signaling pathway involved in transcriptional misregulation in
cancer. 
Our bivariate analysis used JSW at the superior site of the hip joint, which seems to be
thicker than JSW at other joint sites in both studied populations (both older than 65
years). Therefore, we might conclude that this site of the hip joint is probably less
affected by cartilage degeneration during OA. Subsequently, not all the identified signals
necessarily showed association with hip OA. The reported signals might have a role
during joint development, embryogenesis and in general endochondral ossification
process, including formation of cartilage thickness and not necessarily in OA. One
example of a gene involved in skeletal development and here reported associated with
cartilage thickness but not with hip OA is DYM. DYM encodes a protein which is
necessary for normal brain function and skeletal development having a crucial role on
chondrocyte differentiation. Mutations in this gene are associated with two types of
recessive osteochondrodysplasia syndromes which involve skeletal defects, short stature
and radiological changes in different joints [49, 50]. Additionally, Dym mutant mice
exhibit disorganized chondrocytes surrounded by thicker ossified regions containing
numerous small islands of chondrocytes [51]. Degeneration of articular cartilage in OA
is also associated with changes in chondrocytes some of them similar to those observed
in Dym mutant mice during endochondral bone formation[52]. It might be the case that
sever forms of mutation in this gene are required to produce a OA-like phenotype.
Rs1368380 is localized on FBXW11. FBXW11 encodes a member of the F-box protein
family which is characterized by approximately 40 aminoacid motif, the F-box. The F-
box proteins constitute one of the four subunits of ubiquitin protein ligase complex
called SCFs (Skp1-Cul1-F-box protein). This gene has a role in protein translation, cell102
    grow and survival [53]. FBXW11 is implicated in the Hedgehog signalling pathway and
its expression is negatively regulated by Wnt/beta-catenin pathway. Additionally, we
found here that this gene together TEAD1 are part of the Hippo signalling pathway,
which has been studied as a potential target for limb and tissue regeneration. It might be
also a possibility in the field of regeneration of cartilage tissue
Another signal was localized on the Insulin Growth Factor-2 Binding Protein 3
(IGF2BP3), that is a Glioblastoma-specific marker that activates Phosphatidylinositol 3-
Kinase/Mitogen-activated Protein Kinase (PI3K/MAPK) Pathways by Modulating IGF-
2. IGF2BP3 interacts with Insulin-like growth factor 2 which has a major role as growth
promoting hormone during gestation [54].
Altogether these elements show the relevance of identification of the variants associated
with both traits: height and cartilage thickness and candidates genes for this association
that participate in relevant pathways that might play a role in OA. 
In conclusion, we found variants in different genes associated with cartilage thickness on
the superior part of the hip joint and height, possibly underlying common processes of
endochondral bone formation. Mild forms of variation in these genes might produce
small to moderate phenotypic changes in cartilage and surrounding joint structures that
might predispose to OA. Replication of these findings in other populations and studying
effect of expression and mutation in these genes on articular cartilage of the hip joint will
be pursued.
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    Supplementary table 1.   Studies included in TREAT-OA GWAS meta-analysis.
Study N_cases (n=5244)
N_controls 
(n=17836) Genotyping platform
Imputation 
method
arcOGEN 1728 4896 Illumina Human610 (cases) + Illumina 1.2M Duo (controls) Impute
deCODE 2318 2318 Infinium HumanHap 300 + humanCNV370 Impute
EGCUT 64 2531 Illumina HumanCNV370 or HumanOmniExpress Impute
GARP 106 1671 Illumina Infinium HD Human660W-Quad Impute
RSI 760 3233 Illumina HumanHap550v3 MACH
RSII 159 1472 Illumina HumanHap550v3 MACH
RSIII 41 1487 Illumina HumanHap550v3 MACH
TwinsUK 68 228 Infinium HumanHap300 Impute107
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    ABSTRACT
To determine how well measures of hip geometry can predict radiological incident hip
osteoarthritis (OA) compared to well known clinical risk factors. The study population is
part of the Rotterdam Study, a prospective population-based cohort. Baseline pelvic
radiographs were used to measure hip geometry by two methods: Statistical Shape
Modeling (SSM) and predefined geometry measures (PGP). Incident hip OA (Kellgren
and Lawrence (KL) ≥=2) was assessed in 688 participants after 6.5 years without
radiographic OA at baseline. The ability to predict hip OA was quantified using the area
under the Receiver Operating Characteristics curve (AUC). Comparison of the two
methods showed that both contain information that is not captured by the other method.
At 6.5 years-follow up 132 hips had incident HOA. Five PGPs (Wiberg angle, Neck
Width, Pelvic Width, Hip Axis Length and Triangular Index) and 2 SSM (modes 5 and
9) were significant predictors of HOA (p=0.007). Hip geometry added 7% to the
prediction obtained by clinical risk factors (AUC= 0.67 (geometry), 0.66 (gender, age,
BMI) and combining both: AUC=0.73, respectively). Mode 12 (associated with position
of the femoral head in acetabulum) and Wiberg angle were predictors of OA in
participants without radiological signs at baseline (KL=0). Contribution of variables to
predict hip OA at a longer follow decreased however, was still significant for hip
geometry (p=0.01). Hip geometry has a moderate ability to predict OA in participants
with and without initial signs of OA, similar to and largely independent of the predictive
value of clinical risk factors. 
Keywords: Hip Geometry, hip osteoarthritis, prediction.113
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    INTRODUCTION
Variations from what it is considered a “normal hip morphology” have been associated
with hip osteoarthritis (OA). The reason might be that certain morphologies of the hip
joint result in mechanical loads that increase stress at the articular surface (1-3). Certain
extreme morphologies, such as congenital hip dysplasia can cause hip at a relatively
young age (4, 5). For individuals with a less unfavourable morphology of the hips, OA
might only develop when other risk factors are present as well and consequently hip OA
occurs at older age. 
Different approaches to quantify hip geometry exist. Generally, many predefined
geometry parameters (PGP) applicable to radiographs have been described in literature
that measure distinct traits of the hip joint (acetabulum, pelvis and proximal femur) in
terms of distances, areas or angles. Within the group of PGPs, the Wiberg angle also
known as Center Edge Angle (measuring acetabular dysplasia and position of the hip in
relation to the acetabulum), femoral neck width and the triangular index (measuring
asphericity of the femoral head) have been associated to the development and
progression of hip OA (6-9). Other parameters have also been associated to hip OA in
small studies without conclusive evidence: neck shaft angle, hip axis length, spherical
sector, offset and pelvic width (9-13). In general all these PGPs have been studied in
small separate efforts and their contribution to the prediction of incident hip OA is not
well known.
Alternatively, the geometry of the hip joint might be quantified in a more general sense
using Statistical Shape Models (SSM). SSM offer a relatively new and conceptually
different approach that captures the entire shape. Each of the SSM measures, which are
called modes, describes a distinct pattern of variation present in a population (14). SSM
analysis has identified some distinct aspects of femoral shape that have been associated
to clinical or radiological hip OA (15-17). However, it is unknown whether these modes
capture the same aspects of hip geometry as the predefined geometry measures. In
addition, it is unknown if hip geometry can be used to identify subjects that will develop
hip OA in the future. 
The aim of this study was to compare these two approaches to quantify hip geometry
(PGP and SSM) with respect to predicting OA, and more specifically to determine the
contribution of hip geometry to the prediction of incident radiographic hip OA.114
    METHODS
Study population 
We used data of the Rotterdam study, a large prospective population-based cohort study
among men and women 55 years of age. The study design and rationale are described
elsewhere in detail (18). In summary, the objective of the study is to investigate the
determinants, incidence and progression of chronic disabling diseases in the elderly. The
medical ethics committee of Erasmus Medical Center approved the study and written
informed consent was obtained from each participant. The baseline measurements were
conducted between 1990 and 1993. In total, 7,983 participants were examined. The
present study used a randomly selected sample of 750 subjects from Rotterdam study I
(RS-1) among participants with a Kellgren and Lawrence score (KL) at baseline 1 in
both hips. Participants with hip fracture and participants with low quality radiographs or
with artifacts on both hips were not included. Only subjects with completed follow up
were included. This resulted in a total of 1,283 hips from 688 participants.
Clinical evaluation and physical examination
At baseline, medical information and physical examination, including measurements of
height and weight were obtained.
Radiographic assessment 
Weight-bearing antero-posterior pelvic radiographs were taken with both of the patient’s
feet positioned in 10° internal rotation and the x-ray beam centered on the umbilicus.
Both at baseline and at 2 follow-up visits (mean time to follow-up: 6.5 and 11 years) hip
joints were scored using the KL-grading system, by two independent observers who
were trained by an experienced physician in OA and advised by a radiologist (19). The
presence of OA features (osteophytes and joint space narrowing) was evaluated using as
reference an atlas of individual radiographic features in OA. The final KL-score was a
composite score according to the presence of both features: narrowing of the joint space
(superior, medial, axial) and superior osteophytes (femoral and/or acetabular) scored
from 0-3 according to the atlas (20). Incident hip OA, determined at each follow-up visit
separately, was defined as a KL of 2 or more (Definite narrowing of the joint space and
at least possible osteophytes; equivalent to grade 1 in the atlas for each feature) or a total
hip replacement (THR). KL was scored for both hip joints. Kappa statistic for KL-score
was 0.68 (inter-rater reliability).115
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    Statistical Shape Modeling (SSM)
A set of 67 points were placed by one observer (MC) and used to delineate the contours
of proximal femur, pelvis and acetabulum to create the statistical shape model (Figure 1).
Using the freely available ASM toolkit (Cootes et al. Manchester, UK), we constructed
an SSM of the 1,283 hips (Figure 1a). The independent modes of variation in hip shape
were extracted by Principal Component Analysis. The first 24 modes that were used in
this study, explained 90% of the variance in hip shape (Supplementary figure 1).
Predefined Geometry Parameters (PGP)
Using the contour points of the SSM, we automatically calculated 12 geometry
parameters (PGP) that describe different aspects of the femoral head, acetabulum,
femoral neck and pelvis: triangular index, head radius, neck shaft angle, head-neck ratio,
spherical sector, Wiberg angle, neck width, neck length, hip axis length, Isquiopubic
index, pelvic width and offset (Figure 1b and 1c). Explanation about methods for
calculating PGPs was included in the supplementary data (supplementary table 1).
Figure 1 a) set of 67 points were used to delineate the contours of proximal femur, pelvis and acetabulum to 
create the Statistical Shape Model (SSM). b & c) Schematic representation of the predefined geometry 
parameters used in this study. b) Neck Width (NW), Head Radius (HR), Wiberg angle (W) “in dark gray”, 
Neck Shaft Angle (NSA), Triangular Index (TI), dotted line (red line shows resulting Radius (R)). c) shows in 
dark gray: Spherical Sector (SS), Pelvic Width (PW), Isquiopubic Index (IPI) “orange triangle”, Hip Axis 
Length (HAL) and Offset.
Intra and Inter-Observer agreement for shape modes and 
geometry parameters
A subset of 46 hips was used to measure within and between observer agreement in
shape modes and predefined geometry measurements. Two observers (JW and MCC)
placed the 67 points for each hip. Intraclass Correlation coefficients were used to analyze
intra and inter-observers agreement. 
a) b) c)116
    Supplementary figure 2a and 2b show the intra- and inter-observers agreement values for
each of the modes and predefined geometry parameters, respectively. For the shape
modes, we found a mean ICC value of 0.78 for intra- and 0.80 for inter-observer
agreement. Some modes had an ICC below 0.7: mode 7, 9, 12 and 13 (Supplementary
figure 2a). Mean ICC for the predefined geometry parameters were 0.92 for intra- and
0.86 for Inter-observer agreement. Almost all PGPs had an ICC above 0.7
(Supplementary figure 2b). Triangular-index had a low inter-observer ICC but a high
intra-observer ICC (Supplementary figure 2b. 0.54 and 0.90 respectively). For this
parameter it is necessary to fix specific points around the femoral head, which apparently
was done slightly different by the two independent readers. 
Correlation among PGPs and among modes
We studied correlations between all predefined geometry measures using Pearson
correlation test statistic (Supplementary Table 2, r-squared). We observed a high number
of significant correlations between the PGPs, most significant were the correlations (r-
squaredx100) between hip-axis length and head radius (72%), head radius and neck
width (69%), triangular index and neck width (67%), neck width and pelvic width
(55%), neck width and hip- axis length (54%), spherical sector and Wiberg (52%), offset
and hip-axis length (45%). We defined moderate correlation as a R2>70% and high
correlation as a R2>80% between two parameters.
Theoretically, all modes should be independent of each other. However, we found some
significant correlations between some of the higher (explaining less variance in shape)
modes, which could be due to mild non-linear correlation between variation in points.
Variation in geometry explained by modes
We examined how much of the variation in PGPs is captured by the modes. Using linear
regression we found that all 24 modes together explain between 37% and 95% of the
variation in each predefined geometry parameter (Supplementary Figure 3a). These
percentages are lower for parameters that represented angles or ratios like spherical
sector and head/neck ratio (Supplementary Figure 3a, Neck-shaft angle: 64%, Wiberg
angle: 60% and triangular index: 57% and head/neck ratio: 37% respectively).117
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    Variation in modes explained by PGP 
Similarly, we examined how much of the modes were explained by the PGPs
(Supplementary figure 3b). A model for each mode was constructed, including the PGPs
that were significant for that respective mode. Only significant PGPs contributed to
explain the variation in modes. In general the  PGPs explained only a small part of the
total variation in hip shape as represented by SSM. The selected PGPs explained a high
proportion of variation only for the two first modes (Supplementary figure 3a, R²: 0.5
and 0.53 respectively). PGPs explained between 30% and 50% of the variation for
modes between 4 and 8 and generally less than 30% after mode 9 (Supplementary Figure
3b). For each mode a different set of geometry parameters was significant.
Statistical Analysis 
We calculated Pearson’s correlation coefficients within the set of modes and within the
set of geometry parameters. R2 from linear regressions was used to estimate the
proportion of variance in each mode of the SSM explained by PGPs and the percentage
of variation in each PGP explained by the 24 modes of the SSM.
The associations between the SSM modes and the PGPs with incident hip OA (defined
as KL>=2 or having had a THR at follow up) were determined using Generalized
Estimating Equations (GEE) which takes the correlation between left and right sides into
account. The analyses were further adjusted for gender, age, height and BMI. When two
PGPs were correlated (R²?0.7) the most significant was included in the final model. To
correct for multiple testing we set for significance a P-value of 0.05 divided by the
number of parameters tested (Bonferroni adjustment). Testing the SSM modes, we
considered P-values lower than 0.0021 (=0.05/24) to be significant. Similarly, P-values
lower than 0.0042 were considered significant for the analysis of the 12 PGPs. All P-
values lower than 0.05 were reported. 
To assess the contribution of PGPs and SSM modes to the prediction of incident hip OA,
multivariable GEE models were constructed using the significant PGPs and SSM modes.
These models were compared using DeLong’s method (21) on the area under the ROC
curves (AUC). SPSS v.15 (SPSS Inc., Chicago, IL, U.S.A) and MedCalc v12.2.1.0
(MedCalc Software bvba, Belgium) were used for the statistical analyses.118
    RESULTS
Baseline characteristics
Baseline characteristics of the study population are described in table 1. The mean age of
the population was 65.6 years. At first follow up, 119 subjects (132 affected hips) had
incident hip OA. At second follow up only 56 new incident cases were registered
(comprising 65 new incident hips with OA). Participants with incident OA (KL>=2) at
follow up were at baseline older, taller and more often females (Table 1). Results for
intra- and inter-observer agreements for the assessment of the geometry parameters of
both SSM and PGP methods, correlation between variables of each method and
percentage of variation explained of the measures of one method by the measures of the
other method are presented as supplementary material.
Table 1. Baseline characteristics of the study subjects.
No-OA: subjects without hip osteoarthritis (OA) after 6.5 years follow up. OA= cases with radiological
osteoarthritis (KL2) at first follow up. N=688 individuals, 1,283 hips. Presented values are means with SD
between brackets for continuous variables and numbers with percentages between brackets for categorical
variables. 
Statistical Shape Modes
Mode 5 and mode 9 were significantly associated with incident hip OA after Bonferroni
adjustment for multiple testing (Pthreshold0.0021, table 2). We used the graphic tool of
the ASM toolkit to visually interpret the shape variations that each mode represented.
Mode 5 appeared to represent internal and external rotation of the femur and
Baseline Characteristics No-OA                                 OA
(n=569)                            (n=119)
 P value
Age (years) 65 (0.27) 68(0.58) < 0.0001
Female* 315 (55.4) 84 (70.6) 0.002
Height (cms) 168.6(0.55) 170.3(0.20) 0.03
Weight (Kg) 74.7(0.4) 75.9(0.89) 0.24
BMI (kg/m2) 26.4(0.29) 26.7(0.10) 0.37
KL 0* 280(49.2%) 13 (10.9%)
< 0.0001
KL 1* 289 (50.8%) 106 (89.1%)119
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    corresponding variation in the pelvis, such that the femur is placed slightly in and out of
the acetabulum (Figure 2). Higher risk of incident OA appears to be associated with less
covering of the femoral head by the acetabulum. (Odds Ratio per standard deviation in
mode 5 (OR): 1.54, and 95% Confidence Interval (CI): 1.30-1.85). Mode 5 was the
variable more significantly associated with narrowing of the joint space at follow up
(p=0.001), positively associated to the Wiberg angle and negatively to the triangular-
index (p< 0.01, not in table). Visually, mode 9 mainly represents variation in length of
the femoral neck, due to variation in the superior neck (Figure 2). Mode 9 was negatively
associated to the Wiberg angle and positively to the triangular-index. A higher risk for
incident hip OA corresponded to mode 9 values that represent a shorter neck (OR: 1.40,
CI: 1.14-1.72). 
Mode 12 was the only geometry parameter associated to incident OA in participants that
had KL=0 at baseline (Table 4, OR:1.69, CI: 1.24-2.30). It appears to represent variation
in acetabular version with corresponding rotation of the femur (Figure 2). Mode 12 was
positively associated to the spherical sector, triangular-index and pelvic width (more
covering of the femoral head and wider pelvis) (P<=0.01) and to a higher risk for OA in
subjects without initial osteoarthritic changes (OR: 1.69, CI: 1.24-2.30).
Figure 2 A visual representation of the extremes of the range of variation of SSM modes 5, 9 and 12               
(-2.5 and +2.5 times the population standard deviation). The left and right columns contain true radiographs of 
subjects with extreme scores on the specific modes.
Predefined geometry parameters
After Bonferroni adjustment, higher values for neck width, pelvic width, hip axis length
and triangular index and lower values for the Wiberg angle corresponded to a higher risk
-2.5 SD +2.5 SD
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    for incident hip OA at first follow up (Table 2, P<0.0042). Adjustment for pelvic
rotation (FOI) and hip size (scaling factor) did not influence the association with incident
hip OA for these parameters. Gender was negatively correlated to scaling factor (r²=-
0.56) and influenced the association of PGPs, especially those “bone size related
parameters” and OA. 
Table 2. Association between hip geometry (shape modes and predefined geometry parameters) and incident 
hip OA at first follow up.
*Odds ratios (OR) and Confidence Interval (CI) are presented as for SD change in each parameter. All
Statistical Shape modes (SSM) and Predefined Geometry Parameters (PGP) with p0.05 are presented. Each
parameter was analysed in relation with incidence of hip osteoarthritis (OA) at first follow up after adjustment
for gender, age and BMI. 
Prediction models of incident hip OA
Hip geometry alone (PGPs+modes) demonstrated moderate discriminative value for
incident hip OA at first follow up (Table 3, AUC: 0.67). This value was similar to the
6.5 years incidence hip OA
n. cases =119 (132 hips)
Parameters *OR (CI) P value
SSM
Mode 5 0.65 (0.54-0.77) < 0.0001
Mode 6 0.80 (0.66-0.97) 0.026
Mode 7 1.23 (1.02-1.50) 0.034
Mode 8 1.31 (1.08-1.58) 0.005
Mode 9 1.40 (1.14-1.72) 0.001
Mode 10 1.35 (1.11-1.64) 0.003
Mode 12 1.22 (1.02-1.45) 0.026
PGP
Wiberg 0.76 (0.63-0.92) 0.004
Spherical Sector 1.26 (1.06-1.50) 0.011
Head Radius 1.41 (1.09-1.82) 0.01
Neck Width 1.60 (1.24-2.05) 2.45x10-4
Hip Axis Length 1.49 (1.18-1.90) 0.001
Pelvic Width 1.43 (1.16-1.75) 0.001
Triangular Index 1.93 (1.54-2.43) < 0.0001121
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    predictive value based on demographic parameters that are known to associate with hip
OA (age, gender, height, BMI; AUC: 0.66). Addition of PGP and modes increased the
predictive value of demographic risk factors by 5% and 6% respectively (Table 3,
p=0.014 for PGPs and p=0.002 for modes). Inclusion of the combination of PGPs and
modes did not further increase the predictive power. The inclusion of all modes and
PGPs that are associated to incident hip OA at p<0.05 (from table 2), increased the area
under the ROC only 2% (N.S.)
Table 3. Area under ROC curves for models to predict hip OA at 6.5 and 11 years follow up.
AUC-ROC= Areas under the receiving operator characteristics curve and 95% confidence interval (95%CI).
*P values are given for AUC comparison between baseline characteristics (gender, age, BMI and height) and
the following models: 1) Only geometry parameters; Predefined Geometry Parameters (PGP): Wiberg, neck
width, pelvic width, hip axis length triangular index and modes: 5 and 9, 2) Baseline characteristics and modes
(5 and 9), 3) Baseline characteristics and the Predefined Geometry Parameters (PGP), 4) Baseline
characteristics and geometry: Predefined Geometry Parameters (PGP) and modes, 5) Baseline characteristics
and Kellgren and Lawrence score (KL) ** P value for comparison of the full model with model 5 (Baseline
characteristics and Kellgren and Lawrence score (KL).
Additionally, we analyzed the contribution of the selected SSM modes and PGPs to the
prediction of the incident cases at second follow up (n=56) compared also to the
demographic risk factors. In general, predictive values decreased at second follow up for
all variables. Prediction given by baseline characteristics was 10% lower. The
contribution of the selected PGPs (Wiberg angle, neck and pelvic width, hip axis length
and triangular index) compared to baseline characteristics was around 11% (Table 3,
P=0.016 for ROC’ curves comparison with baseline characteristics). The two selected
SSM modes did not add to the prediction at second follow-up.
Models First follow-up6.5 years
Second Follow-up
11 years
AUC-ROC
(95%CI) P value
AUC-ROC
(95%CI) P value
Baseline Characteristics 0.66 (0.64-0.69) Ref. 0.56 (0.53-0.59) Ref.
1) PGP + modes 0.67 (0.64-0.69) 0.88* 0.66 (0. 63-0.69) 0.06*
2) Base+modes 0.72 (0.67-0.76) 0.002* 0.59 (0.56-0.62) 0.27*
3) Base+PGP 0.71 (0.68-0.73) 0.014* 0.67 (0.64-0.70) 0.016*
4) Base+PGP+ modes 0.73 (0.71-0.76) 0.007* 0.68 (0.65-0.71) 0.011*
5) Base+KL 0.83 (0.81-0.85) <0.0001* 0.57 (0.54-0.60) 0.72*
6) Base+KL+PGP+modes 0.82 (0.80-0.84) 0.42** 0.68 (0.65-0.71) 0.014**122
    Table 4. Incident hip OA at first follow up and modes based on selection of KL=0 or KL=1 at baseline.
Association of SSM= Statistical Shape Modes, PGP= Predefined Geometry Parameters and incident hip OA at
first follow up was evaluated according with the Kellgren and Lawrence score (KL) at baseline (KL=0 or
KL=1). Values presented are odds ratios (O.R) and 95% confidence intervals (CI) per SD change in the
respective parameter. 
Since many of the KL=1 cases probably have early OA and thus do not represent true
incident OA, we stratified the group according to KL at baseline. For the KL=0 cases,
mode 5 and 9 still showed association with incident hip OA, albeit not significant
anymore for mode 9 (Table 4). In these subjects, mode 12 also gave a significant
association to incident hip OA.   Mode 12 contributed around 9% to the prediction of OA
given by baseline characteristics in individuals with KL=0 at baseline (Not in table,
ROC: 0.61, CI: 0.54-0.67). Of the PGPs, only Wiberg angle reached significance when
hips with KL=0 were selected (Table 4), though the effects of the other PGPs did not
disappear.
Predictions based on hip geometry for OA were of very low specificity for incidence OA
using the first follow up the sensitivity was 0.998 while specificity was very low, around
0.05. Thus, the probability that a positive prediction was a true positive is around 0.104
while the probability that it was a false positive is 0.896 for any particular positive result
(+OA). On the other hand, the probability that a negative prediction was a true negative
was around 0.995 while the probability that it was a false negative is very low: 0.0047.
KL=0
O.R. (CI) Pvalue O.R.(CI)
KL=1
Pvalue
SSM
mode5 0.43 (0.26-0.70) 6.6x10-4 0.71 (0.58-0.87) 8.0*10-4
mode6 1.04 (0.65-1.67) 0.86 0.80 (0.64-1.00) 0.05
mode7 1.52 (0.88-2.61) 0.13 1.19 (0.93-1.51) 0.17
mode8 0.94 (0.59-1.50) 0.80 1.41 (1.12-1.78) 0.003
mode9 1.41 (0.83-2.34) 0.20 1.30 (1.04-1.64) 0.023
mode10 1.10 (0.74-1.63) 0.64 1.36 (1.09-1.69) 0.007
mode12 1.69 (1.24-2.30) 9.4x10-4 1.01 (0.80-1.28) 0.94
PGP
Wiberg 0.44 (0.26-0.73 0.001 0.74 (0.59-0.93) 0.009
Spherical Sector 0.93 (0.66-1.32) 0.70 1.33 (1.07-1.64) 0.010
Head Radius 1.54 (0.93-2.56) 0.09 1.37 (1.02-1.84) 0.039
Neck Width 1.31 (0.76-2.27) 0.33 1.57 (1.06-2.33) 0.025
Hip Axis Length 1.70(1.11-2.62) 0.015 1.47(1.14-1.90) 0.003
Pelvic Width 1.42 (0.91-2.21) 0.12 1.26 (0.99-1.60) 0.06
Triangular Index 1.26 (0.60-2.62) 0.54 1.69 (1.32-2.17) < 0.0001123
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    DISCUSSION
In this study we investigated the extent to which hip geometry contributes to the
prediction of radiological incident hip OA. In line with previous studies, we showed that
distinct aspects of hip shape are clearly associated to incident hip OA.  Additionally, we
demonstrated that hip geometry can improve the prediction given by clinical risk factors
in subjects with or without initial signs of OA (KL=0/1). Ability of hip shape to predict
incident hip OA was similar and slightly better than the common demographic risk
factors age, gender, height and BMI.   Hip geometry contributes between 8 and 12% to
the prediction given by clinical risk factors for participants with or without initial
radiographic changes respectively. Two different approaches were used to quantify hip
geometry: predefined measures and a Statistical Shape Model (SSM). In the first
approach, we selected specific measures from literature, which have been shown to be
related to mechanical load on the hip or to OA. The second hypothesis-free approach
used a SSM to find measures of hip shape that represent distinct patterns of correlated
aspects of hip geometry within the total variation of hip shape in our cohort. In theory,
the SSM represents the most complete information on hip shape. Indeed, the predefined
geometry measures could only partly explain the variation in the SSM modes. Vice
versa, the modes explained well the measures of size, but could not fully describe those
measures that represented angles and ratios. Both methods appear to contain information
that is not captured well by the other method; since they describe different aspects of hip
geometry we consider that depending of the study’ subject they might complement each
other.
Since the OA process alters the shape of the bones in the affected joint, the question
arises whether the geometry aspects associated with OA represent a cause or
consequence of OA. The strength of the association for many measures was similar in
subjects with KL=0 at baseline when compared to the overall association, suggesting
that these measures might represent shape variants that pre-date radiological OA.
Exceptions were Neck Width, Triangular Index, Spherical Sector and a few modes that
showed a lower association with OA and thus might reflect changes in shape related to
bone remodelling during early OA. Interestingly, Wiberg angle and mode 12 were
predictors of OA in subjects without initial signs of OA (KL=0), and also contributed to
the prediction of incident OA at second follow up. These measures might thus represent
shape aspects that are a causing factor for OA. However, these statements remain only as
tentative explanations, since we had low power in the group with KL=0 to derive
conclusions on the differences between the groups (KL= 0/1).On the other hand, for
many of the association with hip geometry parameters the relation was stronger or only124
    present for those with KL=1. This indicates that at least part of the observed associations
might actually represent active bone remodelling that it is known to occur at early stages
of OA and that might be considered as an important components of the pathogenic
process that leads to OA (22). Alternatively, bone adaptation in OA can be mechano-
regulated with structural changes that might occur independent of cartilage degeneration
(23).
According with our results, subjects with OA had higher values of bone size related
parameters and gender adjustment increased the strength of the associations between
geometry and OA. It was not the case for adjustment of the scaling factor. Association
between bone size, geometry and OA might share common etiological factors; It has
been recently discussed that genes implicated in bone formation and growth have also a
role in OA (pleiotropic effects), what could be part of the explanation. Prediction of OA
decreased for all variables using a longer follow up. The demographic risk factors for
OA, gender, age, height and BMI lost their predictive value for the 11 years follow-up.
The predictive power of geometry also decreased to a value between 6 and 16%. The
decrease in predictive value of geometry at second follow up was not exclusive for
shapes but, it was more pronounced for them. It might be explained by the sensitivity of
shapes to detect early OA-changes, including bone remodelling. On the other hand,
larger variations in geometry might cause OA earlier in life as is the case for subjects
with severe dysplasia and impingement where OA develops several years earlier than for
subjects without these large geometrical differences (24, 25).
Many shape aspects that were found to be relevant for hip OA, appear to be related to the
congruency between femur and acetabulum determined by asphericity of the femoral
head, more specifically the shape of the superior head-neck junction, and the shape of the
acetabular socket (acetabular dysplasia). Asphericity of the femoral head results in
impingement of the head against the labrum, eventually resulting in damage which might
trigger the development of OA. Typical is the anterolateral prominence or cam deformity
which is thought to be formed during adolescence as a result of physical activity (26, 27).
Also less severe forms of asphericity like a flattening of the head-neck junction (pistol
grip deformity) have been associated to OA (9). These shape aspects are generally
measured by the alpha angle or the triangular index, while other measures like the width
of the neck or the head-neck ratio are also influenced. This study further supports these
findings, with significant associations of the triangular index, neck width.Our results
corroborate earlier publications on mild dysplasia as a risk factor for hip OA (7), in the
current study indicated by the effects of the Wiberg angle and mode 5. Besides, the
association of high values of the spherical sector with increased OA-risk supports the125
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    idea that deep placement of the femoral head predisposes for OA as in cases of
protrusion acetabuli where there is a progressive migration of the femoral head into the
pelvic cavity (28, 29).
The conclusions of this study extend only to cases of radiographic OA since we did not
consider information on clinical OA symptoms. Other limitation derives from the
interpretation of geometry from 2D x-ray images that might be simultaneously
influenced by true changes in geometry and by positional variation in the bones. Thus,
we cannot be certain whether the found association with OA is due to true geometry
variants or due to differences in bone position, especially since variation in position of
the bones could reflect hip pain and OA-related limitations in internal rotation of the hip.
Visual inspection of the modes of the SSM, however subjective, does give some
indication of whether positional variation plays a role (30). In the same manner,
interpretation of what modes represent is subjective of nature. Thus the diagnostic value
of SSM is rather limited. Further, although reproducibility of the predefined geometry
measures was good, we did not validate these measures with the same geometry
parameters measured by hand using the original protocols. Finally, in spite of the
significant predictive value of geometry for hip OA in general, predictions based on hip
geometry were of very low specificity. Clinical utility of hip geometry need to be tested
in groups at higher risk, for example in groups at higher genetic risk for OA.
The advantage of the use of predefined geometry measures is that it seems simple and
intuitive. However, some measures correlate hampering statistical analysis and
interpretation of findings. This drawback is absent when SSM is used, since all modes
are theoretically independent, although we found some mild correlations in the higher
modes. When we combined the two methods in a predictive model for OA, we observed
that the PGPs did not contribute additionally to the prediction of incident hip OA made
by the shape modes, indicating that the majority of relevant geometry information for
OA is contained in the modes of the SSM.
In conclusion, this study confirms that hip geometry is strongly associated with OA and
it is able to predict OA similar to known risk factors.  Some variations in hip geometry
are associated with early osteoarthritic changes but others might precede radiologic OA
contributing to the prediction of incident OA in subjects without radiological evidence of
OA. 126
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    SUPPLEMENTARY METHODS
In order to calculate the PGPs, we derived a few reference points and lines from the
manually placed contour points. All measures were defined by a combination of
manually placed landmark points, reference points and lines derived from the landmark
points and the contours. A complete description of the geometry parameters and how
they were calculated are presented in Supplementary table 1. Additionally, a reference
line was formed between the points (point 42) in the corner of the foramen on the
radiographs of both left and right side. It was used as horizontal reference line
representing the inclination of the pelvis. To control for possible pelvis rotation/
inclination and size differences that could affect some measurements we used “the
Foramen obturator index (FOI)” from Tonnis [22] and a scaling factor; The scaling
factor was then defined as the ratio of this summed distance and the mean of these
summed distances of all images. It was used as a covariate to adjust the predefined
geometry parameters in the comparison of predefined geometry parameters and modes.
All geometry parameters were calculated using Matlab.130
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    Supplementary table 2.   Correlation (r2) between Predefined Geometry parameters.
PGP Wiberg SS HR NW H/N NSA HAL PW Offs IPI TI Scaling
Wiberg 1 0.52 -0.18 -0.11 -0.04 -0.22 -0.29 -0.06 0.19 -0.11 0.002 -0.10
SS 0.52 1 -0.13 -0.06 -0.05 -0.01 -0.15 -0.03 0.02 -0.18 0.03 -0.08
HR -0.18 -0.13 1 0.69 0.14 0.13 0.72 0.62 0.32 -0.04 0.56 0.57
NW -0.11 -0.06 0.69 1 -0.48 -0.97 0.54 0.56 0.36 -0.13 0.67 0.48
H/N -0.04 -0.05 0.14 -0.48 1 0.28 0.11 -0.08 -0.15 0.10 -0.2 -0.07
NSA -0.22 -0.01 0.13 -0.9 0.28 1 0.27 -0.23 -0.45 0.03 -0.24 -0.12
HAL -0.29 -0.15 0.72 0.54 0.11 0.27 1 0.66 0.45 -0.03 0.52 0.61
PW -0.06 -0.03 0.62 0.56 -0.08 -0.23 0.66 1 0.72 -0.01 0.62 0.67
Offset 0.19 0.02 0.32 0.36 -0.15 -0.45 0.45 0.72 1 -0.12 0.52 0.55
IPI -0.11 -0.18 -0.04 -0.13 0.10 0.03 -0.03 -0.01 -0.12 1 -0.50 -0.09
TI 0.002 0.03 0.56 0.67 -0.2 -0.24 0.52 0.62 0.52 -0.50 1 0.51
Scaling -0.10 -0.08 0.57 0.48 -0.07 -0.12 0.61 0.67 0.55 -0.09 0.51 1132
    Supplementary figure 1   Individual and cumulative variance explained by each of the 24 SSM modes.
Supplementary  figure 2a. Intraclass correlation coefficient for SSM modes.
Supplementary figure 2b   Intraclass correlation coefficient for predefined geometry parameters.
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    Supplementary figure 3a   Variance in predefined geometry parameters explained by SSM modes.
Supplementary figure 3b   Variation in SSM modes explained by predefined geometry parameters. 
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    ABSTRACT
To determine if structural bone parameters obtained from dual energy X-ray
absorptiometry (DXA) contribute to the prediction of progression of hip osteoarthritis
(OA) and to test if the difference between the most affected (OA) hip and the
contralateral hip adds to this prediction. The study group involves a prospective cohort of
189 patients that met the ARC classification criteria for hip OA. Progression was defined
as 20% joint space narrowing or total hip replacement within a two years follow up.
Software was developed to calculate geometrical aspects and BMD in different regions
of interest of the proximal femur. Logistic regression was used to test if Kellgren and
Lawrence (K-L) scores and DXA parameters can predict “progression” of OA. Models
were compared using -2log likelihood tests, R² Nagelkerke and areas under the Receiver
Operator Characteristic curves, assessed using 10-fold cross validation.The model that
included the DXA variables was significantly better in predicting hip OA progression
than the model with K-L score of the affected side alone (P<0.01). The addition of the
differences in DXA parameters between the most affected and contralateral hip in the
superior part of the femoral head, trochanteric and intertrochanteric area further
improved the prediction of progression (P<0.05). K-L score of the affected side was still
the most significant single variable in the models. DXA parameters can significantly
contribute to the prediction of progression in patients with hip OA. The analysis of the
DXA differences between the hips of the patient represents a small but significant
contribution to this prediction. These analyses show the importance of bone density
changes in the etiology of OA. 
Key Words: hip osteoarthritis, progression, densitometry, femoral head.137
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    INTRODUCTION
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive damage
of the articulate cartilage, occasional inflammation of the synovium, osteophytosis and
alterations in the subchondral bone. It is often hypothesized that subchondral bone
changes play an important role in either initiation or progression of OA [1-2]. Changes in
bone shape, bone mineral density (BMD) and subchondral bone mechanical properties
were reported in the presence of radiographic signs of hip OA [3-8]. A number of studies
were performed that correlate radiographic osteoarthritis and/or clinical symptoms with
bone measurements based on DXA that are typically performed in relation to
osteoporosis. These measures concern BMD in the hip or spine at specific regions of
interest such as e.g. the femoral neck. This data is rather confusing and conflicting in
many aspects. An increased local and remote BMD has been reported in patients with
radiographic hip OA [9], suggesting an inverse relationship between OA and
osteoporosis. This was confirmed by Goker et al. [10] in patients that underwent total hip
replacement, where the subjects with high progression of Joint Space Narrowing (JSN)
at their contralateral hip had elevated BMD in both hip and spine. 
Antoniades et al. only found this inverse relationship between local BMD and
osteophytosis and not with JSN [11]. Other studies report an inverse relationship only in
the affected hip and even a decreased BMD at remote sites and the contralateral hip [12-
13]. This was further substantiated by Sandini et al, finding higher Bone Mineral Content
(BMC) and larger area in the DXA data from patients with hip OA [14]. Changed muscle
conditions and weight bearing may alter the load conditions in OA and local bone
density changes may be the result of adaptation to an altered load distribution through
the bone structure. Altogether, there seems to be conflicting data concerning the
relationship between bone related parameters in OA. The variables that have been
analyzed using DXA are often defined only in regions of interest that are relevant for
osteoporosis, for which DXA has been specifically designed. These regions are e.g. the
femoral neck and vertebral body. Beck and co-workers have designed methods to
analyze a number of other parameters that are related to biomechanical aspects of the
narrowest region of the proximal femur, an area of high interest in osteoporosis [15].
However, for OA other regions might be of more interest, such as the subchondral bone
BMC or BMD.
The rate of progression of hip OA varies largely between patients. Some patients with
radiographic signs of initial hip OA do not show disease progression for years.   In other
cases the disease progresses relatively fast, e.g. needing total hip replacement after less138
    than two years after onset of the first symptoms. The determinants of this progression are
largely unknown [16]. It is also unclear what the role is of BMD, BMC or morphological
bone variations on progression of hip OA. Better understanding of the involvement of
alterations in the bone might allow early identification of cases and maybe even provide
opportunities for early intervention. Therefore, this study aims to determine if structural
bone geometry and density parameters as determined by hip DXA scans in the proximal
femur, contribute to the prediction of OA progression. Furthermore, we tested if the
difference in these DXA-based variables between the most affected and contralateral hip
adds to this prediction. Since left-right differences are independent of biological
variation in bone size or density we hypothesize that these are better predictors of disease
progression.
MATERIALS AND METHODS 
Study Population
This study includes primary care patients with osteoarthritis of the hip derived from the
“Glucosamine sulphate in hip osteoarthritis” (GOAL) trial of the Erasmus Medical
Center, with data collected at baseline and every three months up to two years follow-up.
Details of the study have been described earlier [17]. In summary, patients were eligible
for inclusion in the GOAL cohort when they met one of the American College of
Rheumatology (ACR) criteria for hip OA [18]. Patients that had already undergone hip
replacement surgery or those on the waiting list for joint replacement were not included
in the study. In addition, eligible patients with a Kellgren & Lawrence (K-L) score of 4,
people with renal and/or hepatic disease, diabetes mellitus or with disabling co-
morbidity were excluded. Sex, age, height, weight, duration of complaints and body
mass index (BMI) were registered or measured in all OA patients. For this study only
participants with bilateral radiographs and dual energy X-ray absorptiometry (DXA
scans) of adequate quality measured at baseline and after two years follow up were
included in the analyses. The Ethical Committee of Erasmus MC approved the study
protocol, and patients provided written informed consent. 
Radiographic Assessments 
A strict protocol was used to enable correct measurements of joint space narrowing at
baseline and two years follow up. Pelvic radiographs were taken in weight bearing
position with the patient’s hips at 15° internal rotation. From the digitized x-rays the139
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    minimal joint space width (JSW) was assessed at the medial, axial, superior and lateral
points of the joint or any other site where the JSW was minimal. The intraclass
correlation coefficient of the minimal joint space width measurement was 0.98. All the
radiographs were scored at baseline according to the Kellgren-Lawrence score from
grades from 0 “no OA” to 4 “severe OA” [19].
DXA Scan Analysis
DXA-scans (DPX-Lunar GE) from both hips were made at baseline ensuring 15°
internal rotation of the hips, similar to the protocol used for the radiographs. A software
tool was developed that enables evaluating bone geometry and density parameters from
DXA scans in specified (non-conventional) regions of interest in the hip. Regions of
interest (ROI) of which we calculated BMD, BMC and area size included the femoral
head (divided in quarter and arcs), femoral neck, acetabulum, trochanteric and inter-
trochanteric areas. Figure 1 present a detailed definition of all the DXA parameters.
The analysis was performed using Matlab (version 7.1.0, MathWorks Inc, Natick,
Massachusetts). The software calculated the parameters in a semi-automatic way.
The major and minor trochanters were indicated manually, as was the size and position
of the femoral head according to the location of the bony margins of the acetabulum or
acetabular rim, which were used as points of reference; all other parameters were
measured automatically. The neck axis was positioned in the middle of the femoral neck,
bisecting the centre of the neck. The femoral axis was determined as a line parallel to the
femoral shaft passing through the middle point localized between the most external
margins of the femur. Geometry parameters and regions of interest (ROI) for BMD,
BMC or area measurements included the femoral head, femoral neck, acetabulum,
trochanteric and inter-trochanteric areas. Figure 1 and figure 2 show a detailed definition
of all the DXA parameters. 
Progression of hip osteoarthritis
We defined progressive cases as those patients that presented joint space narrowing
(JSN); a decreased joint space width (JSW) compared to baseline of twenty percent
(20%) or more was considered positive for progression of hip OA according to
previously described criteria [20]. It takes in account for the big variability in the joint
space that exists between individuals. We included in the progression group also those
patients that received a total hip replacement (THR) during the 2-year follow up.140
    Figure 1 DXA image that shows the parameters that are determined in the software of the DXA analysis.             
a) Trochanteric area (TA), Neck shaft angle (NSA), femoral neck length (NL): line from the center of the 
femoral head to the intersection point of the femoral shaft and femoral neck (FN). The femoral head was 
divided in four quarters: Superior (S), Medial (M), Inferior (I), and lateral (L). b) Arcs dividing the upper part 
of the femoral head in four sub regions ranging from the center of the subchondral region and acetabular area 
(A), neck width (NW) measured on the narrowest neck region and intertrochanteric area (ITA). For all areas the 
BMD, BMC and area size were determined.
Figure 2 DXA image that shows the parameters of the DXA scan that are part of model 5, which provides 
the overall best prediction of OA progression. Superior area size (S), superior and medial (M) BMD and BMC 
from the femoral head, Intertrochanteric and trochanteric area size (ITA and TA) respectively).
Statistical Models
We evaluated a number of statistical regression models with different combinations of
the following variables: baseline Kellgren and Lawrence (K-L); baseline DXA-based
parameters (both geometry and BMD or BMC related parameters); the K-L score
difference between the most affected and contralateral hip at baseline (K-L) and the
difference between the most affected vs. contralateral DXA-based parameters at baseline
(DXA). All models were adjusted for age, weight, height, and sex. To reduce the
a) b)141
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    number of DXA variables to a significant subset we used a backward stepwise method
using the Likelihood ratio test. Progression of OA was predicted using five different
models: the first model (1) was used to investigate the contribution of the K-L score of
the most affected side to the prediction of progression (K-L); model 2 was used to
investigate the contribution of the DXA based parameters of the most affected side to
progression (DXA); model 3 revealed how the combination of DXA parameters and the
K-L score of the most affected side contribute to the prediction of progression (DXA +
K-L); model 4 was used to test if adding the K-L difference within hips to the K-L score
of the affected side only improved the prediction of progression of model 1 (K-L + K-
L); and model 5 was used to test if the difference of the most affected (OA) and
contralateral hip between the DXA parameters added to the prediction based on K-L
score of the affected side (K-L+DXA).   
The likelihood-ratio test was used to determine if the differences between the models
were significant [21]. Using the software package “R” we calculated “An Information
Criterion (AIC)” values of the various models. R is a programming language and open
source software environment for statistical computing and graphics widely used for data
analysis. AIC is an index of the amount of information that is lost when the model is
used to describe the data [22].  The preferred model is the one with the AIC value closest
to zero. In all regression models areas under the Receiver Operator Characteristic curves
(ROC) were determined and used to compare the discriminatory capacity of the models.
The Areas under the Curve (AUC) represent the prediction probability that a randomly
selected pair of diseased and non-diseased subjects will be correctly classified. A perfect
predictive model has the value AUC=1.0. Conversely, a non-informative test has
AUC=0.5. True positive and true negative rate were separately analysed to identify the
percentage of OA cases and non-cases correctly predicted by the models. In addition,
Nagelkerke R² was used to measure the proportion of variability in a data set that is
accounted for by the statistical models. Nagelkerke's R2 is a modification of the Cox and
Snell coefficient to assure that it can vary from 0 to 1. Ten-fold cross validation was used
to reduce the error due to over-fitting for the statistical estimates (AIC and AUC).  All
statistical analysis were performed using SPSS, version 14 (SPSS inc., Chicago USA)
and R version 2.7.2 (Free software foundation, Inc, Boston USA).142
    RESULTS
Participant characteristics and progressors characteristics
Out of the 222 patients that were enrolled in the trial, 189 patients had DXA scans of
sufficient quality to be included in the current study. Using our definition for progression
43 out of 189 patients (22.8%) were considered to have developed radiographic
progression of hip osteoarthritis after 2 years of follow- up (Table 1). Of the 43 patients
that progressed, 17 (39.5%) received a total hip replacement and 26 had a JSN of 20% or
more. We did not find significant differences in age, sex, weight and height between the
progression and non-progression groups (Table 1). The majority of the progressors were
found among patients with a K-L score of 2 and 3. There were no progressors in the
group with a baseline K-L score of zero (Table 1). JSW decreased with increasing K-L
score, with slightly (but not significantly) lower baseline values for the progressor group
(Table 2). The biggest differences in BMD or BMC between progressors and non-
progressors were found in the regions close to the joint space (superior and medial part
of the head and the outer arcs 3 and 4, Table 3 and Figure 1). As expected, these values
were higher (Z-score 0.39 to 0.48) for the progressors. The area of the entire femoral
head (all four quarters) and the femoral neck width also were significantly higher in the
progressor group (Table 3). 
Table 1. Baseline population characteristics of studied population.
Characteristic Total n = 189
Progressor
n = 43
Non-progressor
n =146
Age (years) mean +/-SD 63.5+/-9.0 64.2+/-8.7 63.2+/-9
- Age 41-60, n (%) 72 (38) 16 (37) 56 (38)
- Age 60-70, n (%) 117 (62) 27 (63) 90 (62)
Female, n (%) 131 (69) 26 (60) 105 (72)
Height, mean +/- SD 1.69+/-.08 1.69+/-.08 1.69+/-.08
Weight, mean +/- SD 78.8+/-12.5 80+/-11.5 78.5+/-12.8
BMI (kg/m²), mean +/- SD 27.7+/-4.0 27.9+/-3.3 27.7+/-4.2
K-L score 0 12 0 12
K-L score 1 95 6 89
K-L score 2 57 21 36
K-L score 3 25 16 9143
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    Table 2. JSW at baseline and follow up in progressor and non-progressor groups according to KL score at 
baseline. Values represent JSW in mm (mean and SD) at baseline and 2 years follow up. 
Model results
The Kellgren and Lawrence score (K-L) proved to be a significant predictor for
progression. After cross-validation the area under the Receiver Operator Curve (AUC)
for Model 1 was 0.76 (Table 4). The true positive rate (TPR) of this model is 37.2%.
In the next model we analyzed the DXA scan parameters of the affected side. The
backward stepwise regression left only three variables in the model: the BMC of the
medial part of the femoral head, the BMC of the inferior part of the femoral head and the
BMC of the femoral neck (Model 2). After cross-validation the model’s performance
was inferior to K-L in model 1 (AUC=0.69, table 4). Similarly the true positive rate
(TPR) of this model was lower (9.3%).
In Model 3 we combined the predictors from model 1 (K-L score) with the predictors
from Model 2 (the three BMC DXA variables), which resulted in a model with
reasonable good predictive performance after cross-validation (AUC = 0.83). The
difference in AUC score of this model with the previous two models proved to be
significant (P<0.05). The TPR of 34.92 was slightly less than model 1, table 4. 
In Model 4 we added the K-L score difference (K-L) between the hips of each patient
as a predictor to model 1 (K-L score of the affected side only). Adding K-L resulted in
a significant increase in AUC (P<0.05) compared to model 1. Both the AUC (0.82) and
the TPR (34.9%) were similar to the values for model 3, table 4. 
Progressors Non-progressor
KL score JSW bas JSW fu JSW bas JSW fu
0 N.A N.A 3.0 (0.7) 3.0 (0.6)
1 2.67 (0.9) 2.31 (1.2) 2.8 (0.5) 2.8 (0.6)
2 1.62 (0.83) 1.15 (0.64) 1.89 (0.75) 1.93 (0.73)
3 0.75 (0.7) 0.57 (0.7) 0.8 (0.9) 0.8 (1.1)144
    Table 3. DXA variables for progressors and non-progressors. Values represent the distance between the 
mean value of each variable for progressors and non progressors and the population mean in units of the 
standard deviations. Z is negative when the group’s mean is below the population mean. P value was adjusted 
by gender, age, height and weight.
In the last model (Model 5) we combined K-L of the affected side (Model 1) with the
difference in DXA values between the most affected and contralateral hip. The backward
regression resulted in a different set of DXA parameters than those identified by Model
2: The area size of the superior part of the femoral head, the area of the major trochanter,
the intertrochanteric area and both the BMD and BMC of the superior part and medial
Variables Z-scorenon-progressors
Z-score 
progressors
Adjusted
p-value
BMC
Femoral Neck (FN) -0.07 0.16 0.17
Intertrochanteric Area (ITA) 0.02 0.07 0.9
Trochanteric area (TA) -0.01 0.02 0.6
Superior quart femoral head (S) -0.13 0.44 0.009
medial quart femoral head (M) -0.10 0.39 0.019
inferior quart femoral head (I) -0.07 0.24 0.08
lateral quart femoral head (L) -0.08 0.27 0.06
acetabular arc (A) -0.10 0.36 0.01
arc4 -0.12 0.45 0.003
arc3 -0.13 0.48 0.001
arc2 -0.11 0.37 0.02
arc1 -0.07 0.24 0.19
Areas / size
Femoral Neck (FN) -0.08 0.21 0.6
Intertrochanteric area (ITA) 0.02 -0.02 0.16
Trochanteric area (TA) 0 0 0.4
Superior quart femoral head (S) -0.15 0.47 0.002
medial quart femoral head (M) -0.12 0.50 0.002
inferior quart femoral head (I) -0.15 0.47 0.003
lateral quart femoral head (L) -0.15 0.49 0.003
Acetabular arc (A) -0.08 0.20 0.04
arc4 -0.01 0.04 0.005
arc3 -0.15 0.06 0.001
arc2 -0.10 0.10 0.007
Arc1 -0.07 0.32 0.2
Geometry
Neck width (NW) -0.14 0.38 0.04
Neck length (NL) 0.00 -0.04 0.41
Neck shaft angle (NSA) -0.02 0.08 0.7145
Ch
apt
er 
3.2
    part of the femoral head were selected (Fig 2). This model is significantly different to the
model that only includes K-L score of the affected side (Model 1) and to the model that
uses the K-L score difference and the value of the K-L score of the affected side (Model
4) based on comparing AUC differences after cross-validation (P<0.05). The AUC of
Model 5 (0.84) was not different from the AUC of Model 3 (K-L + DXA most affected
side; AUC: 0.83), but the model is much better in the prediction of progressive cases
(With a TPR of 51.2%). Additionally, this model has the lowest -2Log Likelihood ratio
and AIC value (Table 4).
Table 4. Models using clinical, radiological and DXA variables. Abbreviations: K-L: Kellgren and Lawrence 
score of the affected side. The difference in values between affected hip and contralateral side is expressed in 
percentage (%). Positive values represent an increase in the affected hip. No applicable (NA) in the cases that 
the variable only reflect the affected side. Level of significance codes: '***' p value<0.001, '**' p value<0.01, 
'*' p value<0.05.   All models were corrected for patient characteristics. True positive rate (TPR) and true 
negative (TNR) columns correspond to the percentage correctly predicted by the models. *Area under the 
curve value obtained after 10-fold cross validation process.
Variables % Diff. 
& P -2 Log R² AIC
AU
C
TN
R TPR
KL score affected side: 30.7 *** 159.5 0.31 163.5 0.76 93.2 37.2
DXA affected side:
- BMC medial part femoral head
- BMC inferior part femoral head
- BMC femoral neck
13.9 ***
7.2 ***
5*
184.2 0.15 192.2 0.69 97.3 9.3
DXA affected side + KL:
- BMC medial part femoral head
- BMC inferior part femoral head
- BMC femoral neck
- KL affected side
13.9 *
7.2 *
5**
NA***
148.6 0.38 158.6 0.83 93.9 34.9
KL affected side + Delta KL
- KL score affected side
- Delta KL
NA***
32*
154.0 0.35 160 0.82 93.9 34.9
DXA ROI’S difference:
- Difference superior area fem head
- Difference trochanteric area size
- Difference BMD sup. part fem. head
- Difference BMC sup. part fem. head
- Difference BMD med. part fem. head
- Difference BMC med. part fem. head
- Difference Intertrochanteric area size
- KL score affected side
16.5*
2*
5.7**
9**
4.6**
4**
-4.5*
NA***
135.6 0.45 153.6 0.84 91.7 51.2146
    DISCUSSION
In this study we analyzed how well selected DXA parameters of the hip that were
specifically chosen to be relevant for osteoarthritis, together with the accepted Kellgren
and Lawrence score contribute to the prediction of OA progression. 
We found that both the K-L score and the selected DXA parameters alone were not good
predictors for OA progression, with K-L performing marginally better than the DXA
parameters alone. Interestingly, when both models were combined the resulting model
exhibited a small but significant increase in performance as shown by the increase in
AUC. Apparently, the DXA parameters that were investigated in this study refer to
measures of OA that are relatively independent of the Kellgren & Lawrence score. 
Many of the DXA parameters themselves however, were not independent but highly
correlated among each other. The number of DXA variables used in the regression
models was reduced using the backward stepwise method in the likelihood ratio test.
Therefore the resulting regression models are dependent on the backward stepping
procedure and other models that include other parameters (representing similar aspects)
might work just as well. What is important here is not so much the meaning of the
specific parameters used in the regression models, but the potential of DXA parameters
for the prediction of OA progression, which justifies a more in depth study.
We further investigated if the prediction based on DXA parameters would improve when
the difference between most affected and contralateral side was used rather than the
affected side itself. We assumed that looking at the DXA difference between the most
affected and contralateral side would correct at least partly for the biological variation in
bone sizes and bone density. Thus, this measure could highlight how the disease process
has affected the bone and therefore be a better predictor for disease progression. Even
though the AUC for the model that included this DXA (model 5) was only slightly
higher than the AUC of model 3 (DXA parameters of the most affected side and K-L
score of the most affected side), the percentage of correctly classified progression cases
(TPR) is much higher than in model 3. Additionally, this model (model 5), showed a
better statistical performance, lowest –2Log, AIC and higher R² (Table 4: -2Log: 135.6,
AIC: 153.6 and R²: 0.45) than any other model.The definition of progression in this
study included patients with both JSN (more than 20%) and patients that received a total
hip replacement (THR) within the follow-up period of 2 years [20]. The latter is maybe a
possible limitation of this study, because we cannot determine if the THR patients truly
exhibited joint space narrowing. We tested the effect of excluding the THR patients to147
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    the models in a sensitivity analysis. In all models the exclusion of THR cases affects the
percentage of correct predictions and AUC. However, the general trends were similar
and the model that included the difference between the most affected- and the
contralateral side (model 5) still remained the best predictive model. 
Other limitations of this study are related to the relatively short follow-up and the
inaccuracies inherent to the DXA measurements. The limitations of the DXA method
itself have been exposed previously by other authors [23]. Radiological progression of
OA is better defined when patients have longer follow up. In addition the study
population is rather heterogeneous with patients that varied in (subjective) pain scores
and ranged from mild OA (K-L 0 and 1) to advanced stages (K-L 2 and 3). It seems
likely that the more degenerated joints at baseline progress differently than a joint in the
early phase of the disease. In terms of our definition of progression it is clear that
advanced OA joints with an already small JSW do not have to progress much to reach a
20% narrowing. The majority of the progressors are in the K-L scores 2 and 3 and since
a K-L score of 4 was an exclusion criterion we have no patients with extreme low JSW
(Table 2).
 Different hypotheses exist about the role of BMD changes during the OA process. We
had defined different regions of interest of which some were close to the joint with a
putative effect on osteoarthritis development. Not only femoral head regions were found
to be relevant, but also the more distant regions such as the femoral neck and trochanteric
regions. The difference in intertrochanteric area size (between affected and contralateral
hip) had a negative correlation with progression and might be the consequence of
muscular dysfunction of the hip abductor group that has been found in patients with hip
OA [24, 25].
We also identified an increase in size at the femoral head and trochanter and increased
BMD and BMC of the superior and medial part of the most affected femoral head
compared to the contra lateral side in the group of patients where the disease progressed
(Figure 2). The BMD and BMC increase in the head regions is in concordance with
published literature and we suppose that the differences are acquired as part of the
osteoarthritis process and subsequent bone adaptation. However we cannot exclude the
possibility that some of these left-right differences existed previous to the onset of the
disease. 148
    CONCLUSIONS
We have shown that DXA scans of the hip contain information that can be used to
predict OA progression. Patients that presented OA progression had a higher BMC in the
medial and inferior region of the femoral head compared to those that did not progress.
Also, the bone mass in these regions was higher in the most affected hip compared to the
contralateral side. These differences between the most affected hip and the contralateral
hip appear promising to predict progression of the disease. Further study of DXA scans
with improved resolution could lead to the development of useful clinical tools to
diagnose OA and predict the chances of fast progression.
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    ABSTRACT
Atrophic type of hip osteoarthritis (OA) is characterised by cartilage degradation without
formation of osteophytes. Individuals with atrophic OA have been less studied and it is
unknown whether they differ from osteophytic types regarding bone tissue. We here
examined BMD, hip structural properties and fracture risk in individuals with atrophic
OA type compared to individuals with osteophytic types (normotrophic/hypertrophic)
and to individuals without OA. This study is part of the Rotterdam Study, a large
prospective population based cohort study. We examined 5006 participants who were
assessed for osteoarthritis, BMD, and geometry measures at baseline and incident non-
vertebral osteoporotic (OP) fractures (mean follow-up time of 9.6 years). We estimated
differences in bone characteristics between the OA-groups and controls. Cox's
proportional hazards regression was used to calculate OP fracture risk. 
Results. Participants with atrophic OA had systemically lower BMD compared to
normotrophic type and controls respectively (6.5 and 9% in total body and 4 and 5% in
skull-BMD respectively). Participants with osteophytic OA had approximately 4 and 5%
higher total body- and skull-BMD, wider femoral neck and greater bone strength (12 and
5% higher section modulus) compared to controls or atrophic OA. However, the risk of
OP fractures was almost 50% higher in the atrophic group compared to controls (HR:
1.48, p: 0.008). It was not explained by differences in BMD, falling, disability or
corticosteroid use. Individuals with atrophic hip OA have an increased risk for OP
fractures not fully explained by systemically lower BMD compared to controls.
Keywords: Osteoarthritis, atrophic, hypertrophic, hip, joint space, osteophytes, bone
mineral density, bone geometry, osteoporotic fractures.157
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    INTRODUCTION
Hip osteoarthritis (OA) is a common joint disorder and a major cause of pain and
disability in the elderly population. OA is characterised by cartilage degradation, new
bone formation and changes in the subchondral bone. Although OA was once considered
a primary disorder of articular cartilage, it is now generally appreciated that bone
structure play a role in OA pathology.
Individuals with OA are known to present higher bone mineral density (BMD) and
hence, be protected against osteoporosis (1-4). However, both conditions can co-exist (5-
7) and some reports even suggest that subjects with OA may have increased fracture risk
(8-11).
Hip bone geometry parameters have been shown to influence the risk of fracture (12-18).
Differences in bone geometry have also been observed in subjects with hip OA as
compared with controls, presenting with wider femoral necks and alterations of mass
distribution which are associated with both incident and prevalent OA (19). Yet, only
few studies have examined the relation of hip OA with fracture risk and none of them
considering the different subtypes of the disease (2, 4, 8, 10-11, 20-22).
 
Radiographic hip OA is frequently defined by the presence of both cartilage
degeneration (radiographically defined as joint space narrowing (JSN)) and formation of
new bone spurs at the joint margins (osteophytosis; OPH). However, both radiographic
features are not always present, which makes it possible to sub-classify OA in different
types (23-25). The most frequently studied form of hip OA (classical or “normotrophic”)
presents with both JSN and OPH. When only OPH are present is called “hypertrophic”
and when only JSN is observed, it is called “atrophic” (23). The atrophic form of hip OA
is far less studied. However, it is suggested that subjects with atrophic OA have a higher
risk of presenting hip joint destruction (26-27) and faster disease progression (28). In
addition, patients with atrophic OA have been shown to present with micro-architectural
disorganization, lower bone volume and thinner trabeculae than controls, as assessed by
bone histomorphometry of iliac crests (27). Therefore, atrophic OA might be the result
of reduced bone forming capacity. 
The aim of our study was to examine bone density and structural properties across
individuals with different types of OA: atrophic and osteophytic (normotrophic/
hypertrophic) and their relation with fracture risk as compared to controls. 158
    METHODS
The Rotterdam Study
The Rotterdam Study (RS) is a large prospective population-based cohort study of men
and women aged 55 years and older. The design and rationale of the study has been
described in detail elsewhere (29). In summary, the objective of the study is to
investigate the determinants, incidence and progression of chronic disabling diseases in
the elderly. The medical ethics committee of Erasmus University Medical School
approved the study and written informed consent was obtained from each participant.
RS-I refers to the baseline examination of the original cohort that included 7,983
participants. For this study we used data from 5,006 (62.7%) participants for whom both
hip OA and BMD data were available. 
Clinical assessment
At baseline, trained interviewers performed an extensive home interview on
demographic characteristics, medical history, risk factors for chronic diseases and use of
medication that was verified by a physician. We also used information about smoking
(current and former vs. never), use of analgesics (in the last month: yes/no). Falling was
assessed using structured personal interviews by trained medical research nurses. A
faller was defined as an individual with a history of one, two or more falls without
precipitating trauma (e.g., car accident or sport injury) in the 12 months preceding the
baseline interview. A lower limb disability index was obtained by calculating the mean
score of answers to questions concerning rising, walking, bending, and getting in and out
of a car. The index is represented by a continuous score ranging from 0 to 3, where 0
indicates no impairment and 3 indicates severe impairment. Detailed definitions for
lower limb disability are described elsewhere (30). Height and weight were measured at
baseline examination with the subject in a standing position with indoor clothing without
shoes. 
Corticosteroids use: Persons who received a corticosteroid prescription for oral, rectal,
parenteral, or inhaled use within 1 month before the index date were defined as current
users; all others were considered non-current users.
CRP measurement: At baseline (1990–3) and follow-up (1996–9), blood was drawn by
venous puncture, initially stored at –20°C and thawed and assayed for hs-CRP using
Rate Near Infrared Particle Immunoassay (Immage Immunochemistry System; Beckman
Coulter, Brea, California, USA). This method can accurately measure protein159
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    concentrations from 0.2 to 1440 mg/l with a within-run precision <5.0%, a total
precision <7.5% and a reliability coefficient of 0.995.
Radiographic assessment and hip osteoarthritis definition
Weight-bearing antero-posterior radiographs of the hip were obtained at 70 kV, a focus
of 1.8, and a focus-to-film distance of 120 cm, using High Resolution G 35 _ 43–cm film
(Fuji Photo Film Company, Kanagawa, Japan). Radiographs of the pelvis were obtained
with both of the patient’s feet positioned in 10° internal rotation and the x-ray beam
centred on the umbilicus. Hip radiographs were scored for the presence of OA features
(osteophytes and joint space) by two independent observers who were trained by an
experienced physician in OA and advised by a radiologist. The trained observers used as
reference an atlas of individual radiographic features in osteoarthritis (31). After each set
of approximately 250 radiographs the scores of the two trained observers were evaluated.
Whenever the score of the two readers differed more than one grade (osteophytes) or
more than 30% for JSW (Intraclass Correlation Coefficient (ICC) a consensus reading
was carried out. Readers were blinded to all data of the participants. Additionally, there
was no indication of sex or age on the X-rays. Joint space width (JSW) of the hip was
measured using a 0.5-mm graduated magnifying glass laid directly over the radiograph.
Superior and inferior compartments of the femoral head were reviewed in both hips as
lateral, superior and axial (32). We determined JSN at axial, lateral and superior sites for
all hips. The axial site was most frequently affected by JSN, this was true in
normotrophic as well as atrophic hip OA. The Intraclass correlation coefficient (ICC) for
the minimal joint space was 0.73 (0.69-0.77) and the Kappa statistic for femoral
osteophytes was 0.76. These estimates were an average that included ICC taken from the
first till the last reading sessions. 
Table 1. Definition of OA according to bone response.
Ref= People without Joint Space Narrowing (JSN) or Osteophytes (OPH) were taken as reference.
Description Type of hip OA
1 Participants without JSN or OPH (33) No OA
2 Participants with OPH and JSN Normotrophic
3 Participants with only OPH Hypertrophic
4 Participants with only JSN Atrophic160
    We defined joint space narrowing (JSN) as a JSW equal or lower than 2.5 mm in at least
one compartment. We defined osteophytosis (present/absent) if at least 1 definite
femoral osteophyte was present. These two features, JSN and osteophytosis were used as
dichotomous outcomes and used to classify participants as presenting with one of four
different types of hip OA including: No OA, Normotrophic OA, Hypertrophic OA and
Atrophic OA (Table 1). 
BMD and bone geometry measurements
                                                                                                                                                            
DXA BMD (g/cm²) of the right proximal femur and lumbar spine were measured at 
baseline using a Lunar DPX-L densitometer (Lunar Radiation Corp., Madison, WI, 
USA) and analyzed with DPX-IQ v.4.7d software as described previously (35-36). Total 
body scans were performed at the third follow-up visit (mean follow-up 6.5 years) using 
a ProdigyTM fan-beam densitometer (GE Lunar Corporation Madison, WI) and analyzed 
with the enCORETM software. The software employs an algorithm that divides body 
measurements into areas corresponding to total body, head, trunk, arms and legs. All 
analyses were verified by a trained technician who performed adjustments when 
necessary. Hip structural analysis (HSA) software was used to measure hip bone 
geometry from the DXA scan at the narrow neck region across the narrowest point of the 
femoral neck (NN). BMD and narrow neck width (outer diameter) were measured 
directly from mineral mass distribution, while section modulus (an index of bending 
strength) and buckling ratio (index of cortical bone instability) were calculated using 
algorithms previously described (35).
Assessment of incident fracture
All events, including fractures and death were reported by general practitioners (GPs) in
the research area (covering 80% of the cohort) by means of a computerized system.
Information from GPs outside the research area was obtained by regular checking of
patient records by research physicians. All reported events were verified by two trained
research physicians, who independently reviewed and coded the information.
Subsequently, all coded events were reviewed by a medical expert for final
classification. Subjects were followed from their baseline visit until January 1, 2007 or
until a first fracture or death occurred resulting in a mean fracture follow-up duration of
9.7 years (SD=5.1 years). All fractures that were considered not osteoporotic (fractures
caused by cancer and all hand, foot, skull, and face fractures) were excluded. 161
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    Statistical Analysis
We compared the baseline characteristics of the study population and the DXA- derived
BMD and geometry parameters from the narrow neck region (NN) between the OA
types and controls using analysis of variance (ANOVA). Categorical variables were
tested using the chi squared statistic. All the BMD measurements and the DXA-derived
geometry analyses were adjusted for gender and age. We also presented BMD from
femoral neck (FN), total body and skull-BMD. Additionally, Z-scores values were
included to compare differences between different types of OA and controls. DXA-
derived geometry analyses were adjusted by NN-BMD to test its independence. Cox's
proportional hazards regression was used to study association between the different
types of hip osteoarthritis and fracture risk. Hazard ratios with 95% confidence interval
were reported. We introduced in the Cox regression model for OP fractures type of hip
osteoarthritis as categorical variable. The analysis was adjusted by gender, age, height,
weight (additionally by FN-BMD to evaluate the effect of BMD and corticosteroid use).
All analyses were run using SPSS V. 15.0.
RESULTS
Table 2 shows the baseline characteristics of individuals with the different types of OA
and those without OA. Participants with OA were on average older and more frequently
females except for the hypertrophic OA group, where more men were present. There
were no significant differences in height, weight and BMI between the groups.
Participants in the hypertrophic or normotrophic groups had more disability in lower
limb compared to participants without OA.
Table 3 presents the results of the adjusted baseline bone and geometry parameters
measured by DXA at the femoral narrow neck region (NN). BMD from NN, FN, and LS
BMD was higher in the osteophytic groups compared to controls (Table 3). The atrophic
group had similar BMD to controls and significantly lower compared to osteophytic
groups (P values<0.05, not in table). In spite that total BMD and skull BMD were
measured at a later time point having less participants (2018) to include in the analysis,
head and total BMD followed the same trend, higher in osteophytic groups (N.S) and
significantly lower BMD-values in atrophic group compared to controls (Not in table,
P=0.007 for head BMD and 0.002 for Total body BMD). Figure 1 shows the Z-scores of
the BMD values between the different OA groups compared to controls. 162
    Table 2. Baseline characteristics.
*No-OA: No definite osteophytes or narrowing. Values for each joint at baseline: mean ± SD for continuous
variables and frequency (% of women) for categorical variables. P value from x² test or ANOVA. **P
values<0.01. Height and BMI were gender and age adjusted, Weight was gender, age and height adjusted and
LDD was gender, age and weight adjusted. CRP and falling were adjusted for gender, age and BMI. BMI is
body mass index and LLD is lower limb disability.
Table 3. Hip bone parameters measured at the NN-region & FN/LS BMD.
Values are means and standard deviations (sd) adjusted for age and gender. LS: Lumbar spine and FN: femoral
neck BMD. ^Total body BMD and Skull BMD were measured in 2018 individuals and hip structural
parameters in 4007 individuals. P value from ANOVA are means and P values<0.05, **P values<0.01.
OA Cases (n=1289)
Variables No OA*(n=3717)
Normotrophic
(n=178)
Hypertrophic
(n=925)
Atrophic
(n=186)
ANOVA
P-value
Gender female (%) 58 64.6 48.6** 63.4 0.84
Age (years) 67.2±5.6 71.3±6.0** 69.2±6.4** 68.7±5.3** 3.7x10-20
Height (cm) 166.5±9.5 167.2±9.7 166.4±9.0 166.9±10.7 0.80
Weight (kg) 72.9±11.9 72.3±12.3 73.2±12.6 72.8±11.3 0.73
BMI (Kg/cm²) 26.3±3.7 26.0±3.5 26.4±3.9 26.2±3.2 0.69
LLD 0.29±0.75 0.49±0.43** 0.39±0.65** 0.32±0.26 4.4x10-4
Total CRP (mg/l) 3.06±5.4 2.24±2.7 3.20±6.5 3.42±5.2 0.61
Falling > 1 per year (%) 14.5 21.9 14.3 18.8 0.35
OA Cases (n=120wq9)
DXA parameter No-OA(n=3507)
Normotrophic
(n=  167 )
Hypertrophic
(n=874)
Atrophic
(n= 168 )
ANOVA
P-value
LS-BMD 1.09±0.18 1.16±0.21** 1.11±0.18* 1.07±0.19 1.1x10-6
FN-BMD 0.87±0.13 0.93±0.15** 0.88±0.13* 0.86±0.13 5.2x10-8
Total-BMD 1.12± 0.12 1.15± 0.13 1.13± 0.13 1.08± 0.11* 0.002
Skull-BMD 1.94± 0.28 2.01± 0.26 1.96± 0.28 1.85± 0.31* 0.008
NN-BMD 0.70±0.13 0.75±0.15** 0.72±0.13* 0.69±0.11 1.4x10-4
Neck Width (cm) 3.21±0.32 3.34±0.38** 3.29±0.33** 3.19±0.28 1.1x10-19
NN-cortical buckling 13.73±3.1 14.48±3.3 14.16±3.0 13.56±2.7 1.9x10-15
NN-section modulus 1.15±0.33 1.29±0.44** 1.21±0.37** 1.14±0.33 8.6x10-28163
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    Figure 1 BMD differences between different types of hip OA and controls. Values represent bone mineral 
density (BMD) Z-scores from Femoral Neck (FN), Lumbar Spine (LS), skull and total body. * Represent P 
values <0.05. Comparison was made between types of OA (hypertrophic, normotrophic, atrophic) and controls. 
The analysis was adjusted for gender and age.
As compared to subjects without OA, participants with normotrophic or hypertrophic
OA had 4.1 and 2.5% wider femoral necks and 12.3 and 5% greater bone strength
(higher section modulus) respectively. No significant differences were found for these
parameters in subjects with atrophic OA compared to controls.
In total, 1071 participants with OA-scored radiographs sustained a fracture during the
period of investigation. Participants with the atrophic hip OA type had almost 50%
increased risk for fractures as compared to controls with or without BMD adjustment
(Figure 2, HR: 1.48, CI: 1.11-1.98, p: 0.008 and HR: 1.44, CI: 1.08-1.92, p: 0.012
respectively). Normotrophic and hypertrophic group did not differ significantly in
fracture risk from that of controls (Figure 2, after BMD adjustment: normotrophic HR:
1.18, CI: 0.84-1.66, p: 0.35; hypertrophic HR: 0.89, CI: 0.74-1.06, p: 0.20 and without
BMD adjustment: Normotrophic HR: 0.98, CI: 0.70-1.36, Hypertrophic HR: 0.88, CI:
0.74-1.05). Additional adjustment for lower limb disability did not change the risk
estimate as it was expected because disability in the atrophic group was not significantly
different from controls (Table 2, P>0.05). Similarly, the adjustment for falling did not
change the risk estimates. Falling at baseline was not different between OA types and
controls (table 2, P>0.05 for each OA group compared to controls). Finally, adjustment
for use of corticosteroids at baseline changed the risk estimates to a slightly higher
fracture risk for participants with atrophic type (HR: 1.69, CI: 1.19-2.41, P: 0.004). The
risk for osteoporotic fractures remained no significant for participants with other OA
types. 164
    Figure 2 Osteoporotic fracture risk by OA type. Values presented are Hazard ratios (H.R.) and their 95% CI 
from Cox regression model. P values are for comparison of risks with controls after adjustment for age, height, 
weight and FN-BMD. 
DISCUSSION
In this large prospective population-based study we found differences in bone structural
geometry across individuals with different types of OA. Individuals with osteophytic OA
(both normotrophic and hypertrophic) had higher BMD, wider femoral necks and greater
bone strength than individuals with atrophic OA and individuals without OA. While
individuals with atrophic OA had lower head and total BMD than individuals without
OA, no differences were observed in parameters of hip geometry. A 50% increased of
osteoporotic fracture risk was observed in individuals with atrophic OA as compared to
both subjects with osteophytic OA and without OA.
Previous studies have found increased BMD and differences in DXA-derived geometry
values in hips with OA as compared to controls (19, 37-40). However, the majority of
those studies used the classical definition of OA where cartilage degradation (joint space
narrowing) and osteophytes need to be present. Such definition excludes individuals with
atrophic forms (only joint space narrowing), despite some reports indicating that these
individuals present with clear signs of cartilage degradation (24) and rapid disease
progression (41) in the absence of osteophytes. In line with our findings, Javaid et al.
found in subjects from the Study of Osteoporotic Fractures (SOF), that individuals with
an osteophytic type of hip OA had wider femoral necks and displacement of the center of
mass (19). In general, Individuals with atrophic type of hip OA have been discarded
from previous works analyzing the relation of OA and osteoporosis.165
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    Even though we found no differences in hip structural parameter in subjects with the
atrophic form of OA we did find a consistent systemically lower BMD than subjects
without OA and with osteophytic forms of OA. The fact that the BMD of subjects with
atrophic OA is also lower than that of subjects without OA suggests this phenomenon is
not explained alone by the absence of osteophytes (i.e.artifactual elevation of BMD in
participants with osteophytic forms). This seems to be the result of a systemic process
considering that total body BMD is also decreased; and the fact that this decrease is also
evident on skull BMD, a site less prone to be influenced by environmental factors,
mechanical strain and weight bearing (42). Overall, these measurements are less affected
by artefactual elevations arising from osteoarthritic changes. 
We evaluated if the observed differences in skeletal properties observed across the
different types of OA were translated in differences in fracture risk. Even though
participants with osteophytic types of OA had higher bone mineral density, wider
femoral neck and greater bone strength than controls we observed no significant
differences in fracture risk. Inversely, subjects with atrophic hip OA who did not differ
in DXA-derived geometry but who had lower BMD, had a ~50% increased risk for
osteoporotic fractures, which was still present after BMD adjustment. Further, this
increased risk is not likely to be explained by lower BMD consequence of immobility or
differences in falling risk since correction for lower limb disability and falling did not
essentially modify the risk estimate. Finally, adjustment for corticosteroid use made
more pronounced the osteoporotic fracture risk difference between the atrophic group
and controls. It is known that prior and current exposure to corticosteroids confers an
increased risk of fracture (43). 
There are possible explanations to the increased osteoporotic risk fracture in participants
with the atrophic type of osteoarthritis. Subjects affected with the atrophic OA type
might have lower bone quality, characteristics that are not captured by DXA or DXA-
derived geometry measures. Indeed, earlier studies of hip replacement patients showed
that patients with OA had lower bone volume and thinner trabeculae than controls (27).
The most affected were patients with hip joint destruction that was three times more
common in atrophic cases than in the other OA types. The study of bone properties using
other methods different than DXA scans could elucidate bone differences between OA
types that might have influence on fracture risk. 
Examination of biomarkers of bone metabolism might also clarify important differences
between OA types. In our study we did not have data available on markers of cartilage166
    and bone resorption and formation which could help in the classification of the OA
subtypes. 
We consider that our study has some limitations. Even though we have a large
prospective population with prospective fracture assessment less susceptible to biases,
dividing in OA types limits sample size and hence the power of the study. A possible
selection-bias due to different response-rate and inclusion of participants according with
availability of hip radiographs and DXA scans has been previously discussed (44). There
was a high response-rate in the Rotterdam study (>=80%) and therefore selection-bias
for this reason will be limited. Yet people who refused to participate were generally
older (especially above the age of 80) and more often seriously ill. Additionally, the fact
that subjects had to be mobile enough to visit the research centre for radiographs and
DXA examinations caused a possible health selection bias in our study population.
Taking into consideration these aspects, it can be expected that our risk estimates are
biased towards lower levels. 
Other limitation is given by DXA scan’s inherent properties and missing information on
markers of bone metabolism. In spite of the information on bone structure that is gained
using HSA, the major limitation of HSA is imposed by the two-dimensional nature of
DXA (36). The ideal situation could be presented by adding CT-measurements to assess
3-d structural configurations. Finally, there is a limitation inherent to reproducibility of
manual measurement of JSW among different observers. Interobserver reproducibility of
ICC using manual measurement techniques ranges from 0.71 to 0.78 for JSW
measurements (45). Our ICC-measures fall within these boundaries. The variability in
measuring JSW was principally due to difficulties in determination of exact points on
femoral head and acetabulum and directions to measure joint space in the different sites
of the hip joint (lateral, superior, and medial). However, this ICC estimate was an
average that includes interobserver values for the first reading session were observes had
less expertise. JSW is considered a reliable method for measuring progression of
osteoarthritis in hip joints with higher reliability compared to scoring of osteophytes
(25, 46).
In conclusion, we identify BMD and DXA-derived differences principally between the
atrophic and osteophytic sub-types of hip OA. It confirms that different types of OA
exist with specific bone structural properties and relation with fracture risk. Classifying
individuals in sub-types of hip OA can help identifying distinct aetiologies and
pathogenic courses of the disease, which may be translated in appropriate therapeutic
interventions. 167
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    ABSTRACT
To investigate the relation between Lumbar Disc Degeneration (LDD) and all type of
osteoporotic (OP) fractures including vertebral. This study is part of the Rotterdam
study, a large prospective population-based cohort study among men and women aged
55 years and over. In 2,819 participants spine radiographs were scored for LDD
(osteophytes and Disc Space Narrowing (DSN)) from L1 till S1, using the Lane atlas.
Osteoporotic (OP) fracture data were collected and verified by specialists during 12.8
years. We considered two types of vertebral fractures (VFx): Clinical VFx (symptomatic
fractures recorded by medical practitioners) and Radiographic VFx (using the
McCloskey-Kanis method). Meta-analysis of published studies reporting an association
of LDD features and VFx was performed. Differences in Bone Mineral density (BMD)
between participants with and without LDD features were analyzed using ANOVA.
Risk of OP-fractures was analyzed using Cox regression.   In a total of 2,385
participants, during 12.8 years follow up, 558 suffered an OP-fracture. Subjects with
LDD had an increased OP fracture risk compared to subjects without LDD (HR: 1.29,
CI: 1.04-1.60). LDD-cases have between 0.3-0.72 standard deviations more BMD than
non-cases in all analyzed regions including total body and skull BMD (P<0.001). Only
males with LDD had increased risk for OP-fractures compared to males without LDD
(adjusted-HR: 1.80, 95%CI: 1.20-2.70, P=0.005). The risk was also higher for VFx in
males (HR: 1.64, CI:1.03-2.60, P: 0.04). The association LDD-OP-fractures in females
was lower and not significant (adjusted- HR:1.08, 95%CI: 0.82-1.41). Meta-analyses
showed that the risk of VFx in subjects with LDD has been studied only in women and
there is not enough evidence to confidently analyse the relationship between LDD-
features (DSN or/and OPH) and VFx due to low power and heterogeneity in phenotype
definition in the collected studies. Conclusions: Subjects with LDD, especially males
have a higher osteoporotic fracture risk, in spite of systemically higher BMD.
Author keywords: Lumbar Disc degeneration, osteoporotic fractures, Bone mineral
density, disc space narrowing, vertebral fractures. 175
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    INTRODUCTION
Lumbar Disc Degeneration (LDD) and osteoporosis are two age-related skeletal diseases
which are very prevalent in elderly and known to be related to pain, increased morbidity
and disability in this population [1, 2]. In Europe, the mean prevalence of vertebral
fractures (VFx) in women between 60 and 64 years is 17% and this increases up to 35%
when they are aged 75 years or more[1]. Both, osteoporotic (OP) fractures and LDD
occur also in men however, it has been more studied in women [3, 4]. The relationship
between LDD and bone health is unclear. As it has been previously shown, the presence
of LDD is associated with higher spine Bone Mineral Density (BMD) [5-7]. In addition,
LDD has been found associated with higher BMD of the femoral neck, which suggests a
systemic increased BMD in subjects affected by LDD [5, 6, 8]. In this respect LDD
behaves very similar to knee or hip osteoarthritis (OA), where also an increased systemic
BMD has been found [9, 10]. In theory, the higher BMD found in subjects with LDD
should corresponds to lower fracture risk compared to subjects without LDD. However,
the few studies examining the relationship between LDD and vertebral fractures (in
women) found conflicting results [7, 11-14]. In part it might be explained by the
different radiological definitions used for both, LDD (based exclusively on presence of
osteophytes (OPH) or Disc Space Narrowing (DSN)) and vertebral fractures (scored by
different methods). Additionally, there are no studies examining the relationship
between LDD and all types of OP fractures which would indicate whether the increased
BMD found in LDD cases correspond to a decreased fracture risk.
Therefore, we investigated the relation between LDD and all type of osteoporotic
fractures including vertebral, in a large prospective cohort that includes men and women.
In addition, we performed a systematic review or previously published studies. 
MATERIALS AND METHODS
The Rotterdam Study 
This study is part of the Rotterdam study (RS), a large prospective population-based
cohort study among men and women 55 years of age and older. The study design and
rationale are described elsewhere in detail [15]. The objective of the study is to
investigate the determinants, incidence and progression of chronic disabling diseases in
the elderly. The baseline measurements were conducted between 1990 and 1993. In total,
7983 participants were examined. The current study was performed in 2,385 study
participants for whom data on incident vertebral fractures, BMD and LDD was available.176
    The medical ethics committee of Erasmus University Medical School approved the study
and written informed consent was obtained from each participant. Data Collection for
potential risk factors.
Home interviews on medical history was performed by trained interviewers. Smoking
habit was categorized binary as current or former versus never. The lower limb disability
index used was composed of the mean score from six different questions regarding
activities of daily living, using a modified version from the Stanford Health Assessment
Questionnaire [16]. At baseline measurement, medical information and physical
examination including height and weight were obtained. Body mass index (BMI) was
calculated by dividing weight by height squared (kg/m²).
Radiographic Assessment of LDD
Each vertebral level from L1 to S1 was reviewed for the presence and severity of
osteophytes (OPH) and vertebral narrowing (Disc Space Narrowing (DSN)), using the
Lane atlas [3, 4]. In this atlas the categories are as follows: grade 0 = none; grade 1 =
mild; grade 2 = moderate; and grade 3 = severe. DSN was defined as present when there
was a grade 1 narrowing at two or more vertebral levels. Because of the small proportion
of subjects without osteophytes, we used a higher cut-off value for this feature; OPH was
positive when there were osteophytes of at least grade 2 at two or more vertebral levels.
When DSN and OPH were both positive and present at 2 or more levels, the participant
was assigned as “LDD case”. The definition suggested for LDD was previously found as
the best related to clinical symptoms including lumbar pain [17]. A severity score for
each participant was calculated adding the individual scores of DSN and OPH (1-3) of
all intervertebral levels.
BMD measurements
DXA BMD (g/cm²) of the right proximal femur and lumbar spine were measured at
baseline using a Lunar DPX-L densitometer (Lunar Radiation Corp., Madison, WI,
USA). Total body scans were performed at the third follow-up visit (mean follow-up 6.5
years) using a ProdigyTM fan-beam densitometer (GE Lunar Corporation Madison, WI)
and analyzed with the encoreTM software. The software employs an algorithm that
divides body measurements into areas corresponding to total body, head, trunk, arms and
legs. Other methodological details have been described previously [18]. 177
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    Assessment of osteoporotic fracture
Follow-up started either on January 1 1991 or at the time of inclusion into the study. For
this analysis, follow-up ended either at January 1, 2007 or, when earlier, at the
participant's death or loss to follow-up. For 80% of the study population, medical events
were reported through computerized general practitioner diagnosis registers. For the
remaining 20%, research physicians collected data from the general practitioners'
medical records of the study participants. All collected fractures were verified by
reviewing discharge reports and letters from medical specialists. Fracture events were
coded independently by two research physicians according to the International
Classification of Diseases, 10th revision (ICD-10). Finally, an expert in osteoporosis
reviewed all coded events for final classification. Fractures coded as incident vertebral
fractures were considered clinical fractures if they were identified on radiographs when
subjects with symptoms (principally pain) visited the medical practitioner. All fractures
that were considered not osteoporotic (fractures caused by cancer and all hand, foot,
skull, and face fractures) were excluded. The period of follow-up was calculated as the
time from enrolment in the study to the first fracture, death, or the end of the planned
follow-up period, whichever occurred first. The participants were followed for the
occurrence of fracture for approximately 12.8 years (±3.1 SD yr.).
Assessment of prevalent and incident radiographic vertebral 
fracture
Radiographic vertebral fracture: both at baseline, between 1990 and 1993, and at the
second follow-up visit, between 1997 and 1999, a trained research technician obtained
lateral radiographs of the thoracolumbar spine of subjects who were able to come to the
research center. The follow-up radiographs were available for 2,819 individuals, who
survived an average of 6.3 years after their baseline center visit and who were still able to
come to our research center. All follow-up radiographs were evaluated morphometrically
in Sheffield by the McCloskey-Kanis method, as described previously [19]. If a vertebral
fracture was detected, the baseline radiograph was evaluated as well. If the fracture was
already present at baseline, it was considered a prevalent fracture. All vertebral fractures
were confirmed by visual interpretation by an expert in the field to rule out artifacts and
other etiologies, such as pathological fractures [20]. Participants with missing data on
one or more risk factors were excluded (n=434).     178
    Literature Study
Relevant articles were identified by a systematic search using the database of PubMed
with the words [“spine osteoarthritis” or “spine OA” or “disc degeneration”] and [21] as
keywords in the title or abstract. The following inclusion criteria applied for this review:
a) listed in PubMed, b) publication in the English language, c) study in humans, d) the
article represents original data, e) subjects with and without disc degeneration features
are compared in the study in relation to vertebral and/or osteoporotic fractures, f) the
full-text article was available. Methodological quality assessment is found in the
supplementary material.
Statistical Analysis
We compared the baseline characteristics of the study population and the FN- and LS-
BMD between the LDD cases and controls using analysis of variance (ANOVA).
Categorical variables were analyzed using chi squared test. Cox's proportional hazards
regression was used to assess association between LDD and OP fractures (or only
clinical vertebral fractures). The analyses were adjusted by gender (or stratified by
gender), age, BMI, lower limb disability and FN-BMD as continuous variables.
Departure from additive effect of the risk factors was tested using interaction terms in the
model. All these analyses were made using SPSS V. 15.0. Meta-analyzed results and
forest plots included in the literature study were obtained using the Comprehensive
Meta-analysis Software Version 2, Biostat, Englewood NJ (2005). Power calculations
were done with PS version 2.1.31.
RESULTS
Study population
Characteristics of the cohort comprising 2,385 participants with data for the two major
outcomes: LDD and vertebral fracture are shown in table 1. At baseline, 362 participants
had LDD (moderate OPH and mild-DSN) in two or more intervertebral levels. Subjects
with LDD were older and heavier than controls. Also, LDD subjects had 0.72 and 0.32
S.D. higher LS- and FN-BMD at baseline compared to controls (Figure 1, P<0.001 for
both, FN and LS-BMD differences). Additionally, figure 1 shows that total body- and
skull-BMD (measured at a later time point) were also significantly increased in subjects
with lumbar disc degeneration. All BMD analyses were adjusted for age, gender, BMI,
lower limb disability. 179
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    Table 1. Baseline Characteristic for subjects according to LDD features in two or more levels.
Abbreviations: LDD: Lumbar Disc Degeneration, **defined as mild Disc Space Narrowing (DSN) and 
moderate/severe Osteophytes (OPH) in two vertebral levels. *Controls: Participants with less than 2 levels 
affected by DSN and OPH per level. Values presented are mean and Standard Deviations (SD) for each 
continuous variable and numbers and percentage (%) for categorical variables.  BMI (Body Mass Index), 
smoking, LDD (Lower Limb Disability, falling and prevalent radiographic-vertebral fractures (VFx) 
comparisons were adjusted for age and gender. All Bone Mineral Density (BMD) analyses were adjusted for 
age, gender, BMI and LDD.
Figure 1 Bone Mineral Density (BMD; Z-scores) differences between subjects with Lumbar Disc 
Degeneration (LDD) and without LDD in four different regions: Lumbar Spine (LS), Femoral Neck (FN), 
Total Body and Skull. P values were adjusted by age, gender, height and BMI. **P value0.001. Total Body- and 
Skull-BMD were measured in a subset of 1,649 participants at a second follow up. 
The number of prevalent radiographic-vertebral fractures was not different in the LDD
group compared to the group without LDD after adjustment for age and gender (Table 1,
Variables Controls *n=2023(82)
LDD**
n=362(18) P value
Female 1161 (57) 207 (57) 0.9
Age (years) 63.7 (5.7) 65.9(6.2) <0.001
BMI (kg/m2) 26.2 (3.7) 26.9(3.8) 0.04
FN-BMD (g/cm2) 0.88 (0.13) 0.91 (0.14) <0.001
Total-BMD (g/cm2) 1.10 (0.12) 1.12 (0.13) 0.001
Head-BMD(g/cm2) 1.93 (0.28) 2.01 (0.29) <0.001
Smoking (Current/former) 1367 (68) 233 (64) 0.18
Lower limb disability 0.16 (0.38) 0.21 (0.33) <0.001
Falling (yes) 241 (12) 52 (14.5) 0.29
Prevalent Radiological VFx* 88(6.6) 22(7.4) 0.83
-0.2
LS-BMD FN-BMD Total-BMD Skull-BMD
No-LDD
LDD
-0.1
0.1
0.2
0.3
0.4
0.5
0.6
0.7 **
**
**
**
0.8
0180
    P=0.83). The mean LDD severity score was higher in males than in females (mean=6.6
(SD=4.3) for males and 5.9 (SD=4.4) for females (P<0.001, adjusted for age and BMI)).
However, there was no statistically significant association between LDD-severity score
and all type of OP-fractures (P=0.13).
Osteoporotic fracture risk
During 12.8 (SD=3, 12) years of follow-up, 558 participants suffered an osteoporotic
(OP) fracture. Subjects with LDD had an increased risk of OP fractures compared to
subjects without LDD (HR: 1.29, CI: 1.04-1.60). The risk slightly decreased after
adjustment for age, gender, BMI, lower limb disability and FN-BMD (HR: 1.24 (0.99-
1.55). We found a significant interaction between gender and LDD on fracture risk
suggesting differences in OP fracture risk between genders (P for interaction term: 0.03).
Therefore, we stratified the analysis according to gender and observed that only males
with LDD had an increased OP fracture risk. (Table 2, Adjusted HR: 1.80 (1.20-2.70). P:
0.005 for males and HR: 1.08, CI: 0.82-1.41, P=0.59 for females).
Table 2. Risk of vertebral and Osteoporotic fracture in participant with Lumbar Disc Degeneration (LDD).
Risk for osteoporotic and clinical vertebral fractures in participants with Lumbar Disc Degeneration (LDD) 
defined as categorical variable according to presence of at least mild Disc Space Narrowing (DSN1) and 
moderate/severe osteophytosis (OPH) per intervertebral level in at least two intervertebral levels. Lumbar disc 
degeneration was evaluated only at lumbar spine (L1-L5). Risk of vertebral and osteoporotic fracture are 
Hazard ratio (HR) and 95% confidence interval (CI) unadjusted or adjusted for baseline Characteristics 
(gender, age, BMI, lower limb disability, femoral Neck Bone mineral density (FN-BMD). Number of clinical 
vertebral fractures=116, Number Osteoporotic fractures= 558.
n.LDD/n Clinical Vertebral Fractures(HR & 95% CI)
Osteoporotic Fractures
(HR & 95%CI)
Unadjusted P Adjusted risk P Unadjusted P
Adjusted 
risk P
All         
(362/2385)
1.53
(0.98-2.40) 0.06
1.64
(1.03-2.60) 0.04
1.29
(1.04-1.60) 0.02
1.24
(0.99-1.55) 0.06
Males 1.41 (0.68-2.90) 0.36
2.34
(1.09-5.04) 0.03
1.88 
(1.27-2.79) 0.002
1.80 
(1.20-2.70) 0.005
Females 1.22 (0.71-2.10) 0.47
1.39
(0.78-2.50) 0.26
1.11 
(0.85-1.43) 0.45
1.08 
(0.82-1.41) 0.59181
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    Clinical Vertebral Fracture: 
After the follow-up time, 21% of participants having fractures (n=116) had a clinically
defined vertebral fracture. Participants with LDD had an increased hazard of having a
clinical vertebral fracture during the follow-up (Table 2, adjusted-HR: 1.64, CI: 1.03-
2.60, P: 0.04. As it was for overall OP-fractures, the hazard for a clinical vertebral
fracture was higher only for males with LDD (HR: 2.34, CI: 1.09-5.04 in males and 1.39,
CI: 0.78-2.50 for females).
Radiographic Vertebral Fracture: 
During 6.3 years of follow-up, 106 participants had an incident radiographic-vertebral
fracture. After adjustment for age, gender, BMI, FN-BMD and prevalent radiographic
vertebral fracture, subjects with LDD had 2.14 increased odds of having a radiographic
vertebral fracture. However, this was not statistically significant and the broad
confidence interval revealed low power in the analysis (CI: 0.82-5.58, P=0.12). Hence,
we reviewed the existent literature on the relationship between LDD and (vertebral)
fractures.
Figure 2 Meta-analysis of lumbar disc degeneration features and their relation with vertebral fractures in 
women. Values are Odd Ratios (OR) and 95% confidence interval. Abbreviations: Mild disc space narrowing 
(DSN>=1), minimal or mild osteophytes (OPH>=1). Studies were included when they had similar adjustments.
0,01
Meta Analysis of reviewed studies (women only)
Lumbar Spine Disc Space Narrowing (At least mild: DSN≥1)
Lumbar Spine osteophytes (At least mild: ≥1)
Study name and n. Fractures Statistics for each study Odds ratio and 95% CI
Odds
 ratio
Rendu et al. (n=42) 3,27 1,19 8,98 0,02
Roux et al. (n=215)
Castaño et al. (n=108)
0,74 0,47 1,16 0,19
1,27 0,71 2,27 0,42
1,05 0,75 1,46 0,79
Lower
  limit
Upper
  limit p-Value
Study name and n. Fractures Statistics for each study Odds ratio and 95% CI
Odds
 ratio
Arden et al. (n=41) 0,46 0,21 1,00 0,05
Rendu et al. (n=42)
Castaño et al. (n=108)
0,94 0,10 8,90 0,96
1,12 0,65 1,94 0,63
0,84 0,54 1,30 0,43
Lower
  limit
Upper
  limit p-Value
0,1 1 10
0,01 0,1 1 10182
    Results of the literature study: 
A total of five studies (four from the literature search + current results from our study)
analysing the relation LDD and radiographic vertebral fractures were included in this
review. There were no studies analysing the relation of LDD with other types of fractures
according with the selection criteria previously explained. Further details of the selection
procedure of studies can be found in the Supplementary material. From these five
selected studies, two were done in the same population therefore, only the most recent
“longitudinal prospective” (Sornay et al.) was included in the meta-analysis (Figure 2).
These studies fulfilled the inclusion criteria requirements and methodological quality
assessment, including adjustment for age, gender, BMI and BMD in the analysis. Only
one study (Roux et al.) did not perform BMD adjustment in the analysis of vertebral
fracture risk. 
All selected studies were done in post-menopausal women, one of them in women with
osteoporosis [11]. In all studies, radiographic-LDD features were evaluated from the first
till fifth lumbar segment (L1-L5). LDD was defined as presence of osteophytes (OPH),
or disc space narrowing (DSN) in at least one intervertebral level. A detailed description
of the studies and definition of LDD and vertebral fracture assessment is presented in the
supplementary table 1. 
Table 3 shows the results of the studies reviewed. Prevalence of at least minimal/mild
osteophytes in the studied populations differs between 56 to 90% (Table 3). In the study
of Roux et al. there was also a protective effect of OPH for vertebral fractures, however
in that study, the association was not adjusted for BMD; what seems to modify the
relationship osteophytes-Vertebral fractures (Table 2). Post-hoc power calculation
demonstrated that to have 80% power to detect OR>=1.2 having an incidence of
radiographic vertebral fractures of around 5%, a sample size of around 4200 participants
would be needed. Consequently, confidence intervals are wide and associations of
separate features of combined LDD definition did not reveal conclusive evidence
(Figure 2, OR: 0.70, CI: 0.39-1.25, P: 0.23 and OR: 1.05, CI: 0.75-1.46, P: 0.79 for
presence of at least mild osteophytes and disc space narrowing, respectively).183
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    DISCUSSION
This study shows that individuals affected with lumbar disc degeneration (LDD), in spite
of having a systemically higher BMD, are not protected of osteoporotic fractures.
Contrarily, male subjects with LDD had an increased risk for osteoporotic fractures,
including clinical vertebral fractures. Results of the meta-analysis of the literature
showed that LDD has been studied only in women for its association with radiographic
vertebral fractures. Additionally, this is the first study analysing the association of LDD
with all type of fractures in males and females. 
The results of the meta-analysis were not conclusive regarding the relation of separate
LDD features (osteophytes and disc space narrowing) and risk of radiographic vertebral
fractures in females. We found a higher systemic BMD in participants with LDD.
Participants with LDD had a higher bone mineral density not only in lumbar spine
(where BMD measurements are known to be influenced by the presence of osteophytes),
but also in femoral neck, total body and skull. 
This is in line with previous findings of higher BMD in LDD patients not only in lumbar
spine but also in other body regions [6, 7]. Measurement of skull-BMD has been shown
to be less subjective to change during aging and influence of environmental and
mechanical factors (strain and weight bearing) [22]. Higher skull-BMD in subjects with
LDD suggests that a systemically higher BMD might be present before LDD. In spite of
higher BMD in participants with LDD, we found a higher osteoporotic fracture risk. It is
possible that the increased BMD in subjects with LDD is not enough to compensate for
other detrimental effects of disc degeneration on trunk stability and flexibility that might
result in an increased fracture risk. Loading on the spine is determined by a person's
height, weight, muscle forces, and activity, but can also be affected by intervertebral disk
degeneration [23-25]. Loss of disc height and its properties produce high tensile strains
in the endplate and they have been shown as causal factors for “failure of the vertebra”
[26, 27]. 
Additionally, disc degeneration can affect other structures (vertebra itself, muscles and
ligaments) producing modification in the distribution of compressive and tensional
forces through the column that in normal conditions are evenly distributed. Ligaments of
the anterior region have changes as a consequence of LDD, causing its remodelling and
thickening [28, 29]. Consequently ligaments loses elasticity and the trunk’s flexibility
decreases; this becomes evident during aging where the range of spine movement is
severely affected. Individuals with LDD have more stiffness in trunk and lower legs that185
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    could increase the reaction time during falling and other demanding occupational
activities which are major situations where fractures occur in elderly [30, 31]. We found
a higher osteoporotic fracture risk in males. Severity of LDD was higher in males,
principally because of higher severity of disc space narrowing. Additionally, there is
some evidence for an association between disc space narrowing and lower back pain
especially in men proportionally increasing with a higher number of affected
intervertebral disc spaces [17]. However, severity itself did not explain the increased OP
fracture risk in males. Neither was the risk explained by other factors such as lower limb
disability, which was found to be higher in males with LDD and other common risk
factors including age and falling risk. In older males (>=65years), clinical vertebral
fractures are caused by no known trauma or by low-energy trauma. It is known that most
fractures occur in men with normal BMD and clinical vertebral fractures are particularly
common in the oldest men [21]. Clinical vertebral fractures have been also related to
important comorbidities, negative effects on quality of life and increased mortality [27-
29]. 
The systematic review showed some important aspects. Previous studies analysing the
association between LDD and fractures have been done only in females, the majority had
small sample size and they defined LDD using only separate features. There were also
important methodological differences between these studies in type (cross-sectional
versus longitudinal) and fracture assessment. In spite of trying to meta-analyze the
results of studies included in this review, using homogeneous definitions, power was still
insufficient to draw significant conclusion on the relation of separate LDD features and
radiological vertebral fractures. The review made evident that there is need for consensus
in the definition of radiological LDD. In our opinion, more stringent radiological
definitions are needed; some studies only consider osteophytes to define LDD.
Osteophytes are a common feature in older populations and its prevalence depends of
how stringent the definition is, reaching 90% for presence of minimal/ mild osteophytes.
Presence of disc space narrowing and osteophytes (at least moderate) in the same
intervertebral level should be considered when LDD is defined because it has been
shown to be more clinically relevant;  this combination radiological definition was found
to best correlate with clinical symptoms: lumbar pain and stiffness [17, 26]. 
There are strengths and limitations in this study. This study is unique in examining the
relation of LDD, osteoporotic and vertebral fractures in a large prospective cohort that
includes males and females. In addition, the composed definition of several radiographic
features used in this study is an advantage because it is more stringent and clinically
relevant. We also examined separate LDD features in order to compare results with186
    earlier published studies. However, we concluded that even after the meta-analysis the
number of radiographic vertebral fractures was insufficient to get conclusive evidence in
the relation of radiographic vertebral fractures with separate LDD features. Finally, the
conclusions of this study are limited to radiographic findings of LDD.
CONCLUSIONS
To conclude, we consider that subjects with LDD in spite of having higher systemic
BMD are at higher risk of osteoporotic fractures, especially males for whom LDD seem
more severe.The exact mechanisms to explain this association merits further
investigation, considering that both, LDD and clinical vertebral fractures are common,
associated with comorbidities and decreasing quality of life. 
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    SUPPLEMENTARY MATERIAL
Radiographic Assessment of LDD
Lumbar lateral radiographs were obtained at 70 kV, a focus of 1.8, and a focus-to-film
distance of 120 cm, using High Resolution G35_43–cm film (Fuji Photo Film Company,
Kanagawa, Japan). Radiographs were scored by a single observer trained by a radiologist
for the presence of the individual radiographic features of disc degeneration. The
observer was blinded to clinical characteristics of the participants. Inter-observer
reproducibility was assessed by a second independent observer who evaluated a random
selection of 140 (5%) radiographs. The ICC was 0.83 for osteophytes and 0.77 for
vertebral narrowing, indicating good reproducibility. More details have been described
elsewhere [17].
Methodological quality assessment review
The presence of the following quality criteria was verified in all studies: 1) information
on recruitment of cases, 2) information on recruitment of controls, 3) size of the study
(n>100 cases or controls), 4) information for all subjects on age, gender and BMI (or
weight and height) 5) clear definition of disc degeneration and fracture, 6) clear
description of statistical methods, 7) adjustments were made for age, gender, BMI and
BMD in the analyses of fracture risk, 8) results are presented as OR with 95% confidence
limits. Procedure to Select studies for Review: In total, there were 296 studies identified
in PubMed. Only 36 had the selected words in the title or abstract. 28 studies were
excluded on the basis of the abstract. Of the 8 studies retrieved for full examination, 3
studies were excluded because they did not fulfil the inclusion criteria after reading the
complete manuscript.191
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    ABSTRACT 
Osteoarthritis (OA) is the most prevalent joint disease affecting elderly individuals
worldwide. However, limited information exists regarding its effect on mortality. To
determine the effect of OA on mortality and its underlying causes. We assessed whether
duration of OA influences mortality risk. We studied this in a prospective population
based cohort of general population living in the city of Rotterdam (The Netherlands),
consisting of 4,848 individuals 55 years and over with scored radiographs and data of
covariates. Participants were evaluated for radiographic and clinical hip and knee OA at
baseline and first follow-up visit. The OA-duration was estimated considering
radiographic OA-evidence at baseline and follow up. Relationships of all-cause and
cause-specific mortality and survival-time differences in years were assessed from first
follow-up visit (between 1990-1993) through 2011. Radiological and clinically defined
OA (hip or knee), was associated with higher overall mortality (Radiological-OA,
Hazard Ratio [HR]: 1.36, 95%CI: 1.23-1.51). Rates were higher only for individuals
with disease of long duration (OA>4years-HR: 1.44, 95%CI: 1.29-1.60). OA was
associated with an increased hazard risk for all cause-specific mortality rates. Diabetes,
dementia, overweight, difficulty in activities and walking disability were more common
in individuals with OA, and partially explained the increased mortality (fully-adjusted
HR: 1.23, 95%CI: 1.10-1.37). Subjects with hip- and knee-OA died on average three
years earlier compared to subjects without OA (P<0.001). Hip and knee OA of long
duration (>4 years) is associated with higher mortality of all causes, which is partly
explained by comorbidities, disability and functional limitations. 197
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    INTRODUCTION
Osteoarthritis (OA) is the most common joint disease among the elderly and a leading
cause of chronic pain and disability in the elderly population. It is known that
osteoarthritis coincides with other diseases as obesity, cardiovascular disease (CVD) and
diabetes (1-4). OA has a negative impact on general health, which translates into
important differences in quality of life compared to non-affected individuals (4-7). It has
been suggested that subjects with hip or knee OA have a higher mortality compared to
the general population (4, 8, 9). Yet, this information comes from few studies that have
several methodological problems (reviewed in 8), including small sample size as a major
limitation. Two recent reports had large sample size, but were not cohort based (4, 9).
The first estimated quality-adjusted life-years lost by combining the U.S. census and
obesity data from national data sources with estimated prevalence of symptomatic knee
osteoarthritis and then simulated the outcome using the Osteoarthritis Policy Model (4).
The second manuscript selected individuals with joint pain from a general population
and compared their mortality risk with estimates taken from national databases (9). This
makes it difficult, if not impossible, to study the underlying cause of the association and
in addition might limit the generalizability of the observations. The relationship between
OA and mortality merits further investigation since OA is one of the most prevalent and
disabling diseases in the elderly. Possible explanations for the deleterious effect of
osteoarthritis on survival include: reduced levels of physical activity among persons with
osteoarthritis due to disability, adverse effect of medications used to treat symptomatic
OA, particularly non-steroidal anti-inflammatory drugs and presence of comorbidities,
including obesity (4, 8, 9). Therefore, we aimed to determine the effect of OA on
mortality and whether it is affected by the duration of the disease. We further explored
the role of comorbidities, risk factors, functional limitations and/or disability.
METHODS
Study Population: The Rotterdam Study
The Rotterdam Study is a large ongoing prospective population-based cohort study of
individuals 55 years and over in the city of Rotterdam. This study includes participants
from the Rotterdam Study I cohort (RS-I) which was initiated in 1990 and consists of
7,983 individuals and the Rotterdam Study II cohort (RS-II) which was initiated in 2000
and consists of 3,011 individuals. The design and rationale of the studies have been
described in detail elsewhere (10). In summary, the objective of the Rotterdam Study is
to investigate the determinants, incidence and progression of chronic disabling diseases198
    in the elderly. The medical ethics committee of Erasmus University Medical Center
approved the study and written informed consent was obtained from each participant. 
Radiographic assessment and OA definition
Hip and knee radiographs were scored using the Kellgren and Lawrence (KL)-grading
system at baseline (RS-I-1 and RS-II-1) and first follow up visits (RS-I-3 and RS-II-2) in
each cohort (11). Clinical osteoarthritis (hip/knee) was defined as radiographic KL>=2
and complaints in the same joint during the month previous to interview. Further details
of the radiographs’ scoring can be found in the Appendix. A total of 4848 participants
(3,376 participants from RS-I and 1,472 participants from RS-II) had scored knee and
hip radiographs for osteoarthritis, both at baseline and follow-up (mean time between
first and second radiographs was 6.29 and 4.15 years for RS-I and RS-II, respectively).
From them, 115 participants had received a TJR, these were analysed separately for
association with mortality. Consequently, analyses for the association between
osteoarthritis and mortality were performed in 4,733 participants with the most updated
OA status (RS-I-3 and RS-II-2).
We hypothesized that the effect of OA on mortality might be “cumulative”, being
stronger for those participants that had lived longer with osteoarthritis and its associated
comorbidities and functional limitations. To test this hypothesis, we divided the
radiographic osteoarthritis cases into new incident cases (no osteoarthritis at baseline)
and cases with a longer duration (OA from baseline).
Assessment of cause-specific mortality
Participants from the Rotterdam Study are continuously monitored for major disease
outcomes and mortality through computerized linkage of the study database to general
practitioners’ medical files. The cohorts’ cause-specific mortality was coded according
to the International Classification of Diseases, tenth Revision (ICD-10). This
information was available until the first of January, 2011. All different causes of
mortality were recorded according to ICD-10 codes and grouped into seven categories:
cardio- and cerebrovascular diseases, cancer, chronic lung diseases (non-infected
pulmonary diseases), dementia, external causes (composed mainly of severe fractures
that lead to death –most of them hip fractures, also fatal accidents and suicides),
infectious diseases and other causes (heterogeneous group composed of a minority of
non-tumoral gastrointestinal, renal, haematologic and cerebral diseases, senility and199
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http://www.who.int/classifications/icd/en/
Clinical assessment
At baseline and after six and four years follow up for RS-I and RS-II respectively,
trained interviewers performed an extensive home interview on demographic
characteristics, medical history, risk factors for chronic diseases and medication use;
Questionnaires included aspects of joint pain, activities of daily living, walking disability
and ability in Activities of Household and Leisure (from now called “functional
limitations”), smoking, use of analgesics and socio-economic status (SES)/ educational
level. Height and weight were measured to calculate Body Mass Index (BMI). Incidence
of major outcomes and diseases as CVD (including stroke), cancer, dementia and type-2
diabetes were collected through medical registers. Further methodological details are
explained in the Appendix 
Statistical Analyses
Cox proportional hazards models were used to assess the relation between hip and/or
knee osteoarthritis (clinical/radiographic) and mortality after exclusion of the
participants with total joint replacement at follow-up (n=4733). We imputed the missing
covariates data at follow up for 527 participants by using multiple imputation for each
cohort with overall mortality, log transformed survival time, sex, age, smoking, BMI,
comorbidities (cardiovascular disease, dementia, diabetes) use of analgesics, knee and/or
hip OA, walking disability and functional limitations as variables in the imputation
model, to create 50 imputed datasets (12, 13). We evaluated the quality of the imputation
using Monte Carlo error (14). 
The proportional hazard assumption of the Cox models was assessed using the
Schoenfeld residuals-based test. HRs reported in this paper did not violate the
proportionality assumption. Log likelihood statistics was used to evaluate the goodness
of fit of the models. 
We examined the association between OA and mortality-related risk factors (BMI,
walking and functional disability, smoking, analgesic use and SES) including
comorbidities, (CVD, diabetes mellitus, cancer and dementia) using logistic regression
analysis after adjustment for age, cohort study and gender. 200
    Multivariate Cox models for total mortality were adjusted by gender, age and cohort
study. The full regression model included all comorbidities and related risk factors
associated with radiographic/clinical OA and mortality. Additionally, we examined each
of the seven specific causes of mortality in participants with osteoarthritis using Cox
models for each of them after adjustment for age, gender and cohort study and after
adjustment for comorbidities and risk factors included in the previous models (Model 2).
Meta-analyzed results of the association between osteoarthritis and mortality for both
cohorts are presented. All Analyses were performed using SPSS (version 17) and/or
Stata (version 12). 
Survival Analyses
Differences in Hazards between osteoarthritis and no-osteoarthritis groups were
converted to survival difference in years. Mean survival time was estimated as the area
under the survival curve using Kaplan and Meier. The Log-rank test was used to test for
equality of survival time between osteoarthritis groups (hip/knee/hip and knee OA)
compared to participants without osteoarthritis at any joint site. 
RESULTS
Clinical Characteristics and Mortality-related Factors 
There were some differences between the two analysed cohorts (Appendix Figure 1,
baseline characteristics). Compared to RS-II, participants from RS-I were 2% more
females, on average 5 years older, had 5% lower BMI, 11% lower SES and 4% more
smokers. They also had more CVD, cancer, dementia, radiological osteoarthritis, joint
complaints and walking disability than participants from RS-II; which in part might be
due to their older age (Appendix Figure 1). In spite of these differences between cohorts,
we found consistent results of all variables in their relation with mortality (appendix
Figure 1). In RS-I, during a mean follow-up period of 9.6 years, 1,473 subjects died. In
RS-II, 137 participants died during a mean follow-up of 5.7 years. Older age, male
gender, CVD, diabetes mellitus, dementia, walking disability, functional limitations,
current or former smoking, radiological hip and knee OA, lower SES were significant
factors associated with higher mortality in both cohorts. A total of 115 participants
underwent TJR before starting the follow up period for mortality. Those participants
with TJR were 20% more females and 3 years older compared to participants without
TJR (both: P<0.001, not in table). A separate analysis of mortality in participants with
total joint replacement at baseline due to osteoarthritis was performed considering that201
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    elderly patients with osteoarthritis who have undergone TJR might be healthier than
participants with OA without replacement (15). They indeed had a decreased mortality
compared to participants without replacement without achieving statistical significance
(HR: 0.80 (0.53-1.04, P=0.08, full adjusted model). 
Mortality Risk in Participants with Osteoarthritis
We had a total of 4,733 individuals assessed for OA-status at baseline and first follow-
up. OA (radiographic/clinically defined) was significantly associated with overall
mortality (Table 1. HR for radiological OA: 1.36, 95%CI: 1.23-1.51 and HR for clinical
OA: 1.36, 95%CI: 1.19-1.55, respectively). The association with mortality was stronger
in females compared to males (Table 1). We examined whether the effect of OA on
mortality is dependent on disease duration and therefore stratified the analysis into cases
that had osteoarthritis from baseline versus new incident cases. A total of 1,334
participants (28.2%) had osteoarthritis from baseline and 387 (8.2%) were new incident
osteoarthritis-cases (Figure 1). The increased mortality risk was confined to those
individuals that already had OA from baseline (Figure 1. HR: 1.44 [1.29-1.60],
P<0.001), while the new osteoarthritis cases did not have an increased mortality risk
(Figure 1. HR: 1.05 [0.86-1.28]). This analysis was adjusted for age, gender and cohort
study. 
Figure 1 Association of Osteoarthritis with Mortality according with the disease duration. Values presented 
are Hazard Ratios and 95% confidence intervals (CI).
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    Association of OA with Comorbidities, Clinical 
Risk Factors and effect on Mortality risk
Figure 2 shows the association between OA and comorbidities after gender, cohort and
age adjustment. Participants with hip or knee osteoarthritis had more disability and had
more functional limitations. Other diseases and risk factors that strongly associated with
osteoarthritis were: dementia (OR:2.05, CI:1.35-3.13), being overweight (BMI higher
than 26, OR: 1.81, CI: 1.59-2.06) and diabetes mellitus (OR: 1.36, CI: 1.11-1.666). The
use of analgesics was also significantly increased in the osteoarthritis group (OR: 1.24,
CI: 1.01-1.51). Low education level (SES), CVD and smoking were not associated with
osteoarthritis. The association of osteoarthritis with mortality was attenuated after
adjustment for comorbidities. The majority of this attenuation was due to adjustment for
walking disability and functional limitations (Table 1-model 2, radiological osteoarthritis
HR: 1.23, 95%CI: 1.10-1.3 and clinical-OA HR: 1.20, 95%CI: 1.04-1.39). 
Figure 2 Comorbidities and Mortality-related Risk Factors in individuals with Hip or Knee Osteoarthritis 
Compared to Non-affected Individuals. osteoarthritis was defined as KL-score >= 2 in hip and/or knee. Values 
presented are Odd Ratios (OR) and 95% Confidence Intervals (CI). Comorbidities were analyzed in its relation 
with OA. Abbreviations: Cardiovascular Disease (CVD), Socio Economic Status (SES), Functional limitations 
in Activities of Household and Leisure (AHL), Body Mass Index (BMI). The associations shown were adjusted 
for age, gender and cohort study.
Cause-specific Mortality in Participants with OA
We subsequently examined cause-specific mortality risk and found that mortality risks
were higher in participants with radiographic hip or knee OA than in participants without
osteoarthritis for all specific causes of mortality (Table 2). The significant causes of
mortality in subjects with hip or knee OA irrespective of gender and age were trauma,
dementia, cardiovascular disease and others in order of effect-size (HR: 2.00, P=0.03;
HR: 1.61, P=0.006, HR: 1.36, P=0.002 and HR: 1.36, P=0.01, respectively). There was a
significant decrease in effect size for all specific causes of mortality after adjustment for
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    the comorbidities and risk factors previously described. Mortality risk due to trauma,
infections and cardiovascular events were not significant after adjustment (Table 2, full
adjusted model HR: 1.68, P=0.12, HR:1.24, P=0.36 and HR: 1.15, P=0.16 respectively).
The attenuation of the HR for the specific causes of death was explained for a large part
by walking disability and functional limitations. Mortality due to CV causes was
partially explained by prevalent diabetes mellitus, analgesic use and walking disability in
that order of importance. Prevalence cardiovascular disease was not a significant factor
explaining mortality in participants with OA compared to participants without OA.
Table 2. Cause-specific mortality in participants with hip or knee osteoarthritis. 
Abbreviations: OA: Radiological hip or knee osteoarthritis, H.R: Hazard risks and, 95% Confidence Interval 
(95%CI) for cases of hip or knee osteoarthritis (OA) versus no-cases (No-OA). Model1: adjusted by age, 
gender and cohort study. Model 2: adjusted by age, gender, smoking, prevalent diabetes, cardiovascular 
disease, dementia, BMI, walking disability, analgesics-use, functional limitations and cohort study.
Analyses of Survival Time
Participants with hip or knee OA had a shorter survival time compared to participants
without OA (Mean survival time difference: 2.11 years, SD: 0.15, Log rank test:
P<0.001 for these differences in survival time). There were also differences in the
survival time according to the joints affected with osteoarthritis (Figure 3). Participants
with both hip and knee OA had the shortest survival time; approximately 3 years less
lifetime compared with participants without OA. Participants with only hip osteoarthritis
Cause of death
n.events(%) Model 1 Model 2
No-OA OA Hazard Risks
(95%CI)
P Value Hazard Risk
(95%CI)
P Value
Cardiovascular 238 (29) 241 (31) 1.37 (1.13-1.66) 0.001 1.16 (0.95-1.42) 0.14
Cancer 266 (32) 174 (22) 1.22 (1.00-1.49) 0.05 1.21 (0.99-1.49) 0. 07
Respiratory 36 (4) 25 (3) 1.19 (0.70-2.04) 0.52 1.27 (0.73 -2.22) 0.40
Other causes 156 (19) 172 (22) 1.36 (1.08-1.72) 0.008 1.21 (0.95-1.55) 0.12
Dementia 63 (8) 90 (12) 1. 61 (1.15-2.26) 0.006 1.43 (1.00-2.05) 0.05
Trauma 18 (2) 31 (4) 2.00 (1.09-3.71) 0.03 1.68 (0.87-3.22) 0.12
Infections 44 (5) 46 (6) 1.39 (0.90-2.15) 0.14 1.25 (0.79-1.98) 0.34205
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    or only knee osteoarthritis had 1.7 years and 0.84 years respectively shorter survival time
compared to participants without osteoarthritis (Fig 3, P value of Log rank test<0.001). 
Figure 3 Kaplan and Meier Curves for the Mortality Risk of osteoarthritis According with Joints Affected. 
Comparison of cumulative survival in participants according to joints affected with radiological osteoarthritis 
(OA) at follow up. Log rank test P value <0.001 demonstrates significant differences between groups. 
Participants with hip and knee OA have a decreased survival time compared to controls (P value<0.001).
DISCUSSION
Results of this study on 4,733 individuals indicate that subjects with hip or knee OA
(radiological or clinically defined) have a higher overall mortality. Mortality risk was
increased for those with longer disease duration, suggesting that the negative effect of
OA on survival is cumulative. Additionally, subjects with OA had more comorbidities
than subjects without OA. Diabetes, dementia and other mortality-related risk factors as
walking disability and functional limitations were independent mortality-related factors
that partially explained the higher mortality in subjects with OA. Subjects with both
joints affected: knee and hip, are the most vulnerable group and dye on average three
years earlier than subjects without OA.
We here demonstrated that mortality risk for individuals with OA differ between those
who received a joint replacement and those who did not. Subjects with OA who received
total joint replacements had nearly 20% lower mortality risk, close to significant. This
has been reported before, which indicates a truly different mortality hazard for
individuals receiving a TJR compared to the rest of the individuals suffering from OA
(15). This finding may be due to confounding by indication. In general, individuals that206
    receive a TJR are considered healthier and with greater life expectancy than the average
general population, (15) the latest confirmed by our results. Joint replacement therapy is
generally done in healthy low risk patients who are less affected by chronic diseases (16,
17). Thus, there is no surprise that OA patients who are elected for joint replacement
have a better life expectancy compared to the general population (15, 18, 19).
Excess of mortality in participants with hip or knee OA was present for all specific
causes, being more pronounced for trauma, dementia, infections and cardiovascular
causes. The relation of OA with dementia as cause of death in subjects was previously
reported in a single study (9). In our study, the majority of deaths in this group were due
to Alzheimer’s disease (86%, result not shown). Interestingly, a recent investigation
using a mice model suggested that OA might exacerbate Alzheimer disease
pathology.(20) However, the underlying biological mechanism is not yet clear. More
studies will be needed to further elucidate this association between OA and dementia.
Regarding cardiovascular fatal events, there are previous reports that associate OA with
CVD and cardiovascular mortality (9, 21-24). NSAID use, inflammatory factors,
decrease in physical activity and disability have been suggested as possible explanatory
factors for this relation (9). In this study diabetes, analgesics use, functional limitations
and walking disability were important factors associated with OA, explaining the
variation in the mortality risk due to cardiovascular causes in subjects with OA. Diabetes
has recently been shown to be a predictor of severe OA independent of BMI and age (3).
In this study, subjects with OA were more affected by diabetes than subjects without
OA. Additionally, our results suggest that diabetes might have an important role in
survival of subjects with OA. Research in this area is needed to elucidate the metabolic
component that is involved in pathogenesis of OA. Prevalent cardiovascular disease did
not explain the higher CV mortality in participants with OA. It might be possible that
other cardiometabolic morbidities not included in the analysis would explain the rest of
the CV mortality. It is known by previous publication (Hoeven TA et al.) that
atherosclerosis is associated with knee OA. Atherosclerosis between other factors would
explain the increased mortality due to CV causes in participants with OA. In conclusion,
a significant part of mortality risk in participants with OA is due to consequences of OA
(disability and analgesics use). Another part is due to diabetes, BMI (in those with knee
OA only) and possibly other factors not included in this study. 
Functional limitation was a covariate that explained also part of the mortality risk due to
infectious, lung diseases and other causes. This variable comprised four questions that
evaluate the ability to perform house-chores and social activities outside house as207
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    shopping and travelling. This type of functional limitations, might be an adequate proxy
to evaluate the severity and prognosis of the disease reflecting the impact of OA not only
on the affected joints but, on the overall functionality of the affected subjects. Disability
was a predictor of mortality not only for cardiovascular but also for traumatic causes.
Disability itself is considered as an important risk factor for mortality independent of age
and concomitant diseases in the same individual and it is known that disability it is also a
risk factor for other adverse events related to a higher mortality risk (25).
We found a stronger association of OA with mortality in females than in males. There
are important sex differences in OA and also in their relation with metabolic endpoints.
OA is more prevalent, severe and symptomatic, with higher rates of progression in
females (26-28). Women with OA have more pain and poorer joint function that translate
in major limitations (29, 30). This could explain the higher mortality risk due to OA in
women.
This is the first population-based study analysing the relation between mortality and OA,
considering their possible causes and the effect in this relation of the disease duration.
Previous reports recruited patients from hospitals, general practices or with joint pain
and then they compared the mortality rates to that of the general population statistics
affecting generalizability of their findings. Additionally, in other studies definitions of
OA were not stringent; only based on the presence of possible osteophytes and/or only
based on radiological criteria (8, 9, 31). 
Our study has also some limitations. We estimated the disease duration using as
reference the radiographic assessment at baseline and follow up. We cannot point out the
exact duration of the disease (based on first symptom or first radiological evidence). We
used multiple imputations to handle missing data on covariates. We compared these
results with those obtained only in individuals with complete data, finding similar
results. In spite that we analysed important comorbidities and risk factors, data on other
comorbidities (such as depression) were not collected at the time of radiographic
assessments and therefore were not included. Therefore, we cannot exclude the
possibility that other comorbid conditions here not included might explain part of the
association of OA with mortality. Finally, participants who were included in this study
were those who were able to visit the research center for radiographic examination.
Indeed, subjects who did not undergo radiographic examination had a higher disability
index than those that visited the research center. This might introduce a health bias
towards underestimation of the effect of OA. 208
    In conclusion, we found a strong positive association between hip and/or knee OA and
mortality due to all causes with the exception of cases of joint replacement where the
association is inverse. The association was partially explained by the increased
prevalence of comorbidities and risk factors as diabetes, dementia, high BMI, walking
disability and functional limitations in this population.
The results from this study have implications for the management of patients with OA.
Subjects with hip and/or knee OA should be targeted in programs for prevention of
physical and functional decline and control of chronic diseases. Additionally, subjects
with OA will benefit of alternative therapies for pain control beyond analgesics.
Therefore, these results might also have consequences on policies, guidelines and
treatment of subjects affected by OA. 
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    APPENDIX
Clinical assessment
For this study we used information at baseline that was collected between 1990-1993 for
RS-I and 2000-2002 for RS-II and approximately six and 4 years follow up respectively.
We analysed the presence of hip pain (joint complaints of right/left hip during the last
month), activities of daily living based on the Instrumental Activities of Daily Living
scale and lower limb disability assessed with a modified version of the Stanford Health
Assessment Questionnaire (32, 33). For the purpose of this study, two items were
considered: Ability to walk outdoors on flat ground for both cohorts (at baseline and
follow-up) and ability in functional Activities of Household and Leisure (AHL), for
practical purpose called functional limitations along the manuscript. Ability in AHL was
evaluated using four different questions: Are you able to run errands and shop? Are you
able to get in and out of a car? Are you able to travel? Are you able to do chores such as
vacuuming or housework? These questions including walking outdoors were scored as
follows; 0= without difficulty, 1= with some difficulty, 2= with much difficulty and 3=
unable to do (needs help). Other methodological details of the definitions are described
elsewhere (34).
We also used information about smoking (current and former vs. never), use of
analgesics (in the last month: yes/no) and education level as a proxy of socioeconomic
status (SES). Height and weight were measured at baseline examination with the subject
in a standing position with indoor clothing without shoes and BMI was calculated
(kg/m2) and included as linear variable or categorical (BMI>26 kg/m2). 
Other comorbidities were also assessed; specifically myocardial infarction, dementia and
type 2 diabetes mellitus. Myocardial infarction was verified by cardiologist, general
practitioner or ECG. Diabetes mellitus was defined as use of antidiabetic medication
and/or abnormal fasting glucose and/or abnormal oral glucose tolerance test; a
nonfasting or postload glucose level of 11.1 mmol/L or over was considered abnormal.
Dementia was assessed as a three-phase approach: brief cognitive test, neurological
testing and diagnosis confirmation through detailed examination or medical records (35).
All these variables were collected at baseline and during the follow up period.212
    Radiographic assessment and OA definition
Radiographic hip OA was defined as definite Joint Space Narrowing (JSN) and at least a
possible femoral osteophyte and knee OA as possible JSN and at least a definite
osteophyte, i.e. a score of 2 or more in one or both joints according to Kellgren and
Lawrence (KL≥=2). Inter-rater agreements for KL score (Kappa coefficients) were 0.74,
076 and 0.71, 0.68 for hip and knee respectively in RS-I and RS-II.
Appendix Figure 1 Clinical Characteristics of the Study Populations.Associations between characteristics at 
baseline and all cause mortality for Rotterdam study I (RS-I) and Rotterdam Study II (RS-II). Hazard ratios 
(HR) with corresponding 95% confidence intervals (95%CI) from multivariate Cox proportional hazards 
models in the complete data set for all covariates at baseline after adjustment for age and gender. P values were 
calculated by using two sided Wald tests. Values are mean and standard deviations (SD) or number of cases and 
percentages (%) for categorical variables. Age in years (y), BMI: Body Mass index, SES: Socio Economic 
Status according with educational level; risk are shown for lower education. † Individual without osteoarthritis 
in the joint(s) as reference category.
0.5
N. of participants 3308 1425
N. of events 1473 137
Mean follow up-time 9.6 (3.6) 5.7 (1.2)
Age mean (SD), y 72.7 (7.2) 68 (7.2)
Gender male N. (%) 1387 (42) 625 (44)
SES (Low educational level) 589 (18) 104 (7)
BMI mean (SD) 26.5 (3.7) 27.8 (4.1
Cardiovascular disease N (%) 584 (18) 109 (8)
Diabetes mellitus N (%) 308 (9) 191 (13)
Dementia (%) 108 (3) 18 (1)
Smoking current and former N (%) 602 (18) 194 (14)
Walking disability N (%) 426 (13) 261 (19)
Analgesics use N (%) 320 (10) 190 (13)
Difficulty in AHL (%) 784 (26) 401 (29)
Radiological Knee OA    (%) 1051 (32) 327 (23)
Radiological Hip OA    (%) 307 (9) 168 (12)
Hip and knee OA    (%) 99 (3) 34 (2)
Knee or hip pain (%) 1065 (57) 613 (67)
Baseline Characteristics
RS-I Lower
Mortality
Higher
Mortality
Lower
Mortality
Higher
Mortality
RS-II
1.0 2.0 3.0 0.5 1.0 2.0 3.0 4.0213
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 Hip osteoarthritis (OA) is a complex disease in which genetic and environmental factors
play a role. In the previous chapters, new genes and risk factors for hip OA were
identified and the burden of the disease was analyzed; increased fracture risk, more
comorbidities and a decreased survival time are common outcomes for subjects with OA.
The main findings and limitations of each study were previously discussed. In this
chapter, the main points and considerations addressed in this thesis are presented and
suggestions for future research are given.
Genetics of hip OA: defining the phenotype
Hip OA is a multifactorial disease in which diverse factors including genetics interact
causing a process of change and deterioration of cartilage and subchondral bone and new
bone formation on the cartilage edge. However, OA is a heterogeneous disease in which
is possible to identify different sub-phenotypes, each of them with their own risk factors.
For example, bone changes are not always present, which would allow defining different
hip OA sub-phenotypes according with the bone response during OA. The genetic
architecture of OA has also demonstrated complexity, as it does not follow a pattern of
Mendelian inheritance while not many associated genetic variants have been identified.
Therefore, a genome wide association study (GWAS) seems to be a good approach to
identify new genes and genetic factors that might help to explain the genetic component
of the disease and identify new biological pathways. 
In a GWAS, the selection of a correct phenotype is critical for the interpretation of the
study as well as for the power to find true significant and plausible results. Previous
efforts using multiple dichotomous-composed definitions in GWAS of OA yielded few
genomic loci. Reasons for this include, low power in the discovery phase of the GWAS
and phenotypic heterogeneity. Phenotypic heterogeneity can substantially reduce power
in GWAS [1] and it is clear that OA suffers from this as well. In OA, some cases only
exhibit joint space narrowing and not osteophyte formation (as we show in chapter 4.1).
A way to decrease phenotypic heterogeneity is through the use of intermediate
phenotypes and endophenotypes. Endophenotypes are stable phenotypes that can be
more reliably phenotyped and quantified and additionally, they might be closer to what is
encoded in the DNA sequence. Minimal Joint Space Width (mJSW) is an endophenotype
that represents cartilage thickness. The principal advantage of JSW as endophenotype is
the focus on one structure of the joint (cartilage) and it is primarily “state-independent”
(measurable in an individual whether or not illness is active). Additionally, gradual
narrowing of the joint space width is part of the definition of OA and it is seen during the217
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    progression of hip OA on radiographs with a very good reliability [2, 3]. The use of a
definition based on the joint space width as endophenotype showed to be a successful
approach to identify genes responsible for cartilage thickness (development and/or
maintenance) and OA as it was presented in chapter 2. In addition, the use of a
quantitative trait such as mJSW to discover signals implicated in hip OA has some
advantages. Quantitative traits are more powerful than dichotomous traits especially
when the accuracy of the measure is better for the quantitative trait [4]. Quantitative
traits are traits with a continuous distribution in natural populations, with population
variation often approximating a statistical normal distribution on an appropriate scale
[5]. 
Unfortunately, studies in OA where DNA is available for subjects with data on diverse
OA-phenotypes or endophenotypes are limited. The largest study so far of subjects
included in a GWAS using mJSW as an endophenotype was presented in chapter 2.2,
N=19,181. For OA, the maximum amount of subjects included in a study was presented
in the arcOGEN study (a maximum of 14,883 cases and 53,947 controls) [6]. 
The use of endophenotypes has demonstrated to be successful also for other diseases as it
is the case for osteoporosis using bone mineral density (BMD). With a similar sample
size as the one used for mJSW in the discovery phase (N=19,195 for BMD and
N=13,013 for mJSW), 20 loci were identified to be associated with BMD [7]. In average,
are required 4 times more participants to identify the same amount of loci in GWAS of
mJSW than in GWAS of BMD. Differences in methods used to measure BMD and
mJSW, with more consensus and calibration in favour of the BMD measure, between
other reasons might explain the differences in the relative number of identified loci [7].
Not all SNPs that are identified using an endophenotype are associated with the studied
(end stage) disease. However, it is still a valid and successful approach to identify new
signals and to understand the pathogenesis of the studied disease. Such is the case for the
relation BMD-osteoporotic fractures. From a total amount of 56 SNPs associated with
BMD at GWS level only 14 are associated with osteoporotic fracture risk (25%) [8]. The
relation of mJSW and OA seems to follow a similar pattern; only some of the SNPs (3
out of 5) associated with mJSW are associated with hip OA (Chapter 2.2). However, the
number of mJSW-associated SNPs is low to make a fair comparison with the findings in
other studies as for example the GWAS on BMD.
The approach of using the endophenotype mJSW to identify genes for the end stage
disease OA demonstrated to be successful not only to identify genes tat are relevant for218
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 OA but, also to elucidate the role of variants that were previously found related to OA.
Some of the SNPs that are approaching GWS level for mJSW (Chapter 2.2) are in
linkage with SNPs in genes previously identified as associated with OA which allow
inferring their relation. It was the case for the variant close to SUPT3H (rs10948155) and
the variant from ASTN2 (rs4837613), with respective variants rs10948172 and
rs4836732 identified in the arcOGEN study for OA [6]. It indicates that the association
with OA of the variant near of SUPT3H and ASTN2 might be mediated by differences in
cartilage homeostasis rather than bone changes or pain, which might be possibly
suggested by the association of variants in SUPT3H with height or by the role of ASTN2
in the central nervous system.
In addition to an increased sample size and studies in other ethnicities where new
variants might be found, further studies in hip OA will need to use other specific
endophenotypes (for example: hip geometry traits, sclerosis, cartilage regeneration,
wound closure) to differentiate between the roles of bone, cartilage and other tissues
implicated in the disease process.
From GWAS hit to gene
The success of GWAS identifying SNPs and genetic loci associated with a phenotype/
disease contrasts with the difficulties to confidently point to the implicated gene. Proving
the involvement of an implicated gene is far from easy and does not follow automatically
from identifying a SNP through a GWAS. A SNP identified using GWAS is likely part
of a large region of linkage disequilibrium, thus making it difficult to correctly point out
the SNP that have a biological link or is responsible for the association. This is also the
case of intergenic SNPs or SNPs localized in a “gene desert area”. It has been estimated
that ~25% of the human genome consists of gene deserts, defined as long regions
containing no protein-coding sequences and without obvious biological functions (9).
There is not consensus about how far the identified SNP should be from the closest gene
to be called gene desert area. Some authors have been using a distance equal or higher
than 500 Kb as cut of point for the regions to be denominated gene desert (10). 
There are different approaches to help in the identification of the responsible gene after
the identification of a genetic locus by GWAS. At first it would be possible to check if
the closest gene(s) is giving rise to a Mendelian disease with a phenotype resembling the
GWAS phenotype or whether there are knock-out (KO) mouse models giving rise to a
phenotype resembling the studied GWAS phenotype and therefore the phenotype might
be observed in humans carrying the corresponding mutations [11]. 219
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    Another approach is to see if the SNP, or an LD partner SNP, is correlated to expression
of a nearby gene (so-called eQTL: expression Quantitative Trait Loci) [12]. SNPs that
influence gene expression have been shown to be significantly enriched for GWAS
associations (13-14). Other methods for identifying SNPs that overlap regulatory
elements, such as transcription factor binding motif, have been also successfully used to
identify specific loci that have a functional role (14-15). 
Pathways implicated in Hip OA and association with mJSW
From our genetic studies we observed several categories of proteins to be implicated in
hip OA. These include transcription factors and signaling molecules which coordinate
chondrocyte and osteoblast differentiation (endochondral bone formation) and finally
help to determine the development of the hip joint including its size, orientation and
height of the individual. This seems to be a plausible conclusion after the studies
presented in Chapter 2 combined with published results from other studies [6, 16-18].
We observed associations between cartilage thickness and DNA variants near genes
involved in joint and/or bone formation such as Wnt-signaling (DOT1L, chapter 2.1),
RUNX2 and Transforming Growth Factor Alpha (TGFA) among others (Chapter 2.2).
Additionally, from other studies, the previously reported variants in Growth and
differentiation factors GDF5 and SMAD (receptors of TGF-beta signaling) have been
associated with hip OA and/or height [6, 17,18]. 
GRAIL (Gene Relationships Across Implicated Loci (GRAIL)) was used to search for
connectivity between genes near the SNPs previously reported as associated with hip OA
at genome wide significant [6,16,19], and the SNPs reported in this thesis as associated
with cartilage thickness (mJSW) discovered both through the use of a GWAS approach
[20]. Only independent signals are included in a GRAIL analysis. Therefore, in this
analysis, a total of 14 genomic regions (from 14 SNPs) were selected; 8 SNPs had been
found associated with hip OA from previous studies (for more details see table 2, chapter
1) and the 6 signals reported in this thesis as associated with mJSW and or hip OA (Table
1, Chapter 2.2). GRAIL assesses the degree of relatedness among genes within regions
that harbor predictive SNPs identified by GWAS, selecting the most connected gene that
corresponds to 1 or more SNPs as the likely implicated gene. For each genomic region, a
P-value is assigned by GRAIL based on he best candidate gene. The candidate gene
reported by GRAIL (Table 1, second column) is the gene with the highest number of
relationships to other associated genes in independent regions. GRAIL corrects its
significance score for multiple hypothesis testing (by adjusting for the number of genes
in the region), to assign a significance score to the region.220
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 GRAIL offers a statistical approach based on connectivity described in literature to
identify functionally related genes from across multiple disease regions that likely
represent key disease pathways. GRAIL identifies the most significant gene as the likely
candidate within a region identified by a GWAS hit. Therefore, not all genes reported by
GRAIL coincide with the corresponding nearby genes for the identified associated SNPs
reported by individual GWAS (Table 1). For each genomic region, a P value is assigned
by GRAIL. From the set of genes reported by GRAIL as candidate for the SNPs reported
associated with mJSW/cartilage thickness (Table 1), the genes with highest significant
connections with others genes identified by GRAIL (according with the literature) were
PTHLH, (reported by arcOGEN), SULF2 (reported gene by Evangelou et al, 2013 was
NCOA3), and PAPPA (the gene reported by arcOGEN was ASTN2) Which might be
more suitable candidate for the association with hip OA because of his role in
proliferative processes such as wound healing and bone remodeling
(http://www.ncbi.nlm.nih.gov/refseq/). Additionally, Lango et al, identified also a SNP
in the same region associated with height and they reported PAPPA as the gene
responsible for the association [21]. 
Table 1. GRAIL data for selected individual SNPs of interest.
Abbreviations: minimal Joint Space Width (mJSW, hip osteoarthritis (hip OA). P-value >0.05 imply that the 
candidate gene reported by GRAIL has not significant connections with other genes within the study.
SNPs
CANDIDATE 
GENE 
REPORTED 
BY GRAIL
GENE 
REPORTED 
BY GWAS
GRAIL   
p-value
OA PHENOTYPE REFERENCES
rs10492367 PTHLH PTHLH 3x10-3 Hip OA (KL or THR) arcOGEN
rs6094710 SULF2 NCOA3 6x10-3 Hip OA TREAT-OA
rs4836732 PAPPA PAPPA 0.04 THR–females arcOGEN
rs11842874 F10 MCFL2 0.09 Hip OA (KL or THR) Day-Williams et al
rs2862851 TGFA TGFA 0.12 mJSW and Hip OA This thesis
rs835487 CHST11 CHST11 0.14 THR arcOGEN
rs10948172 RUNX2 RUNX2 0.15 Hip OA in males, mJSW arcOGEN
rs2236995 SLBP SLBP 0.150 mJSW This thesis
rs12982744 AMH DOT1L 0.22 mJSW and Hip OA This thesis
rs11177 ITIH3 MUSTN1 0.33 THR or TKR arcOGEN
rs10471753 PIK3R1 PIK3R1 0.24 mJSW This thesis
rs496547 DDX6/ TREH 0.63 mJSW This thesis
rs717433 HAO1 HAO1 0.73 mJSW This thesis
rs9350591 MYO6 FILIP1 0.78 Hip or knee OA arcOGEN221
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    Connections between the genes are represented in the figure 1. The strongest connection
between the genes identified by GRAIL was given between the Parathyroid hormone-
like hormone (PTHLH) and other genes as SULF2, RUNX2, TGFA, PIK3R1, PAPPA,
and MUSTN1. PTHLH regulates endochondral bone development and Sulfatase 2
(SULF2), act as co-receptors for numerous heparin-binding growth factor and cytokines
[20].   Other gene with significant connections with the set of genes associated with
mJSW and/or hip OA was NCOA3 with connections with PTHLH, AMH, NISCH and
PAPPA. In spite of significant connections with other genes of NCOA3, the best
candidate gene reported by GRAIL for this SNP (rs6094710) was SULF2 because it was
more functionally related to the other signals included here in this analysis. GRAIL also
assigns a select set of keywords using a text-based similarity metric supported on
statistical text mining methods to suggest putative biological pathways [22]. Based on
existing literature in PubMed till August 2012, GRAIL identified 20 keywords
describing the functional connections of these loci. With these words it is possible to
establish functional connections relevant in processes as development, growing and
differentiation of bone and cartilage tissues. Between the first words from GRAIL are
PTHrP and chondrotin- and heparan-sulfate. PTHrP is a protein member of the
parathyroid hormone family that between other functions regulate bone development by
maintaining the endochondral growth plate at a constant width act to mantein the
proliferative state of chondrocytes and inhibit their maturation [23]. Chondroitin sulfate
is an important structural component of cartilage and provides much of its resistance to
compression [24]. Heparan sulfate is a sulfotransferase enzyme, co-receptor for growth
factors, morphogenesis and adhesion of proteins. Heparan sulfate and chondroitin are
both sulfated glycosaminoglycans which are produced by a biological sulfation reaction
[25,26]. 
Understanding the role of the genes implicated in the development of the hip joint and
OA development requires further research. The identified SNPs and suggested genes,
which are implicated in bone and cartilage phenotypes, might have different roles in
formation of articular cartilage, differentiation processes, maintaining and healing of
bone and cartilage tissue that finally seems to have a direct effect on the risk of
development of hip OA. 222
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 Figure 1 Graphical representation of the connections between the 14 selected SNPs associated with hip OA 
and/or mJSW with the corresponding genes using GRAIL. GRAIL analysis identified non-random 
connectivity (P<0.05) between associated genes (in bold). Only the genes with P-GRAIL <0.05 have 
connections displayed. The 20 keywords describing the functional connections of these loci in order of 
informativeness were: pthrp,chondroitin, sulfate, alpha, mullerian, factor, heparan, growth, histone, sulfation, 
sulfotransferase, hormone, loop, heavy, transforming, chains, parathyroid, bone, pregnancy and inhibitor.
Hip Geometry
From the studies presented in Chapter 3 and previous studies on the relation between hip
geometry and OA, it is possible to conclude that there is a connection between hip
geometry differences and the risk for hip OA. Bone is a dynamic tissue that is subject to
a continuous process of remodelling as response to different physical demands (activity,
load), hormonal, neurological factors, and aging among others. Therefore, it is difficult
to determine whether geometry differences/disadvantages are causal factors of hip OA in
older individuals, since during aging other risk factors might have a role on both
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    remodelling and OA. However, recent studies show that variation in acetabular coverage
(dysplasia and protrusio acetabuli) in children and impingement in young adults are
predisposing to hip OA [27]. This indicates that these alterations are present very early in
life, probably at birth. Additionally, according with our results it seems that such
differences remain until old age and have a significant predictive value for hip OA
(Chapter 3). 
Not much is known about the genetic factors that are responsible for differences in hip
geometry and whether they are relevant for the risk of OA. Considering the role of hip
geometry in OA and hip fracture, it is possible to hypothesize that some of the genes
responsible for geometry differences might be relevant for the risk of OA and fractures.
This aspect was not explored in this thesis, but it will be relevant to further analyse.
There are few GWAS performed on measures of hip bone geometry including cortical
thickness, buckling ratio (BR), cross-sectional area, femoral neck-shaft angle (NSA), the
width of the femoral neck at the narrowest point (NW), femoral neck length, and
proximal femur size in EU populations. Genome-wide significant associations with NW
were found for SNPs located on chromosomes 1p13.2 (RAP1A) and 18q11.2 (OSBPL1A)
[28]. Genome-wide significant associations with femoral neck shaft angle (NSA) were
found for SNPs located on chromosome 2q11.2 (TBC1D8) [28]. A polymorphism within
the RTP3 gene was associated with BR in both EU and Chinese populations [29]. It is
unknown whether these SNPs are associated with OA. Possibly, there will be many more
genetic variants associated with geometric traits that might be relevant for bone and
cartilage tissue and OA but these remain to be demonstrated. 
Atrophic versus osteophytic OA types: differences in bone 
tissue and fracture risk
Hip OA can be classified according to the absence or presence of osteophyte formation
and cartilage loss, expressed as degree of narrowing of the joint space on a radiograph.
The formation of osteophytes is strongly associated with higher bone mineral density
(BMD), not only on the joint affected with OA but also systemically. In this thesis, the
relation between BMD, hip OA and lumbar disc degeneration (Chapter 4) was studied. It
is interesting that BMD in subjects with the osteophytic-OA phenotype was also higher
in areas as skull (Chapter 4.1 and 4.2), where BMD is less subject to changes due to
aging and environmental influences (as physical activity). The fact that individuals that
display the atrophic form of OA, i.e, without new bone formation, also have a lower
systemic BMD suggests that individuals that form osteophytes have a better “bone-
forming capacity” than people who do not. Subjects with osteophytic OA also have a224
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 wider femoral neck, and greater bone strength than subjects with atrophic OA or those
without any OA-feature as we have shown in chapter 4.1. It is plausible that these bone-
differences between OA- sub-phenotypes, BMD and geometry are already there before
to development of OA. 
Differences in BMD seem to be not only systemically but also localized (Chapter 3.2).
The superior part of the femoral head and other areas of the hip also have increased
BMD at initial stages of OA and are predictive of progression of hip OA compared to the
contralateral without-OA side (Chapter 3.2). 
Besides, narrowing of the joint space alone (atrophic OA), without osteophytes, might
indicate some degree of osteopenia/osteoporosis possibly accompanied with bone-
fragility that translates in higher risk for osteoporotic fractures as shown in chapter 4.1.
However, for lumbar disc degeneration (LDD), the relation between disc degeneration
and fractures seems to be different. Osteophytes are very common in subjects with
radiographic evidence of lumbar disc degeneration and those subjects also have a higher
systemic BMD than subjects without LDD. Nevertheless, males with LDD are at higher
risk for osteoporotic fractures including clinical vertebral fractures (Chapter 4.2). It is
known that most of the fractures occur in men with normal BMD and clinical vertebral
fractures are particularly common in oldest men. We did not have data on other bone
properties or markers of bone metabolism to clarify this association. Considering that the
study on the association of osteoporotic fractures and LDD (Chapter 4.2) is the first
realized in males, our findings require further corroboration by other population-based
studies.
There is not much information about the quality of bone tissue in subjects affected by
OA and LDD. It is known that high BMD not always coincides with other measures of
bone properties such as a Trabecular-Bone Score (TBS). TBS is a gray-level texture
measurement that is applicable to DXA images measuring the mean rate of local
variation of gray levels in 2D-projection images. The correlation between BMD and TBS
is lower than expected [30, 31] while not many studies have been performed in males.
Other measures of bone properties as TBS might give more information about the
characteristics in favor of resistance of bone tissue to fractures that might differ in
individuals affected by OA. Until now there are no studies analyzing TBS and BMD in
populations affected with hip OA and LDD. According to our results presented in
Chapter 4, we hypothesize that there are differences in other bone properties related to
fracture risk between individuals affected and non-affected by OA, even in those with
“normal”-BMD. 225
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At the starting point of this thesis, OA was already recognized as a disease strongly
associated with disability, especially walking disability and decreasing the years of
productive live. In chapter 5 we show that individuals with OA had an increased
mortality risk compared to those with the same characteristics without OA. The mortality
risk was especially elevated in those individuals that already had OA for a longer period
(>4 years). It is also of concern that individuals with hip or knee OA have a very limited
participation in functional activities in and outside home that include personal and
leisure activities. Thus the impact of OA on general health is dramatic and it is finally
reflected in a higher mortality. Health professionals therefore need to be more aware of
the serious health impairment that the subjects with hip or knee OA are suffering.
Contingency plans needs to be carefully elaborated to hamper the negative effects of OA
on disability and functionality. Subjects with OA need to be targeted in preventive
programs for chronic diseases in the elderly. Monitoring important daily life activities
could be a good preventive factor for morbidity and survival. 
Suggestions for future research
Based on the finding presented in this thesis there are several research topics that will
deserve further investigation:
Genetics: 
With current GWAS approaches in OA we have identified several genetic factors but
they explain only a modest part of the total phenotypic variation and a modest part of the
genetic variation. The total genetic variation to be explained is indicated by the
heritability (discussed in chapter 1.3) and ranges from 40 to 60% for hip OA and from
51–85% for knee-cartilage volume, being not yet estimated for mJSW at the hip joint
[32]. The limited explained variance is due to the current focus on common variants and
a heterogeneous disease phenotype. Some suggestions to identify more variants that
might explain the genetic component of the disease are given below. GWAS with a
higher number of participants or studying rare variants with novel techniques that have
recently become available such as next generation sequencing. Family-based genetic
studies using GWAS and exome sequencing with very clear and straightforward OA
phenotypes and endophenotypes like the one here analyzed (mJSW) are needed. The use
of linkage analysis on large families identified with co-inheritance of OA followed by
whole exome sequencing of interesting regions might detect mutations that cosegregate
with OA. 226
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 Stratification according to etiological factors. Future studies for example will have to
consider gender and previous trauma not only for finding associated genetic variants but
also to determine the predictive value of the genetic markers. Predictive markers might
have a different value according with their relation with healing of cartilage/bone tissue
and might interact with gender between other possible explanations. Additionally, there
might be specific genetic variants related to inherent properties of the bone formation/
response and OA. Possibly, atrophic hip OA should be studied as a separate phenotype to
give insight in the role of differences in bone density and other bone properties as
etiological factors in the risk for OA. 
Phenotypes. Along this thesis different approaches were explored to measure hip
geometry: predefined geometry parameters (e.g, neck width) and Active Shape
Modelling (ASM). The use of predefined geometry measures might be the option as
endophenotype for genetic studies in OA and osteoporosis, in favour of efficiency,
reproducibility, validation and interpretation needed in a GWAS, compared to ASM.
Geometry as previously explained, might be a useful approach to identify variants
important not only for fracture risk but also to hip OA. It will also be interesting to
analyze the genetic factors that contribute to the differences in hip geometry that as we
presented in chapter 3.1 have a role in the progression of hip OA. 
In this thesis we focused on methods based on DXA scans to measure different bone
properties relevant to hip OA and other bone diseases as LDD. However, other
techniques are suitable to study bone tissue in population affected by OA. For example
the use of TBS and studies with markers of bone/cartilage metabolism will give insight
on the cause of increased fracture risk associated with OA. Additionally, this will give
insight in the role of the bone tissue in the progression of OA.
mJSW demonstrated to be an important endophenotype for hip OA because it is a
continuous trait, normally distributed in population, relatively easy to measure and with
good reproducibility. It might be possible that genetic variants associated with cartilage
thickness are site- and joint-dependent therefore GWAS is advised to be done for
specific sites of the hip joint and for other joints. It might also be a successful approach
for finding genetic associated variants for knee OA, that might be not only relevant for
cartilage thickness of the knee joint but also for knee OA-risk. Similarly, studying
genetics of JSW at other joints such as hand and vertebral joints might result in new
variants associated with the disease.227
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    This thesis focused on hip OA and it has been seen that variants for hip OA are not
associated to knee OA and vice-versa. The genetics of OA seems to be joint-specific
although variants in common for the disease at different joints might exist given the
systemic nature of the disease. Clustering joints affected by OA should be based on
similarities of the disease at different sites. For example, clustering knee and hand OA
seems logical, since they share a similar strong risk factor (BMI) [33]. 
Other approaches to study mJSW more effectively is to examine younger populations.
Studying this endophenotype in children will help to discriminate the genes that are
relevant for cartilage development from those relevant only to cartilage loss that might
occur in joint diseases in elderly.  
It will be of crucial importance to determine the biological mechanism behind the
discovered genetic loci that we present in Chapter 2. Although many of the SNPs/loci
have good nearby candidate genes (such as RUNX2 and TGFA), it remains to be proven
whether these genes are actually the culprit genes underlying the associations. Analysis
of the expression in joint tissue and functional characterization of TGFA, RUNX2,
ASTN2, SLBP will result in better understanding of the implicated signalling pathways
and how they interact during the disease. This will give better insight and might be
opening possibilities for future treatment of the disease.
Re-defining hip OA. Advances in the understanding of hip OA might benefit of a
quantitative definition as is was the case for osteoporosis and BMD. In spite of the
importance of bone phenotypes in OA as it was mention along this thesis and based on
individual differences in bone response during the disease process, I would suggest
narrowing of the joint space measure in mm as a good approach for defining the disease
that deserves to be analyzed. However, reference standards from different young
populations stratified by gender and adjusted by height with cut off values. Therefore,
consensus on radiographic protocols to measure mJSW and narrowing of the Joint space
are needed to be able to establish some parameters. Finally, considering different
etiological risk factors might improve the benefit on future treatments focusing for
example in cartilage repair, bone or hip geometry alterations pointing to a more
personalized medicine.228
   
Ge
ner
al d
isc
uss
ion
 REFERENCES 
1. Ioannidis JP, Thomas G, Daly MJ. Validating, augmenting and refining genome-wide 
association signals. Nat Rev Genet 2009;10(5):318-29.
2. Vignon E. Radiographic issues in imaging the progression of hip and knee
osteoarthritis. J Rheumatol Suppl. 2004 Apr;70:36-44. Review. Mackay TF. Q&A: 
Genetic analysis of quantitative traits. J Biol 2009;8(3):23.
3. Reichmann WM, Maillefert JF, Hunter DJ, Katz JN, Conaghan PG, Losina E.
Responsiveness to change and reliability of measurement of radiographic joint
space width in osteoarthritis of the knee: a systematic review. Osteoarthritis
Cartilage 2011;19(5):550-6. 
4 Donner A, Eliasziw M. Statistical implications of the choice between a dichotomous or 
continuous trait in studies of interobserver agreement. Biometrics 1994;50(2):550-5.
5 Mackay TF. Q&A: Genetic analysis of quantitative traits. J Biol 2009;8(3):23.
6. arcOGEN Consortium; arcOGEN Collaborators, Zeggini E, Panoutsopoulou K,
Southam L, Rayner NW, Day-Williams AG et al. Identification of new susceptibility loci
for osteoarthritis (arcOGEN): a genome-wide association study. Lancet 2012;380 (9844)
:815-23.
7. Rivadeneira F, Styrkarsdottir U, Estrada K, et al. Twenty bone-mineral-density loci 
identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 
2009;41(11):1199-206.
8. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE. Genome-
wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci
associated with risk of fracture. Nat Genet 2012;44(5):491-501
9. Ovcharenko I, Loots GG, Nobrega MA, Hardison RC, Miller W, Stubbs L. Evolution
and functional classification of vertebrate gene deserts. Genome Res 2005;15(1):137-45.
10. Wasserman NF, Aneas I, Nobrega MA. An 8q24 gene desert variant associated with
prostate cancer risk confers differential in vivo activity to a MYC enhancer.
Genome Res 2010;20(9):1191-7.
11. Cox RD, Church CD. Mouse models and the interpretation of human GWAS in type 2
diabetes and obesity. Dis Model Mech 2011;4(2):155-64.
12. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs 
are more likely to be eQTLs: Annotation to enhance discovery from GWAS. 
PLoS Genet 2010;6(4): e1000888.
13. Zhong H, Beaulaurier J, Lum PY, Molony C, Yang X, Macneil DJ, et al. Liver and 
adipose expression associated SNPs are enriched for association to type 2 diabetes. 
PLoS Genet 2010;6(5): e1000932.
14. Xu Z, Taylor JA. SNPinfo: Integrating GWAS and candidate gene information into 
functional SNP selection for genetic association studies. Nucleic Acids 
Res 2009;37: W600–W605.
15. Macintyre G, Bailey J, Haviv I, Kowalczyk A. is-rSNP: A novel technique 
for in silico regulatory SNP detection. Bioinformatics 2010;26 (18): i524–i530. 229
Ch
apt
er 
5.1
    16. Day-Williams AG, Southam L, Panoutsopoulou K, et al. A variant in MCF2L is 
associated with osteoarthritis. Am J Hum Genet 2011;89(3):446-50.
17. van de Laar IM, Oldenburg RA, Pals G, et al. Mutations in SMAD3 cause a syndromic 
form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet
2011;43(2):121-6.
18. Valdes AM, Spector TD, Tamm A, et al. Genetic variation in the SMAD3 gene is 
associated with hip and knee osteoarthritis. Arthritis Rheum 2010;62(8):2347-52.
19. Evangelou E, Kerkhof HJ, Styrkarsdottir U, Ntzani EE, Bos SD, Esko T. A meta-
analysis of genome-wide association studies identifies novel variants associated with
osteoarthritis of the hip. Ann Rheum Dis 2014 Dec;73(12):2130-6
20. Castaño Betancourt MC(1), Cailotto F, Kerkhof HJ, Cornelis FM, Doherty SA, Hart
DJ. Genome-wide association and functional studies identify the DOT1L gene to be
involved in cartilage thickness and hip osteoarthritis. Proc Natl Acad Sci U S A 2012;
22;109(21):8218-23.
21. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F et al. 
Hundreds of variants clustered in genomic loci and biological pathways affect human 
height. Nature 2010;467(7317):832-8.
22. Raychaudhuri S, Plenge RM, Rossin EJ, et al. Identifying relationships among genomic 
disease regions: predicting genes at pathogenic SNP associations and rare deletions. 
PLoS Genet 2009;5(6):e1000534.
23. Miao D, Li J, Xue Y, Su H, Karaplis AC, Goltzman D. Parathyroid 
hormone-related peptide is required for increased trabecular bone volume in 
parathyroid hormone-null mice. Endocrinology 2004;145 (8): 3554–62.
24.  Baeurle SA, Kiselev MG, Makarova ES, Nogovitsin EA. "Effect of the 
counterion behavior on the frictional–compressive properties of chondroitin sulfate 
solutions" Polymer 2009;50 (7): 1805–1813. 
25. Dai Y, Yang Y, MacLeod V, et al. HSulf-1 and HSulf-2 are potent inhibitors of 
myeloma tumor growth in vivo. J. Biol Chem 2006;280 (48): 40066–73.
26. Rabenstein DL. "Heparin and heparan sulfate: structure and function". 
Natural Products Reports 2002;19: 312–331.
27. Agricola R, Heijboer MP, Bierma-Zeinstra SM, et al. Cam impingement causes 
osteoarthritis of the hip: a nationwide prospective cohort study (CHECK). 
Ann Rheum Dis 2013;72(6):918-23.
28. Hsu YH, Zillikens MC, Wilson SG, et al. An integration of genome-wide association
study and gene expression profiling to prioritize the discovery of novel susceptibility
Loci for osteoporosis-related traitis. Plos Genet 2010;10(6):6.
29. Zhao LJ, Liu XG, Liu YZ, et al. Genome-wide association study for femoral neck bone 
geometry. J Bone Miner Res 2010;25(2):320-9.
30. Krueger D, Fidler E, Libber J, et al. Spine Trabecular Bone Score Subsequent to Bone 
Mineral Density Improves Fracture Discrimination in Women. J Clin Densitom 
2014;17(1):60-5.2013.230
   
Ge
ner
al d
isc
uss
ion
 31. Del Rio LM, Winzenrieth R, Cormier C, et al. Is bone microarchitecture status of the 
lumbar spine assessed by TBS related to femoral neck fracture? A Spanish 
case-control study. Osteoporos Int 2013;24(3):991-8.
 32. Hunter DJ, Snieder H, March L, Sambrook PN. Genetic contribution to cartilage 
volumen in women: a classical twin study. Rheumatology (Oxford) 2003;42(12):1495-
500.
33. Bijsterbosch J, Meulenbelt I, Watt I, Rosendaal FR, Huizinga TW, Kloppenburg
M. Clustering of hand osteoarthritis progression and its relationship to
progression of osteoarthritis at the knee. Ann Rheum Dis 2014;73(3):567-72.231
Ch
apt
er 
5.1
    232
   
Su
mm
ary
 / S
am
env
att
ing
 Chapter 7
23.Summary / Samenvatting233
Ch
apt
er 
5.1
    234
   
Su
mm
ary
 / S
am
env
att
ing
 SUMMARY
Osteoarthritis (OA) is the most prevalent joint disease that principally affects articular
cartilage and bone tissue. It is a leading cause of chronic disability, because of its
symptoms, pain, stiffness and limitation in joint movement. OA is regarded as a complex
disease that is not completely understood. There is still lack of information in different
areas including its pathophysiology, risk factors and genetic predisposition. Lack of
knowledge about OA has been reflected in absence of effective treatments. 
Between the most important risk factors for OA, age is considered the strongest predictor
of the disease. However, other factors that have been associated with OA might have an
important role in the disease and prognosis of individuals affected including their
survival. They include height, bone mineral density, elderly comorbidities and genetic
factors.  
The aims of this thesis were to identify genetic and bone-related risk factors for hip OA
and to determine the osteoporotic fracture and mortality risk in subjects affected by the
disease. The majority of studies described in this thesis were conducted within the
Rotterdam Study, a population based cohort study from the Netherlands. Genetic studies
were often done in collaboration with other large studies on OA from Netherlands and
abroad. Chapter 1 gave an introduction of OA focusing on the hip joint, embryological
joint development, geometry, bone related aspects and generalities about hip OA.
In chapter 2, genome-wide association studies on cartilage thickness and hip OA were
presented. Chapter 2.1, using a GWAS approach we describe the association of a
common variant from DOT1L gene with cartilage thickness and hip OA. We additionally
presented functional studies on DOT1L, demonstrating a role in chondrogenic
differentiation and adult articular cartilage through influence on the Wnt Signaling. In
chapter 2.2, we identified five genome-wide significant (GWS) variants localized in or
close to TGFA, SUPT3H, RUNX2, PIK3R1, DOT1L. The variants were associated with
hip OA except for PIK3R1. Another variants were suggestive for association with
cartilage thickness; they are localized in or close to SLBP, TREH and HAO1 being SLBP
the most significant for hip OA.. We found a significant connectivity between the genes
associated with cartilage thickness, principally TGFA and RUNX2 using GRAIL.
Pathways where these genes are implicated are the EGF receptor signaling pathway
(TGFA), TGF-beta signaling pathway (TGFB2), Insulin/IGF pathway protein kinase B
signaling and PI3 kinase pathway between others, according to results of a special
software that can identify functional connections between genes (Chapter 2.2).235
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    Deregulation of these genes and mechanisms might result in an increased risk for OA.
Further studies on the functionality of these variants will improve our understanding of
cartilage, bone tissue and will open the possibility of using them as potential
pharmacological targets. Chapter 2.3 using a different approach (bivariate analysis) and
taking benefit of the mutual correlation that exists between cartilage thickness and height
(~20%) found genetic variants in common for these traits: DOT1L, SUPTH3, ASTN2
(previously identified associated with OA and height), and identified significant variants
for cartilage thickness in other genes previously associated only with height: DYM,
FBXW11, TEAD1, IGF2BP3 and IER3. The variants showed independent effect on
cartilage and height, suggesting a pleiotropic effect of these genes. A role of these genes
in endochondral ossification process is plausible and verification of these findings will
be pursued. 
Chapter 3 describes the results of the prediction of hip OA (incident and progression)
using two bone related factors. In chapter 3.1 using two different methods, we
quantified the variations in hip geometry in subjects without OA at baseline and we
demonstrated how certain aspects of geometry contribute to the prediction of hip OA on
top of the known clinical risk factors, age, gender, height and initial OA changes
measured by Kellgren and Lawrence score. Hip geometry had a moderate but still
significant contribution in the prediction of OA. Chapter 3.2 studied the contribution of
DXA based parameters of the proximal femur and femoral head on the prediction of
progression of hip OA measured as narrowing of joint space width (>= 20%) or total
joint replacement (progressors). Bone mineral density (BMD) and bone mineral content
(BMC) values from areas close to the joint space including superior part of femoral head
were higher in the group of progressors. Femoral head and femoral neck width were also
bigger in the group of progressors. Differences in area, BMD/BMC of the superior part
of femoral head, major trochanter, intertrochanteric between affected and unaffected hip
were significant contributors in the prediction of progression of OA. 
The complexity in the relation between BMD and OA is evidenced in chapter 4. Hip
OA can be classified according with the principal phenotypic characteristics of OA:
narrowing and osteophytes. Atrophic, hypertrophic and normotrophic hip OA types were
analyzed. Subjects with OA characterized by osteophytes (hypertrophic/normotrophic)
demonstrated higher BMD not only at places near to the affected joint but also systemic.
Geometrical and BMD changes as those evidenced in chapter 3 were also found in
participants with different osteophytic types of OA. Besides, subjects with atrophic hip
OA characterized by degradation of articular cartilage without evidence of osteophytes
showed a systemically lower BMD and higher risk for osteoporotic fractures that was not236
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 explained by the lower BMD (chapter 4.1). Subjects with lumbar disc degeneration
(LDD), characterized by disc space narrowing and in the majority of cases multiple
osteophytes have a higher BMD than those subjects without LDD. In spite of higher
BMD, we found that male subjects with LDD had a higher risk for osteoporotic
fractures, principally clinical vertebral fractures (chapter 4.2). 
Chapter 5 presents a comprehensive analysis of the comorbidities and impact of hip and
knee OA in the survival on individuals affected. Participants from the first two cohorts
from the Rotterdam Study were included in the analyses. Seven different causes of
mortality were considered. Clinical and radiological OA was associated with higher
overall mortality due to all causes. Participants with hip and/or knee OA have more
comorbidities; Diabetes, dementia, overweight, walking disability and difficulty in
activities of daily life were more frequent in subjects affected by OA and partially
explained the higher mortality risk. Prevention and control of these chronic diseases in
subjects with OA become relevant. In the treatment of OA, policies and guidelines
should target the negative consequences of the disease, improving functionality,
decreasing disability, controlling and preventing comorbidities in the population
affected.
Finally, chapter 6 offers a general discussion with the most relevant and controversial
aspects of this thesis and give suggestion for future research in the area. 237
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 SAMENVATTING
Osteo artrose (OA), in de volksmond ook wel artrose genoemd, is de meest
voorkomende gewrichtsaandoening die voornamelijk het articulaire kraakbeen en bot
aantast. Het is een belangrijke oorzaak van chronische invaliditeit vanwege de pijn,
stijfheid en bewegingsbeperking die het gevolg zijn van deze ziekte. OA wordt
beschouwd als een zogenaamde “complexe ziekte”, waarvan we weten dat zowel genen
als omgeving een rol spelen, maar we begrijpen de initiatie en proces van de ziekte nog
niet. Er is nog steeds een gebrek aan informatie in verschillende gebieden, waaronder de
pathofysiologie, risicofactoren en genetische aanleg. Gebrek aan kennis over OA heeft
tot gevolg dat er geen effectieve behandelingen zijn voor deze ziekte. Leeftijd wordt
beschouwd als een van de belangrijkste risicofactoren voor OA. Andere factoren die zijn
geassocieerd met OA en de prognose voor het erger worden van de ziekte zijn lengte,
botmineraaldichtheid, comorbiditeit en genetische factoren.
Het doel van dit proefschrift is om genetische en bot-gerelateerde risicofactoren voor
heupartrose en osteoporotische fracturen en het bijbehorende sterfterisico vast te stellen.
De meerderheid van de studies beschreven in dit proefschrift werden uitgevoerd binnen
de Rotterdam Studie, een populatie-gebaseerd cohort onderzoek in Nederland.
Genetische studies werden vaak uitgevoerd in samenwerking met andere grote studies
over OA afkomstig uit Nederland en het buitenland.
Hoofdstuk 1 geeft een inleiding op de embryologische ontwikkeling van gewrichten,
geometrie en bot-gerelateerde aspecten van artrose, heupartrose in het bijzonder.
In hoofdstuk 2, werden genoom-wijde associatiestudies (GWAS) naar kraakbeen dikte
en heupartrose gepresenteerd. Hoofdstuk 2.1, beschrijft de identificatie van de associatie
van een vaak voorkomende variant in het DOT1L gen met kraakbeen dikte en
heupartrose. Ook werden functionele studies van DOT1L gepresenteerd, waaruit blijkt
dat het gen een rol speelt in chondrogene differentiatie en volwassen gewrichtskraakbeen
via beïnvloeding van het Wnt-siganlerings systeem. In hoofdstuk 2.2, identificeerden
we vijf genoomwijde significante (GWS) varianten in of dicht bij TGFA, SUPT3H,
RUNX2, PIK3R1, DOT1L. De varianten waren geassocieerd met heup OA, behalve
PIK3R1. Andere varianten waren suggestief voor associatie met kraakbeen dikte; ze zijn
gelokaliseerd in of dicht bij SLBP, TREH en HAO1. SLBP is het belangrijkste voor
heupartrose. We vonden significante verbanden tussen de geïdentificeerde genen door
middel van speciale software die functionele verbanden kan identificeren. Pathways
waarin deze genen zijn betrokken zijn de EGF-receptor signalering (TGFA), TGF-beta239
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    signalering (TGFB2), insuline / IGF-route, proteïne kinase B signalering en PI3
signalering (hoofdstuk 2.2). Verdere studies naar de functionaliteit van deze varianten
zullen ons begrip van kraakbeen en bot verbeteren en wellicht mogelijkheid bieden om
ze te gebruiken als potentiële farmacologische doelen. Hoofdstuk 2.3 met behulp van
bivariate analyse, welke gebruik maakt van de onderlinge samenhang die bestaat tussen
kraakbeen dikte en lengte (~20%), werden genetische varianten gevonden die
correleerden met verschillen in lengte en kraakbeendikte. Daarbij werden reeds eerder
varianten gevonden (DOT1L, SUPT3H, ASTN2), maar er werden ook nieuwe variaties
gevonden waarvan nog niet bekend was dat ze iets te maken hadden met kraakbeen:
variaties in of vlakbij de genen DYM, FBXW11, TEAD1, IGF2BP3 en IER3. De
varianten vertoonden onafhankelijke effecten op kraakbeen en lengte, wat pleiotrope
effecten van deze genen suggereert. Een rol van deze genen in het endochondrale
ossificatieproces is plausibel en verificatie van deze bevindingen zullen worden
nagestreefd. 
Hoofdstuk 3 beschrijft de resultaten van de voorspelling van heupartrose (incidentie en
progressie) met twee bot-gerelateerde factoren. In hoofdstuk 3.1 werd met behulp van
twee verschillende methoden variatie in heup geometrie gekwantificeerd bij personen
zonder OA bij aanvang van de studie. Vervolgens zagen we hoe bepaalde aspecten van
geometrie bijdragen aan de voorspelling van heupartrose bovenop de bekende klinische
risicofactoren: leeftijd, geslacht, lengte en eerste OA veranderingen gemeten door de
Kellgren en Lawrence score. Heup geometrie had een matig sterke, maar nog steeds
belangrijke bijdrage in de voorspelling van OA. Hoofdstuk 3.2 bestudeerde de bijdrage
van DXA parameters van de proximale femur en heupkop aan het voorspellen van
progressie van heupartrose. Botmineraaldichtheid (BMD) en botmineraalgehalte (BMC)
waarden in gebieden dicht bij het kraakbeen met inbegrip van het bovenste deel van de
heupkop waren hoger in de groep van progressors. Femurkop en femurhals breedte
waren ook groter in de groep van progressors. Verschillen in oppervlakte, BMD / BMC
van het superieure deel van de heupkop, trochanter major en intertrochanterisch dragen
significant bij aan het voorspellen van progressie van OA. 
Zoals te zien is in hoofdstuk 4 is de relatie tussen BMD en OA complex. Heupartrose
kan worden ingedeeld in een aantal groepen aan de hand van fenotypische kenmerken
van OA: kraakbeenverlies en vorming van osteofyten. Atrofische, hypertrofische en
normotrofische heupartrose werden geanalyseerd. Personen met OA gekenmerkt door
vorming van osteofyten (hypertrofisch/normotrofisch) hadden hogere BMD niet alleen
op plaatsen nabij het aangetaste gewricht maar ook systemische. Veranderingen in
geometrie en BMD zoals die uit hoofdstuk 3 werden ook gevonden in deelnemers met240
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 verschillende osteophytische types van OA. Daarnaast hadden patiënten met atrofische
heupartrose, gekenmerkt door afbraak van gewrichtskraakbeen zonder bewijs van
osteofyten, een systemisch lagere BMD en een hoger risico op osteoporotische fracturen,
wat niet werd verklaard door lagere BMD (hoofdstuk 4.1). Personen met lumbale discus
degeneratie (LDD), gekenmerkt door tussenwervelschijfruimte vernauwing en in de
meeste gevallen meerdere osteofyten, hebben een hogere BMD dan personen zonder
LDD. Ondanks een hogere BMD hadden mannelijke personen met LDD een hoger risico
op osteoporotische fracturen, voornamelijk klinische en vertebrale fracturen (hoofdstuk
4.2). 
Hoofdstuk 5 presenteert een uitgebreide analyse van de comorbiditeit en de impact van
heup en knie artrose op de overleving. De relatie tussen het hebben van artrose en
mortaliteit werd bestudeert in de Rotterdam, daarbij werden zeven veelvoorkomende
doodsoorzaken beschouwd. Klinische en radiologische artrose waren geassocieerd met
hogere mortaliteit, dit was te zien voor alle onderzochte doodsoorzaken. Deelnemers met
heup- en / of knie OA hebben meer comorbiditeit; diabetes, dementie, overgewicht,
problemen met lopen en moeilijkheden bij de activiteiten van het dagelijks leven
kwamen vaker voor. Dit verklaarde deels het hogere sterfterisico. Preventie en
bestrijding van deze chronische ziekten bij personen met artrose is relevant. In de
behandeling van artrose, het beleid en richtlijnen moeten richten op de negatieve
gevolgen van de ziekte, het verbeteren van de functionaliteit, het verminderen van
beperking en bestrijding en preventie van cormorbiteit in de getroffen bevolking.
Hoofdstuk 6 tenslotte biedt een algemene discussie met de meest relevante en
controversiële aspecten van dit proeftschrift en geeft suggesties voor toekomstig
onderzoek in het gebied.241
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 LIST OF ABBREVIATIONS
AHL: Activities of household and leisure
AIC: “An information criterion”, it is a measure of the goodness of fit of an estimated 
statistical model. It is a tool for model selection.
AUC: Area under the curve
BMC: Bone mineral content
BMD: Bone mineral density
BMI: Body mass index
CVD: Cardiovascular disease
DXA: Dual energy X-ray absorptiometry
DDXA: Difference in DXA measurements within the hips of each subject.
DK-L: Difference in KL score within the hips of each subject
DSN: Disc space narrowing
ECG: Electro-cardiogram
FN: Femoral neck
FOI: Foramen obturator index
FPR: False positive rate
GWAS: Genome-Wide Association Study
GWS: Genome-Wide Significant
HAL: Hip axis length
HR: Head radius
H.R.: Hazard ratio
K-L: Kellgren and Lawrence Score
IPI: Isquio-pubic index
JSN: Joint space narrowing
JSW: Joint space width
LDD: Lumbar disc degeneration
MAF: Minor allele frequency/ Modelled allele frequency
MJS: Minimal joint space
NL: Neck length
NN: Narrow neck
NSA: Neck shaft angle
NSAID: Non-steroidal anti-inflamatory drugs.255
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    NW: Neck width
OA: Osteoarthritis
OP: Osteoporosis/osteoporotic
OPH: Osteophyte(s)
OR: Odds ratio
PGP: Predefined geomtry measures
PW: Pelvic Width
QC: Quality control
QQ-Plot: Quantile-quantile plot
RefSeq: The Reference Sequence collection
ROC: Receiver Operator Characteristic (curves)
RS: Rotterdam Study
SE: Standard error
SES: Socio-economic status
SS: Spherical sector
SSM: Statistical Shape Model/Modeling
TI: Triangular index
TPR: True positive rate
THR: Total Hip Replacement
VFx: Vertebral fracture256
